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SUMMARY
Since the introduction of p-phenethylbiguanide (DBI)) as an outstanding blood sugar 
lowering drug, considerable attention has been directed towards the synthesis of 
compounds which are in some way related to biguanides as potential anti-diabetic 
compounds. It may be noted that the biguanides when written in cyclic hydrogen bonded 
form ( I ), resemble a triazine-like structure ( II ). On the basis of the consideration as to 
whether stabilisation of the biguanide group by ring formation could enhance the anti 
diabetic activity of these compounds, a series of substituted s-triazine derivatives was 
synthesised and tested as oral hypoglycaemics in various animal models.
n   _ .... M_  © R—H2N
H-N
■nh2 r - h n
H
-N-H N
NH2
N
I II
Guanamine-like compounds have previously been shown to lower blood glucose levels in 
normal as well as diabetic rats.
In the present study a series of biguanide and guanamine derivatives were synthesised 
and tested for their ability to decrease glycogen phosphorylase a in hepatocytes isolated 
from non- diabetic and streptozotocin-induced (STZ) diabetic rats, as a measure of their 
insulin-like action. The biguanides such as the phenyl-, benzyl- and phenethyl (phenformin, 
a therapeutically useful) derivatives were cyclized into guanamines to see the effect of 
cyclization on the activity of the compound. It was also possible to determine the effect of 
changing substituents in various positions and to determine the structure-activity 
relationship of these compounds synthesised for their insulin-like action.
All of the results can be summarised as follows.
X(1). In hepatocytes isolated from control animals, (a) all of the synthesised biguanides and 
guanamines mimic insulin in decreasing glycogen phosphorylase. (b) in the biguanide 
series, the benzyl and phenyl derivatives were more potent than phenethylbiguanide 
(phenformin). (c) cyclization of the biguanide to the corresponding 1,2,3-triazines 
(guanamines) still gives compounds which inhibit the activity of glycogen phosphorylase.
(2). In hepatocytes isolated from diabetic rats, all compounds were seen to increase 
glycogen phosphorylase a activity in contrast to the inhibition seen in cells from control 
animals. The most potent compounds were phenethylbiguanide (phenformin) and 
phenethylguanamine. This effect is opposite to that seen in hepatocytes from control 
animals and may be compensation for the inhibition of glycogen phosphorylase activity 
seen in liver from diabetic animals which is, perhaps, due to the low amount of glycogen 
seen in the liver of these animals. In contrast to the situation in control hepatocytes, 
diabetic hepatocytes showed the greatest response to phenethylbiguanide and only a 
moderate response to benzylbiguanide. As in the control animals, however, biguanides and 
guanamines mimic insulin and thus, the guanamines may prove useful as antidiabetics.
(3). The effect of biguanides and guanamines on glycogen phosphorylase a in the insulin 
treated diabetic rat was much more like the effect of the compounds on normal rat 
hepatocytes.
(4). The next series of experiments was performed to try and elucidate the reason for the 
differences in effects of compounds on glycogen phosphorylase activity in different types 
of cells by preincubation of normal rat hepatocytes in different concentrations of glucose. 
A similar structure - activity relationship was observed in control cells preincubated in 
30mM glucose as in cells isolated from STZ diabetic rats.
(5) It was observed that all of the compounds mimic insulin in stimulating the activity of 
glycogen phosphorylase when the diabetic cells are preincubated in lOmM glucose and by 
decreasing glycogen phosphorylase activity in cells preincubated in 30 mM glucose. This 
result suggests that cells isolated from STZ diabetic rats are not normal and respond 
differently to cells isolated from control liver .
(6). The insulin-mimetic effects of phenethylbiguanide and phenethylguanamine in 
increasing androst-4- ene- 3,17- dione metabolism were examined in order to extend our 
knowledge of the insulin-like action of biguanides and guanamines from glycogen 
metabolism to steroid metabolism. Phenethylbiguanide and phenethylguanamine are both 
able to mimic the effect of insulin in normal rat hepatocytes with respect to androst-4-ene- 
3,17- dione metabolism. However, the cyclization of phenethylbiguanide to 
phenethylguanamine gives a compound which is only effective on the cytochrome P450- 
dependent enzymes (7a- 6p- and 16a- hydroxylases). This possibly indicates that the three 
cytochrome P450 dependent enzymes are more susceptible than the flavin-dependent 
enzymes to the triazine moiety in phenethylguanamine.
Overall, biguanides and guanamines have been shown to have significant, direct, 
insulin-like effects on glycogen phosphorylase a activity and androst-4-ene-3,17-dione 
metabolism in hepatocytes isolated from control and STZ-diabetic rats. The effectiveness 
of the compounds depended on the enzyme under study and on the original state of the 
animal (diabetic or not).
Further investigation is warranted on the usefulness of congeners of the presently used 
biguanide, phenformin, and on the cyclised biguanides, such as the guanamines and, 
perhaps, the five-membered structures, the triazoles.
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INTRODUCTION
11.1. BIGUANIDES.
1.1.1 Historical Background
For more than seventy years it has been known that guanidine itself (Watanabe, 
1918) as well as substituted guanidine , diguanidines (Frank et al.f 1926; BischofF, 
1929) and biguanides (Slotta & Tschesche, 1928) exhibit blood sugar lowering 
activity. A large number of compounds have been developed on the basis of the 
guanidine structure, most of which, however give intolerable side effects. Only a few 
compounds appear in the narrow range between toxicity and useful drug action and are 
still used in the treatment of diabetes mellitus. Some of the guanidine derivatives used 
in the 1920s such as galegine and alkyl biguanides (e.g synthalin A) were found to be 
too toxic for clinical use and were discontinued as insulin became more widely 
available (Beckman, 1971; Sterne, 1969). Chlorguanide hydrochloride, introduced as 
an anti malarial agent in the 1940s, was known to have a weak glucose-lowering effect 
(Chen & anderson ; 1947). However, it was not until the 1950s, prompted by the 
introduction of sulfonylureas, that biguanides were re investigated for the treatment of 
diabetes. In 1957 metformin (Sterne, 1957) and phenformin (Ungar et al., 1957) and in 
1958 buformin (Mehnert & Seitz, 1958) were described as agents suitable for the 
treatment of hyperglycaemia. Structure - activity relationship studies were undertaken 
with an extensive range of biguanide derivatives, but other suitably active compounds 
were not found (Beckmann, 1971). Buformin received only limited use, but 
phenformin was adopted widely in the 1960s and early 1970s (Beckmann, 1971; 
Mehnert & Haese, 1971). An association with lactic acidosis resulted in withdrawal of 
phenformin in some countries (Williams & Palmer, 1975; Nattrass & Alberti, 1978), 
but it is still carefully used in other, either as a monotherapy or in combination with a 
sulfonylurea. A particular interest has been shown in fixed combination tablets 
containing phenformin and glyburide (Raptis et al., 1990).
21.1.2 Mechanism of Action.
In spite of intensive research the mechanism of action of biguanides as anti- 
hyperglycaemics is still a matter of debate (Bailey, 1992). Since the initial step in 
insulin action is binding to its receptor target cells, the effects of biguanides as 
hypoglycaemic agents on insulin binding to its receptor have been studied. Biguanides 
(phenformin and metformin) at concentrations similar to those giving effects in vivo, 
increase insulin receptor binding in vivo and in vitro (Iwamoto & Goldfine, Holle et 
al., 1981, Vigneri et al., 1982). Garcia et al (1992), using different cell cultures (IM- 9 
lymphocytes, H35 hepatoma, cultured breast cells), showed similar results with 
phenformin. In vitro exposure of rat adipose tissue to metformin resulted in an increase 
in insulin binding ( Fantus & Brosseau, 1986). Decrease in insulin binding to the 
plasma membrane of various target tissues of experimental diabetic animals and 
patients of different forms of diabetes is well documented (Fussganger et al., 1976; 
Lockwood et al., 1979). This alteration in insulin binding is essentially due to a change 
in the number and binding affinity of the insulin receptors located on the plasma 
membrane of the cells. All forms of diabetes in experimental animals and patients may 
be broadly classified into two type: insulin deficient and insulin resistant. In insulin 
deficient diabetes, the number of insulin receptor per cell in target tissues is increased, 
but the binding affinity of the hormone with it receptor is reduced. In contrast, in 
insulin resistant diabetes, the number of insulin receptors per cell of the target tissues is 
reduced but the binding affinity of the hormone with its receptors is increased (De 
Meyts et al., 1976). Biguanide (metformin) normalises the binding of insulin to its 
receptor in same diabetic patients (Trischitta et a l, 1983).
Whether the site of biguanide action is at the cell membrane and / or at post 
receptor sites is unclear. Several in vivo and in vitro studies have pointed out one 
possible mode of action of the drug at the cell surface, after demonstrating its ability to 
increase insulin binding to its receptor in various cell types. However, divergent results 
report the failure of metformin to affect the insulin receptor status in monocytes from
3diabetic humans chronically treated with the drug (Prager & Schemthaner, 1983) or in 
normal insulin target cells such as human (Cigolini et al., 1984) and rat adipocytes 
(Jacobs et al., 1987) and mouse (Lord et al., 1983) and rat hepatocytes (Alengrin et 
al, 1987; Wollen& Bailey, 1988).
Alengrin and colleagues (1987) demonstrated that metformin has no direct 
effect on insulin binding in hepatocytes, indicating that alteration of insulin stimulation 
of glycogen synthesis in the liver is due to modifications at the post receptor level. 
Bailey & Puan (1986) showed that metformin increased oxidation of glucose and 
formation of glycogen from ^ C - glucose by streptozotocin diabetic mouse soleus 
muscle in the presence of maximally stimulating concentrations of insulin. Rossetti et al 
(1990) also reported enhanced muscle glycogen synthetic rate in non- insulin- 
dependent diabetic rats. An increase in muscle glycogen synthesis by metformin in the 
presence of insulin has also been described in alloxan diabetic rats (Frayn & Adnitt 
1972). Melin et al (1990) have suggested that biguanide (metformin) improves type 2 
diabetes through an effect at the hepatic level on insulin action by improving insulin - 
mediated [^C ]- glucose incorporation into glycogen in cells isolated from the liver. 
Biguanide (metformin) increased the active form of glycogen synthase (a form) in both 
the liver and muscle of diabetic mice.
Reduced gluconeogenesis is frequently considered as a typical biguanide effect 
(Meyer et al., 1967; Hermann, 1979; Komori et al., 1993). It is generally accepted that 
biguanides reduce hepatic gluconeogenesis via generation of mitochondrial NADH in 
hepatocytes (Cook et a l, 1973; Ogata et a l, 1974). However, hepatic glucose 
production was increased, presumably due to an increased gluconeogenesis and 
glucose recycling, in a study performed in Zucker rats (Penicaud et al, 1989). In liver 
cells high concentrations of metformin (>10"^M) reduce basal and glucagon- 
stimulated gluconeogenesis in the absence of added insulin (Meyer et al., 1967, Cooke 
et al., 1973). However, therapeutic concentrations of metformin (10"^M) act 
synergistically with physiological concentrations of insulin to reduced gluconeogenesis 
in isolated rat hepatocytes (Wcllen & Bailey, 1988). Metformin in isolated rat
4hepatocytes decreased the stimulatory action of glucagon and N, 2-0- dibutyryl- cyclic 
AMP (db-cAMP) on gluconeogenesis indicating an effect even at a post- adenylate 
cyclase step (Alengrin et al., 1987). Glucagon stimulated adenylate cyclase activity 
some 21- fold in liver membranes from obese Zucker rats and treatment of animals 
with the biguanide (metformin) decreased the ability of glucagon to stimulate this 
enzyme (Gawler et al., 1988).
It was observed that biguanides inhibited alanine utilisation in the presence of 
glucagon in isolated perfused livers in normal and diabetic rats, resulting in reduced 
hepatic gluconeogenesis (Hotta et al., 1991; Komori et al., 1993). This finding 
suggests that buformin may have reduced hepatic gluconeogenesis from alanine by 
preventing alanine uptake in liver. Alanine is quantitatively the most important amino 
acid precursor of gluconeogenesis in the liver (Chochinov et al., 1978).
It has also been observed in in vitro studies that metformin increases insulin- 
stimulated glucose up take into skeletal muscle, fat (Frayn & Adnitt, 1972; Bailey & 
Puan, 1986; Galsuska et al., 1991; Matthei et al., 1991). and cultured L6 muscle cells 
of the rat (Hundal et al., 1992). The metformin-induced increase in glucose uptake 
appears to involve increased translocation of glucose transporters from the microsomal 
fraction into the plasma membrane, without changing the total cellular pool of 
transporters (Matthaei et al., 1991; Hundal et al., 1992). In normal fat cells there was 
increased translocation of both GLUT-4, the main insulin- responsive transporter, and 
GLUT-1, which is only slightly responsive to insulin (Matthaei et al., 1991). In rat L6 
muscle cells, metformin increased translocation of GLUT-1 (but not GLUT-4) into the 
plasma membrane (Hundal et al 1992). While it is premature to extrapolate from 
these in vitro models to the in vivo situation, the possibility exists that metformin could 
exert different effects on glucose tranporters in different tissues. Recently, in the 
investigation of metformin on glucose transport in freshly cultured heart muscle cells from 
healthy and streptozotocin- diabetic rats, it was shown that the drug caused an 
approximately 1.6- fold increase in the content of both glucose transporter isoforms, 
GLUT1 and GLUT4, in the plasma membrane of cardiac myocytes, with a
5corresponding decrease in the intracellular membrane fraction. In myocytes from 
diabetic rats, the rate of metformin- activated glucose transport was similar to that of 
cells from control animals, whereas basal and insulin - stimulated transport were 
substantially diminished (Fischer et al., 1995). Tissue- specific differences in 
transporter regulation are known to occur in various physiological and pathological 
states (Pessin & Bell, 1992). Indeed the intestine, which has a very different glucose 
tranporter complement from muscle and fat, shows increased glucose utilisation in 
response to metformin in both the basal and postprandial states (Bailey, 1992). 
Recently it has been reported that the presence, of insulin is required for metformin to 
augment glucose utilisation. Thus it is possible that insulin is necessary to activate the 
cellular processes upon which metformin operates (Bailey & Mynett, 1994).
In an investigation of the effect of metformin and phenformin on the Ca^+ 
signal pathway, it was concluded that the biguanides exert their inhibitory effect on 
phenylephrine- induced [Ca^+] oscillations by a direct negative interference with the 
IP3 sensitive movement of intracellular Ca?+ stores (Ubl et al., 1994).
There is , thus, much evidence as to how biguanides exert their effects as anti 
hyperglycaemic agents but much of it is confusing and contradictory. It is not even 
clear if biguanides can act alone or need the presence of insulin.
1.1.3. Structure - Activity Relationship of Biguanides.
Attempts have been made by Paul and co-worker (1963) to correlate the 
structure of some series of compounds with their hypoglycaemic actions.
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6The analysis of the results with these compounds based on structure I revealed 
that when Rj is phenyl, a little hypoglycaemic activity seems to be developed. Further 
substitution to the phenyl group at the para position, e.g with, methylsulphonyl, 
sulphonamido or benzoylsulphonamido compounds, tends to make the compound 
hyperglycaemic instead of hypoglycaemic. On the other hand, when Rj is benzyl, the 
hypoglycaemic activity of the compound is found to be greatly increased. Branching at 
the -CH2-group of the benzyl moiety with a methyl grouping did not alter the 
hypoglycaemic response but branching with the next higher homologue, i,e ethyl, 
markedly decreased the hypoglycaemic activity, when Rj is B-phenethyl (phenformin), 
the resulting compound becomes very active. Substitution at the a-carbon atom of 6 - 
phenethyl by a methyl group reduced the hypoglycaemic activity to a appreciable 
extent. Further attempts in branching with higher homologues like ethyl, n-propyl, 
isopropyl, n-butyl or with other substituents like phenyl or benzyl, however, markedly 
lowered the activity. Substitution of the N5- atom (R2) of the three potent N l- 
substituted derivatives (benzyl, -phenyl, B-phenylethyl) resulted in compounds of lesser 
activity. This accorded with Shapiro's observation (Shapiro, 1959).
JAV 852 or benfosformin is a phosphorylated biguanide showing powerful 
anti diabetic properties as well as a low toxicity. Its hypoglycaemic activity, which is 
more marked in diabetic animals than in normal ones, is comparable to that of 
phenformin and two to three times as strong as that of metformin. Like the other 
biguandes, JAV 852 provokes hyperlactacidaemia in diabetic or in non- diabetic 
animals, but, on the basis of an equal hypoglycaemic effect, the acidosis produced is 
less than is the case with phenformin or metformin (structure II) (Loiseau et al., 1973).
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Attaching a biguanide group onto monosaccharides resulted in some 
compounds where the most active exhibited nearly equivalent hypoglycaemic activity 
to that phenformin and metformin, such as 6- biguanidino- 1,2: 3,5- bis-o- (1- 
methylethylidene) -6- deoxy- a- D- glucofuranose (structure III) (Reitz, et al 1989).
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Some aspects of the biological behaviour of biguanides, such as the blood 
sugar lowering effect and metabolic interactions, have been widely studied (Bechman, 
1971; Schafer, 1976). Biguanides form stable co-ordination complexes with divalent 
cations of oligoelements existing in living organisms. Phenformin and other related oral 
anti diabetic biguanides form very strong complexes with Zn^+and other divalent 
cations (Ray 1961). This finding suggests that biguanides may produce alterations in 
the distribution and ratio of divalent cations in biological media (Trijueque, 1981). It
8was shown (Haas and Davidoff, 1978) that phenformin administered in vivo produced 
consistent and significant effects on hepatic mitochondrial divalent metal ion content 
through a more complex mechanism than competitive binding. The structure of this 
type of complex has been suggested and the one reported by Ray and Saba (1937) is 
the most widely accepted (structure IV)
The anti diabetic action of biguanides can be derived from this complex 
phenomenon. This action must be consistent with some sequence of events such as
granules (Lacy 1970) and that biguanides form stronger complexes than insulin does
biguanides to form hydrogen bridges with other molecular species such as amino acids
cations. The anti diabetic action of phenformin and other related biguanides may be
biguanide moiety and insulin itself (Vicente-Pedros et al., 1983). Reduction of the 
concentration of zinc ions in the plasma has been associated with hypoglycaemia 
induced by phenformin (Shoka, 1992)
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insulin being stored in /3-cells of the pancreas in the form of insoluble insulin-Zinc
with Zn^+. Formation of such complexes may release insulin from the granules 
allowing it to enter the systemic circulation. The existence of active electron pairs on 
some nitrogen atoms in phenformin is inferred and this finding emphasises the ability of
and proteins, as well as to form co-ordination complexes with zinc and other metallic
explained in terms of competition between these molecules and insulin to co-ordinate 
cationic oligoelements together with their ability to form hydrogen bonds between the
91.2. STUDIES ON RELATED ANTI DIABETIC AGENTS.
Since the introduction of B-phenethylbiguanide (Ungar et al, 1957) (DBI) as an 
outstanding blood sugar lowering drug, considerable attention has been directed 
towards the synthesis of compounds which are in some way related to biguanides. It 
may be noted that the biguanides when written in cyclic hydrogen bonded form (V), 
seem to represent a triazine - like structure (VI). On the basis of the consideration as 
to whether stabilisation of the biguanide group by ring formation would enhance the 
anti diabetic activity of the compounds, Suter and Zutter (1965) have synthesised a 
series of substituted S-triazine derivatives.
Many heterocyclic hypoglycaemic agent similar in structure to biguanides were 
reported to have promising hypoglycaemic activity (El-Kerdawy et al, 1975). 
Pharmaceutical preparations containing heterocyclic guanidine compounds had been 
tested for their anti diabetic effect (Atso et al, 1982).
One of the newer agents shown to reduce elevated glucose level in animal models 
are the guanamines ( structure VTI).
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These have been synthesised and evaluated as oral anti diabetic in rats (Gajewski 
et al., 1983 a,b; Gajewski et al, 1984; Brzozowski et al 1980 a,b). Hypoglycaemic 
activity is found to be critically dependent on the structural characteristic of the group 
R. Certain of the variants of this series are the most active guanamine anti diabetic for 
example 2-amino-4-(5-ethyl-4 methyl-2-pyrazoline)-l,3,5-triazine. A comparison of 
these diamino-1,3,5-triazine derivatives with classical standards (phenformin and 
buformin) in several experiment show that these compound have hypoglycaemic 
activity e.g 6-amino-2-oxyl-l,2-dihydro-4 (3,5,5-trimethyl-2-pyrazolino)-l,3,5- 
triazines on oral administration to rats were comparable in hypoglycaemic activity to 
phenformin (Gajewski et al 1984). Monoacyl butyroguanamine also exhibits muscle 
relaxing and anti diabetic activity (Kreutzberger & Loch, 1985). Tamasdan and 
colleagues (1987) synthesised and tested seven new triazine derivatives including 
Urofort (structure VIII), with a view to establishing their effect on blood cholesterol, 
glucose, sodium and potassium concentrations, as well as on the gastric acidity in rats. 
All of the compounds induced moderate reductions in blood glucose, except Urofort.
h 2n —
N
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VIII
Urofort = Rl, R2, R3, R4 = H
The mechanism of action of the guanamines is, however unclear. This group, of 
compounds thus deserves further attention as a potential treatment of diabetes mellitus.
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1.3. G LYCOG EN PH OSPHORYLASE
1.3.1. Historical Background
We can look back on more than 50 years of research on phosphorylase since 
Carl and Gerti Cori announced their discovery of the formation of glucose-1-phosphate 
from a reaction mixture containing glycogen , inorganic phosphate, and an aqueous 
extract of muscle containing phosphorylase and nucleotide adenylic acid (adenosine­
s '-  monophosphate, AMP), which activaties this enzyme (Cori & Cori, 1936). The 
reverse reaction, namely, synthesis of polysaccharides from glucose-1-phosphate by the 
action of phosphorylase was announced almost simultaneously in 1939 by Cori, 
Schmidt and Cori (Cori et al, 1939).
For a number of years it was reasonably assumed that the in vivo function of 
phosphorylase was to catalyse both the synthesis and the breakdown of the 1,4- 
linkage of glycogen, until 1957 when Leloir and Cardini demonstrated that UDPG- 
glycogen synthase is the liver enzyme catalysing the direct transfer of glucose from 
uridine diphosphoglucose (UDPG) to glycogen. Further work led to the crystallisation 
of phosphorylase by Green and Cori (Green & Cori, 1943). A second form of the same 
enzyme was detected and crystallised later (Cori & Cori, 1945). Whereas the first 
form, the active or " a " form, is active without AMP, the second the " b " or inactive 
form requires AMP for activity. (Cori et a l, 1938). It nevertheless took 20 years for 
the development of the protein chemistry techniques through which Edwin Krebs and 
Edmund Fischer demonstrated in 1959, that phosphorylase a and b correspond to 
forms of the same protein in which a specific residue, Ser 14, is enzymatically 
phosphorylated or dephosphorylated, respectively. Thus, this simple chemical change is 
responsible for the profound differences in enzymatic properties of the two forms.
The current excitement stems from the work of Krebs, Fischer and Lamer over the 
period 1955- 1970, when they discovered that neural and hormonal control of 
glycogen metabolism in skeletal muscle was mediated by changes in the
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phosphorylation state of glycogen phosphorylase (Krebs & Fischer, 1956), 
phosphorylase kinase (Krebs et al., 1959) and glycogen synthase (Friedman & Lamer, 
1963). The three enzymes remained the only examples of this phenomenon until the 
late 1960s, but the situation changed rapidly following the discovery of cyclic AMP- 
dependent protein kinase (Walsh et al., 1968).
In 1972 Graves and Wang observed that, while phosphorylase b is subject to 
control via the allosteric activation by AMP, it was inhibition by ATP, ADP, and 
glucose-6-phosphate. The discovery of cyclic AMP (cAMP) and the development of 
the concept of second messengers came from studies on the control of phosphorylase 
by glucagon and epinephrine which also led to the concept of the cascade of 
phosphorylation reactions. Shimazu and Amakawa (1975) were the first to show that 
glucagon was an activator of liver phosphorylase kinase. It was assumed, by analogy 
with muscle, that this was via a protein kinase and subsequent by using isolated rat 
hepatocytes, Vandenheede et al (1976) have provided evidence that phosphorylase 
kinase activation by glucagon is, indeed, caused by the action of cyclic AMP dependent 
protein kinase. In the late 1970s, it has become progressively apparent that cyclic AMP 
is not the sole messenger to signal changes in glycogenolysis and phosphorylase 
activation in the liver. Sherline et al (1972) were the first to show that the a- 
adrenergic agonist phenylephrine, produces an activation of glycogen phosphorylase in 
the absence of a rise in cyclic AMP in perfused rat liver. This discovery was not fully 
appreciated for several years possibly because it went against the widely prevalent view 
that cyclic AMP was the intercellular second messenger for glycogenolytically active 
hormones. The study of cyclic AMP- independent regulation of liver glycogenolysis 
received new impetus when it was shown (Hems & Whitton, 1973) that vasopressin 
induced an intense glycogenolysis in the perfused rat liver at concentrations likely to 
occur in haemorrhagic shock. Vasopressin is known to stimulate kidney adenylate 
cyclase but this activation of liver glycogen phosphorylase appeared not to be mediated 
by cyclic AMP i.e there was no increase in the liver content of cyclic nucleotide after 
the application of vasopressin (Kirk & Hems, 1974) and neither was liver protein
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kinase activated in rats receiving an injection of vasopressin (Sudilovsky, 1974). It 
appeared therefore that vasopressin, as the a- adrenergic agents, acted in a cyclic 
AMP- independent way and required presumably, another intracellular mediator. Since 
cyclic AMP is not involved in the glycogenolytic effect of a- adrenergic stimuli, 
vasopressin or angiotensin, what could be the alternate second messenger? The most 
obvious candidate is Ca^+, known to play a fundamental role in a whole series of 
cellular events and required for full catalytic activity of liver phosphorylase kinase 
(Shimazu & Amakawa, 1975, Khoo & Steinberg, 1975). The actions of Ca^+ can be 
mediated via calmodulin, (Cohen, 1980) which is known to be present as one of the 
four sub units of phosphorylase b kinase (Ramachandran et al.y 1985; Kee & Graves,
1986). Now it is well established that vasopressin, angiotensin II and a - adrenergic 
agonists stimulate hepatic glycogenolysis via a rise in cytosolic Ca^+ (Exton, 1983; 
Williamson et al.y 1985) by mobilising Ca^+ from the endoplasmic reticulum of the 
liver cell (Benedetti e ta ly 1989; Somogyi & Stuki, 1991).
The activity of glycogen phosphorylase is allosterically controlled, as mentioned 
previously through AMP activation and ATP, G-6-P and glucose inhibition. 
Superimposed upon this allosteric control is control by enzymatic interconversion 
through the action of three enzymes:
1. Glycogen phosphorylase kinase, which specifically phosphorylates Ser 14 of 
glycogen phosphorylase b.
2. cAMP- dependent protein kinase, which phosphorylates and thereby activates 
phosphorylase kinase.
3. phosphoprotein phosphatase 1, which dephosphorylates and thereby deactivates 
both glycogen phosphorylase a and phosphorylase kinase.
We shall specifically focus on how the activity of glycogen phosphorylase is control by 
these three enzymes in detail in the next section.
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1.3.2. Physiological Role and Regulation of Glycogen Phosphorylase.
Glycogen phosphorylase is the rate limiting enzyme for glycogenolysis (Cao, et a\ 
1993). This enzyme catalyses the first step in the intracellular degradation of glycogen 
by adding inorganic phosphate across the a -1,4 - glucosidic links of glucose residues 
to form a-glucose-1-phosphate (Graves & Wang, 1972), the mechanism of glycogen 
phosphorylase is shown in Figure 1, phosphorylase removes glucose residues from 
glycogen by a phosphorolysis reaction. (Cao et a l , 1993).
CHoOH
o  + Pi
GP
O —
Glycogen (partial structure) a-D-Glucose 1-phosphate
Figurel. mechanism of glycogen phosphorylase
Glycogen phosphorylase is known to be highly regulated when catalyzing the 
breakdown of glycogen (Graves and Wang 1972,; Newgard et al, 1989; Johnson, 
1992). The mechanisms responsible for the regulation of glycogen phosphorylase are 
summarised in Figure 2. The enzyme is subject to allosteric activation by AMP and 
allosteric inhibition by glucose, ATP, ADP and glucose-6-phosphate (Newgard et a l , 
1989). Although these effectors are considered to be of physiological significance in 
the regulation of glycogen metabolism, effector control of phosphorylase is integrated 
with a very elaborate control by covalent modification, phosphorylase exists in an “ a ” 
form, which is active, and a “ b ” form, which is inactive. These forms of the enzyme 
are interconverted by the actions of phosphorylase kinase and phosphoprotein 
phosphatase.
In response to nervous or hormonal signals , the enzyme is converted from the 
b form ( predominantly T state) to the a form ( predominantly R state) ( Johnson et al.,
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1989; Newgard et a l, 1989; Johnson, 1992) through the phosphorylase kinase 
catalysed addition of a phosphate to the hydroxyl group of Ser 14, located near the N- 
terminus of the molecule. Glucagon appears to increase the level of phosphorylase a by 
a concerted activation of phosphorylase kinase and inhibition of phosphorylase 
phosphatase (Stalmans et al., 1990). There is also evidence that shows that glucagon 
and insulin have opposite effects on the activity of protein phosphatases in liver 
(Farkas et al., 1986; Toth et al., 1988; Bollen et al., 1989). Phosphorylase kinase is 
responsible for the phosphorylation and activation of phosphorylase (Figure 2). 
Moreover, phosphorylase kinase itself is also subject to regulation by a cyclic 
phosphorylation - dephosphorylation mechanism. Cyclic AMP-dependent protein 
kinase is responsible for phosphorylation and activation of phosphorylase kinase 
(Cherrington et al., 1976; Krebs & Beavo, 1979). Phosphoprotein phosphatase in turn 
is responsible for dephosphorylation and inactivation of phosphorylase kinase.
Phosphorylase kinase has been extensively purified from rat liver (DeWulf et 
al., 1980). Its molecular weight is 1.3x10^ daltons, similar to that of the muscle 
enzyme. It is a large enzyme, composed of four subunits with four molecules of each 
subunit in the complex (a4p4y454). Catalytic activity resides with the y  subunit 
(Skuster et al, 1980); «,/?,& 5 subunits exert regulatory control. The a & subunits 
are phosphorylated in the transition from the inactive b form to the active a form of the 
enzyme. The a- and 0- subunits are the components phosphorylated by cAMP- 
dependent protein kinase (Cohen & Antoniw 1973). Cyclic AMP- dependent protein 
kinase does not interact with phosphorylase directly, this protein kinase can only exert 
an effect on phosphorylase via its ability to phosphorylate phosphorylase kinase 
(Krebs, 1986). Thus, a bicyclic system is required for the activation of phosphorylase 
in respond to cAMP- mediated signals (Krebs, 1986).
The 5 subunit of phosphorylase kinase also plays a regulatory role. The 5 
subunit is the Ca^+ - binding regulatory protein, calmodulin (Kee & Graves, 1986; 
Ramachandran et al, 1985). Calmodulin is not unique to phosphorylase kinase but is 
often found in cells as the free molecule and is also bound to other enzyme complexes
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(Sharma & Kalra 1994). Calmodulin functions as a Ca^-receptor in the cell, 
responding to changes in intracellular concentration and affecting the relative
activities of a number of enzyme systems. The binding of Ca^+ to the calmodulin 
subunit of phosphorylase kinase changes the conformation of the complex, making the 
enzyme more active with respect to the phosphorylation of phosphorylase (Cohen, 
1980). Note that in Figure 2, Ca^+ is shown as an activator of both phosphorylase 
kinase a and phosphorylase kinase b. This means that maximum activation of 
phosphorylase kinase require both the phosphorylation of specific serine residues of the 
enzyme and the interaction of Ca^"1" with the calmodulin subunit of the enzyme. This is 
one mechanism by which Ca^+ functions as an important "second messenger" of 
hormone action.
It is obvious that activation of phosphorylase kinase by phosphorylation and 
Ca^+ will have a substantial effect on the activity of glycogen phosphorylase. It is 
equally obvious that turning off phosphoprotein phosphatase could achieve the same 
effect but ultimate control for the activation of phosphorylase would involve the 
simultaneous turning off of phosphoprotein phosphatase and turning on of 
phosphorylase kinase., and vice versa for the inactivation of the enzyme. Since 
phosphoprotein phosphatase also acts on phosphorylase kinase, turning off 
phosphoprotein phosphatase would also achieve greater activation of phosphorylase 
kinase.
Protein phosphatases are involved in liver glycogen metabolism at three levels : 
they assure the inactivation of phosphorylase and phosphorylase kinase, (Figure 2) and 
the activation of glycogen synthase (not shown). Little is known at present concerning 
the protein phosphatase that dephosphorylate the hepatic phosphorylase kinase. The 
protein phosphatase that acts on phosphorylase and glycogen synthase in the liver is 
classified as AMD (ATP, Mg^+- dependent) or type-1, PCS (polycation- stimulated ) 
or type- 2A, and possibly the Mg2+- dependent or type-2C (Cohen, 1989, Goris et al, 
1989). The AMD protein phosphatase (type-1) in liver and muscle contain the same 
(37kDa) catalytic subunit (Cohen et a l , 1989). Its appears always to be associated
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with other polypeptides that determine its subcellular location ( cytosolic, glycogen - 
bound, microsomal, nuclear) and its substrate specificity, and may govern other 
properties of indivdiual type-1 protein phosphatases (Bollen et a l , 1988; Schelling., 
1988; Cohen, 1989). Type-1 protein phosphatase preferentially dephosphorylates the j3 
-subunit of phosphorylase kinase (Cohen, 1989). The distinctive property of these 
phosphatases is their complete inhibition by two heat stable proteins: inhibitor-1, which 
becomes inhibitory upon phosphorylation by cAMP- dependent protein kinase (Figure 
2) and inhibitor-2 (Cohen, 1989). The latter polypeptide has other regulator functions 
besides inhibitory properties and is therefore also referred to as the "modulator protein" 
(Merlevede et al., 1984). Inhibition by modulator is frequently used as a tool to 
distinguish the AMD enzymes from the other protein phosphatases.
Inhibitor-1 has been identified in the liver of dog, pig, sheep, rabbit and guinea 
pig (Goris et al., 1978; Macdougall et a l , 1989). In rabbit liver glucagon increases the 
extent of phosphorylation of inhibitor-1 (Macdougall et al., 1989) and this suggests 
that the direct actions of cAMP- dependent protein kinase could be reinforced by an 
inhibition of protein phosphatases (Stalmans et a l , 1990). However, inhibitor-1 does 
not qualify as a universal regulator since it cannot be detected in rat or mouse liver 
(Huang et a l, 1977; Macdougall e ta l , 1989).
PCS protein phosphatases (type 2A) constitute a group of polymeric enzymes 
present in the soluble fraction of the cell (Waelkens et a l , 1987; Cohen, 1989). PCS 
protein phosphatases in liver contain two slightly different catalytic subunits. However, 
the different substrate specificities of specific PCS phosphatases have to be attributed 
to different regulatory subunits (Waelkens et a l , 1987). It can dephosphorylate the a 
subunit of phosphorylase kinase and is not affected by inhibitor proteins (Cohen, 
1989).
Mg2+- dependent protein phosphatase is a cytosolic protein that was originally 
purified as a glycogen synthase phosphatase (Hiraga et a l , 1981).
The activation and inhibition of phosphorylase are under hormonal, neuronal and 
metabolic control. There are positive effectors that promote glycogen degradation such
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as adrenaline or Caj^+ signals that results in activation of the enzyme by 
phosphorylation and direct activation, such as AMP and negative effector that inhibit 
degradation and allow the cell to store glycogen for later use, such as insulin-induced 
signals for enzyme dephosphorylation and glucose, ATP and glucose 6-phosphate 
which act directly on the enzyme.
1.3.3. The Effect of Diabetes on Hepatic Glycogen Phosphorylase.
An absolute or relative deficiency of insulin results in a disease called diabetes 
mellitus. Diabetes mellitus is a disease marked by excessive and uncontrolled blood 
glucose concentrations. High blood glucose is caused by lesser utilisation of the sugar 
by peripheral tissues, as well as overproduction by the liver in man. Several studies 
have demonstrated that glycogen phosphorylase is missing or reduced in diabetes and 
can be returend to normal by insulin. In this section we will focus our discussion on the 
effect of diabetes on glycogen phosphorylase.
The rate limiting step in hepatic glycogenolysis is catalysed by glycogen 
phosphorylase and this has been shown by several laboratories to be affected in the 
diabetic animals. In an earlier study, Hombrook 1970 observed that alloxan diabetic 
rats had a lower concentration of glycogen and less phosphorylase activity than livers 
of normal rats. At the same year Gold (1970) demonstrated that, in diabetic animals, 
phosphoprotein phosphatase markedly declines and can be restored by insulin 
treatment. Khandelwal and colleagues (1977) in the study of the effect of 
streptozotocin - induced diabetes and insulin supplementation to diabetic rats on 
glycogen metabolising enzyme in liver, observed that the activity of the glycogenolytic 
enzymes were decreased in the diabetic animals. The enzyme activities were restored 
to control values by insulin therapy. The same observation was noted by Pugazhenthi 
& Khandelwal (1990) that diabetes was associated with the decrease of phosphorylase 
(a and total), cAMP- dependent protein kinase and phosphorylase kinase activities. 
However, phosphorylase phosphatase activity did not change .
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Diabetes- related decreases in total phosphorylase activity have been observed 
using liver homogenates by Miller (1978a) who discovered that there were large 
decreases in hepatic glycogen associated with alloxan diabetes in fed rats and that these 
were accompanied by apparent decreases in total glycogen synthase, phosphorylase, 
protein kinase and synthase phosphatase activities. Bahnak and Gold (1982) examined 
the effects of diabetes on protein turnover in alloxan diabetic rats and concluded that 
rates of both synthesis and degradation of phosphorylase were increased in diabetic rat 
liver compared with control, they also observed a diabetes-related decrease in total 
phosphorylase activity and further concluded that increased degradation relative to 
synthesis must be responsible. In contrast Roesler and Khandelwal (1987) observed 
that the rate of phosphorylase degradation is decreased in the genetically diabetic 
mouse, while the synthesis rate remains unchanged, thus leading to the increased total 
phosphorylase activity in these animals.
Miller and colleagues have demonstrated that insulin together with T3 (tri­
iodothyronine) restores decreased glycogen synthase phosphatase in hepatocytes from 
diabetic animals (Miller et al., 1986). Rulfs et al (1989) using primary cultured 
hepatocytes, showed that glycogen phosphorylase synthesis was significantly decreased 
compared with normal hepatocytes, suggesting that alterations in the rate of synthesis 
plays a major role in regulating the cellular phosphorylase content and consequently 
total activity.
The blunted stimulation of phosphorylase-a activity in the diabetic animals was 
influenced by a decrease in total cell activity of glycogen phosphorylase and decreased 
rise in cytosolic free calcium (increasing Ca^+ leads to stimulation of phosphorylase 
kinase and hence phosphorylase activation as discussed above) . Insulin replacement 
corrected both basal and stimulated changes in the acute diabetes model (Studer & 
Ganas, 1989).
Phosphorylase a is a potent inhibitor of glycogen synthase phosphatase, the 
protein phosphatase that activates glycogen synthase (Stalmans, 1976; Cohen., 1989). 
Protein phosphatase G is unique in that its synthase phosphatase activity is severely
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inhibited by phosphorylase a (Mvumbi & Stalmans, 1987). This regulatory property 
has a key function in the activation of hepatic glycogen synthase in response to 
glucose. It is suggested that a separate subunit is responsible for the allosteric 
inhibition by phosphorylase a (Alemany & Cohen, 1986). The glycogen synthase 
phosphatase activity of hepatic protein phosphatase G almost disappears during the 
development of severe alloxan diabetes (Stalmans et al., 1990). The defect accounts 
for the deficient activation of glycogen synthase in isolated hepatocytes from such rats 
(Stalmans et al., 1987). The same defect occur in the liver of BB rats that develop a 
spontaneous insulin- dependent diabetes (Bollen et al., 1988). In contrast, that 
glycogen synthase phosphatase activity is essentially normal in db/db mice with a non­
insulin dependent diabetes. The phosphorylase phosphatase activity of protein 
phosphatase G is much less affected by a shortage of insulin (Stalmans etal., 1987).
In studies on the effect of phosphorylases and kinases on hepatic glycogen 
metabolism during the fasted to refed transition in normal and streptozotocin- induced 
diabetic rats, it was shown that in diabetic livers phosphorylase (a and total) activities 
were significantly lower than those seen in the normal animals during the fasted to 
refed transition but the activity ratio in both group were comparable. cAMP- 
dependent protein kinase and phosphorylase kinase activity also showed substantial 
reduction in response to the meal. (Pugazhenthi & Khandelwal, 1991).
Recently it has been observed that mRNA levels for glycogen phosphorylase are 
affected by streptozotocin- induced diabetic rats (Barbera et al., 1994). However the 
effect of diabetes on glycogen phosphorylase is not universal since it cannot be detected 
in some kinds of diabetic rats such as the non- insulin dependent diabetic Goto- 
Kakizaki rat (GK rats). (Zhang et a l, 1994).
The amounts of the four isoforms of catalytic subunits of type-1 protein 
phosphatase, PP1-alpha, PP1-gamma-1, PP1-gamma-2, and delta have been 
determined in extracts of various tissues in non- obese diabetic (NOD) mice. The 
amount of PP1- alpha were progressively decreased in livers of NOD mice as a
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function of increasing concentrations of blood glucose, whereas the amount o fPP l- 
gamma-1 and PP1-delta were unchanged (Takizawa etal., 1994).
In summary it can be seen that diabetes markedly affects the enzymes of 
glycogen metabolism including glycogen phosphorylase and that the enzymes which 
regulate the
phosphorylase can be partially or completely restored to normal by treating the 
animals with insulin. The contribution of insulin to the regulation of hepatic glycogen 
metabolism has been demonstrated by many in vivo and in vitro studies which will be 
discussed in the next section.
1.3.4. The Effect of Insulin on Hepatic Glycogen Phosphorylase.
In the transition between feeding and periods of short fasting, the net hepatic 
glucose output is determined by the reciprocal activities of glycogen synthase (UDP 
glucose: glycogen 4-a- glucosyltransferase) and glycogen phosphorylase (1,4-a- D- 
glucan- orthophosphate a-glucosyltransferase). The regulation of the activation and 
inactivation of both of these enzymes is the object of various hormones, including 
insulin, glucagon and the catecholamines, and of glucose.
The first reported effect of insulin on glycogen phosphorylase was in 1967 
when Bishop and Larner demonstrated insulin acting to decrease hepatic glucose 
output. It acts to promote glycogen synthesis by a direct activation of glycogen 
synthase but at the same time inactivates glycogen phosphorylase (Figure3).
It has become widely accepted that insulin promotes the arrest of glycogenolysis 
and the deposition of glycogen in the liver (Stalmans, 1976). The role of insulin in the 
regulation of hepatic glycogen phosphorylase has been the subject of in vivo and in 
vitro studies.
Insulin
|  Insulin
q receptor
I
"Insulin secondary 
mediators"
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Glycogen
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Glucose
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Glucose 6-P 
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Figure 3. Insulin acts via secondary mediators of its action to inhibit 
glycogenlysis and promote glycogen synthesis in liver.
(adapted from Harris, R.A; 1992)
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1. 3. 4 .1 . In vivo studies
In vivo studies demonstrated a suppression of hepatic phosphorylase activity by 
insulin in the intact anaesthetised rat (Hers et al.y 1973). A partial inactivation of 
phosphorylase has also been observed in anaesthetised rats by Stalmans et al (1974) 
and also in the liver of the rhesus monkey with no significant change in hepatic cAMP 
concentrations (Cumow et al, 1975). Van derWerver and co-workers (1977) observed 
a similar inactivation in rabbit liver phosphorylase and phosphorylase kinase but not 
change in the hepatic concentration of cyclic AMP. The observation that insulin 
blocked the effect of hormones which elevated cAMP (Butcher, 1966) and reversed 
the processes which had already been stimulated in response to elevated cAMP 
(Robinson, et al 1971), led to the conclusion that insulin antagonism of these 
hormones is due to lowering of cAMP (Kono & Barham, 1973). However, Lamer and 
co-workers (1979) proposed that insulin caused direct inhibition of cAMP- dependent 
protein kinase by inhibiting dissociation of its regulatory and catalytic subunits. In the 
effect of insulin on the enzymes regulating glycogen phosphorylase, it was 
demonstrated that insulin caused inactivation of cAMP dependent protein kinase was 
in skeletal muscle in vivo (Villear-Palasi & Wengen 1967). This was confirmed and 
extended by Shen et al (1970) and by Walaas et al (1972) in rat diaphragm and by 
Miller and Lamer (1972, 1973) and by Gabbay and Lardy (1984, 1985, 1987) in 
adipocytes and hepatocytes and by Guinovart and co-workers (1987) in hepatocytes . 
Insulin - specific inhibition of the cAMP- dependent protein kinase was of great 
significance since it became the first bioassy for the putative insulin mediator.
Whereas the inactivation of phosphorylase is a constant feature after the 
administration of insulin, the activation of glycogen synthase occurs only occasionally. 
The sequential change in the activities of the two enzymes has been explained by the 
observation that glycogen phosphorylase a strongly inhibits glycogen synthase 
phosphatase (Hers, 1976; Stalmans, 1976). The authors suggested that the ability of 
insulin to activate hepatic glycogen synthase may be accounted for by this hormone's 
ability to inactivate phosphorylase protein phosphatase-1 (Alemany and Cohen, 1986).
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Insulin stimulates dephosphorylation of both glycogen synthase ( Roach, 1986) and 
phosphorylase (Zhange et al., 1989) in skeletal muscle, thereby promoting enzymatic 
changes which favour glycogen accumulation. The same observation came from Dent 
that the reverse reaction of dephosphorylation that inactivates the enzyme is catalysed 
by protein phosphatase 1 (PP1), an enzyme that is regulated in response to insulin 
(Dent et al., 1990). PP1 is the major enzyme that activates glycogen synthesis and also 
the principal enzyme that inactivates the enzymes of glycogenolysis (glycogen 
phosphorylase and phosphorylase kinase). In muscle, PP1 is regulated in response to 
insulin by phosphorylation of the glycogen binding subunit (Cohen, 1992). In the liver, 
the glycogen binding subunit does not appear to be controlled by phosphorylation / 
dephosphorylation events, and instead the dephosphorylation of glycogen synthase by 
hepatic PP1 is inhibited allosterically by low concentrations of phosphorylase a. This 
inhibition is mediated by the glycogen binding subunit (Alemany & Cohen, 1986; 
Bollen & Stalmans, 1992).
In hepatocytes, insulin has been shown to inhibit the stimulatory effects of 
phenylephrine on glycogenolysis that are considered to be mediated through a rise of 
cytoplasmic Ca^+ (Blackmore et al., 1979). This observation was confirmed by 
observations from Somogyi which demonstrated that insulin, the physiological 
counterpart to the gluconeogenic agonists, suppresses phenylepherine- induced 
Cai^+ oscillations (Somogyi e ta l, 1992).
1. 3. 4. 2. In vitro studies
In vitro studies clearly demonstrated that in hepatocyte cultures in serum free 
medium, when insulin and pro insulin are added as the sole hormones, a decrease in the 
activity of glycogen phosphorylase occurs (Beyner and Geelen, 1981; Hartmann et. al,
1987). Insulin reduces the glucagon - stimulated elevation of cAMP and activation of 
phosphorylase (Exton et al., 1971; Gabbay & Lardy., 1984). The glucagon-stimulated 
[14C]-glucose release was decreased by insulin and pro insulin (Hartmann et al., 1987).
24
The same observation was also reported by Deeg et al (1993) and this was associated 
with an appropriate reduction in phosphorylase activity, confirming the role of this 
enzyme as the primary regulatory site for glucose release from glycogen (Revers, 
1984; Probst e ta l, 1985; Hartmann et al., 1987).
The direct effect of insulin on either intracellular levels of cAMP or cAMP- 
dependent protein kinase activation of phosphorylase in hepatocytes (Corbin et al., 
1985) and inhibition of lipolysis in adipocytes (Beebe et al., 1984) in response to 
various cAMP analogs, both in the absence and presence of insulin have been studied. 
It was observed that insulin blocked the effects of only those analogues which were 
readily hydrolysed by the low Km PDE (phosphodiesterase). In both these systems, 
there was a good coordination between the inhibitory effects of insulin and the 
apparent Km of cAMP analogs for PDE, thus suggesting that insulin activates a low 
Km PDE both in adipocytes and hepatocytes (Beebe et al., 1984). Similar studies to 
those described above for adipocytes and hepatocytes were also done with isolated 
cardiomyocytes (Corbin et a l, 1986; Corbin et al., 1988) and concluded that, in 
contrast to adipocytes and hepatocytes, insulin regulates glycogen phosphorylase 
through a mechanism which is independent of PDE activation or the other components 
of the cAMP cascade (Sheorain, 1990).
An inositol phosphoglycan (the polar head group of a glycosyl 
phosphatidylinositol) has been considered as a putative mediator of insulin action. Fetal 
and adult hepatocytes were incubated with insulin or inositol phosphoglycan after 
which glycogen phosphorylase activity was determined. Inositol phosphoglycan 
mimicked the action of insulin on both forms of the enzyme from adult hepatocytes 
with regard to the inhibition of glycogen phosphorylase (Ruiz et. al, 1993).
When insulin was added to cultures of rat hepatocytes before arginine vasotocin 
(which increased tissue cAMP concentration and thus activate glycogen phosphorylase 
), it inhibited the actions of arginine vasotocin, which indicated that insulin activates 
cAMP phosphodiesterase and so reduces the concentration of cAMP (Janssens & 
Grigg, 1993).
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The mechanism by which insulin directly inhibits glycogen phosphorylase still 
remains unclear. Recent evidence strongly suggests that an intermediate step involves 
activation of protein phosphatase activity. Thus insulin has been shown to stimulate 
protein phosphatase 1 activity in rabbit skeletal muscle (Dent et a l, 1990), 3T3L1 cells 
(Chan et a l, 1988), 3T3D1 cells (Villa-Moruzzi, 1989), rat epitrochleris muscle 
(Zhang et al, 1989), as well as in rat fibroblasts tranfected with the human insulin 
receptor cDNA (Begum et a l , 1993).
Recently it was found that insulin blocked the effect of amylin in increasing the 
phosphorylation of phosphorylase in rat diaphragms (Lawrence & Zhang, 1994). As 
noted above, the significance of this data is that glycogen phosphorylase is insulin 
sensitive enzyme activity and can, thus, be used to measure insulin- like activity.
1.3.5 The Role of Glucose in Regulating Glycogen Phosphorylase 
Activity in Hepatocytes.
1. 3. 5. 1. In the normal animal
Glucose has been recognised to be an important regulator of hepatic glucose 
output. This observation extends from the initial studies of Soskin et al (1938) who 
noted that the level of glycemia controls, in part, net hepatic glucose uptake or output. 
In in vivo studies it was observed that when glucose was administered, there was a 
conversion of phosphorylase from the phospho- to dephospho- form (Stalmans & Hers 
et a l , 1973). Stalmans et al (1974) demonstrated that glucose first caused the 
inactivation of phosphorylase in the liver and then an activation of glycogen synthase. 
In in vitro studies, addition of glucose to the incubation medium reproduces these 
changes in the isolated perfused liver and in isolated hepatocytes (Hue et a l , 1975). 
vanderWerve et al (1977) demonstrated that when hepatocytes were incubated in the 
presence of high concentrations of glucose, glycogen phosphorylase was strongly 
inactivated with no change in the activity of phosphorylase kinase. The current
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explanation is that glucose binds to phosphorylase a and that the resulting complex is a 
superior substrate for phosphorylase phosphatase, hence the inactivation of 
phosphorylase and the inhibition of glycogenolysis (see Figure 4). Glucose- induced 
inactivation of glycogen phosphorylase, is explained by the enhanced exposure of the 
phosphorylase- glucose complex to the action of protein phosphatase (Stalmans, 1976).
The removal of phosphorylase a, which is a strong inhibitor of glycogen 
synthase phosphatase, allows the latter enzyme to convert synthase b into the a form, 
which in turn determines the rate of glycogen synthesis (Stalmans, 1976; Cumow and 
Lamer, 1979; Hers, 1981). There is, however, a difference between these observations 
and those of Carabaza et al (1992). The latter authors observed, when they examined 
the compounds; 2-deoxyglucose, 5-thioglucose, 6-deoxyglucose, 1,5-anhydroglucitol 
and 3-O-methylglucose in the same fashion as glucose, that glucose is the molecule 
that triggers the inactivation of phosphorylase but that this inactivation is not the signal 
for glycogen synthase activation. They also demonstrated that glucose 6-phosphate 
was the signal for glucose synthase activation. Ciudad et al (1986) have shown that, in 
rat hepatocytes, the intracellular concentration of glucose-6-phosphate shows a 
positive correlation with the activation of glycogen synthase, suggesting that glucose - 
6- phosphate rather than glucose could constitute the signal for glycogen synthase 
activation.
Glucose inactivates glycogen phosphorylase a by competitive inhibition with the 
substrate glucose-1-phosphate and by favouring the T-state conformation of the 
enzyme. The T-state conformation is a better substrate for the protein phosphatase 
than the R-state (Sprang et al., 1982, Maden et al., 1983) and thus increases the 
formation of glycogen phosphorylase b, relieves the inhibition of PP1 and promotes the 
activation of glycogen synthase. Thus, the balance between glycogen degradation and 
glycogen synthesis is controlled by phosphorylation and dephosphorylation events, and 
these events are modulated by other metabolites, notably glucose.
Since glucose is a physiological regulator of hepatic glycogen metabolism state 
(Witters & Avruch, 1978; Hartmann et a l , 1987). and weak inhibitors of glycogen
Glucose
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Figure 4 Overview of the mechanism responsible for glucose 
inhibition of glycogenolysis and stimulation of glycogen synthesis in 
the liver.
(adapted from Harris, R.A; 1992)
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phosphorylase are weakly hypoglycaemic (Kasinsky et al, 1978), Martin et al (1991) 
investigated a number of glucose analogue inhibitors of glycogen phosphorylase as 
potential drugs for treating diabetes. Several a and anhydroglucohetonic acid 
derivatives and 1-deoxy-l- thio- /?- D- glucose analogues have been synthesised and 
tested in a series of crystallographic and kinetic binding studies with glycogen 
phosphorylase. It has been postulated that, in the liver, glucose analogues with greater 
inhibition of glycogen phosphorylase may be more effective regulatory agents than 
glucose. Recently Watson and co-worker (1994) reported crystallographic and kinetic 
investigations of a number of a- and j3 glucoheptonamides and /3- thioglucose analogue 
inhibitors of T-state rabbit muscle glycogen phosphorylase based on guidelines 
previously established (Acharya e ta l, 1991; Martin et a l, 1991).
The idea that inhibitors of glycogen phosphorylase are useful hypoglycaemic 
agents is, thus, not novel but an establised line of enquiry.
1. 3. 5. 2. In the diabetic animal
The first reported effect of diabetes on hepatic glycogen metabolism was 
made in 1967 when Kreutner and Goldberg demonstrated that an increased glucose 
load activated hepatic glycogen synthase in normal rats but was ineffective in alloxan 
diabetic rats. Results from Miller and co-worker (1973) confirmed the direct effect of 
glucose to activate glycogen synthase in normal perfused liver and in addition 
demonstrated that glucose had no effect on hepatic synthase in perfused liver from 
alloxan diabetic rats. The lack of effect of glucose on glycogen synthase in diabetic 
liver was also associated with a lack of inactivation of glycogen phosphorylase and no 
increase in net incorporation of [^C]-glucose into glycogen. Although the studies 
demonstrated an impairment in synthase activation when liver from diabetic rats were 
perfused with lOmM glucose for 15 min, it was not determined whether synthase 
activation could occur with higher glucose concentrations or longer perfusion times.
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Miller (1977) extended his studies by using different concentrations of glucose (10- 
30mM) and perfusion times (5-90 min) and observed that whereas glucose infusion 
into livers from normal rats resulted in activation of glycogen synthase and inactivation 
of glycogen phosphorylase, glucose was completely ineffective as a modulator of 
synthase and phosphorylase in perfused liver from diabetic rats regardless of perfusion 
time or glucose concentration. Whitton and Hems (1975) reported a defect in glucose- 
induced glycogen synthesis in perfused livers of starved rats made diabetic with 
streptozotocin. These observations plus those of Miller (1977) that the defects in 
glucose modulation of synthase and phosphorylase in liver of diabetic rats can be 
corrected by treating the animals with insulin or glucose plus fructose, suggested that 
the enzymatic apparatus for glycogen synthesis was not totally lacking in diabetic rat 
liver. Ciudad et. al. (1988) also demonstrated that, with fructose and fructose plus 
glucose, the enzymatic system for glycogen synthesis can be operative in diabetic rat 
liver. Interestingly, they also demonstrated that inactivation of phosphorylase by 
glucose is not impaired in diabetic hepatocytes. although basal phosphorylase a activity 
is lower than in normal hepatocytes. Further evidence that glucose- induced 
inactivation of glycogen phosphorylase worked normally in diabetic rats was provided 
by Bollen et. al. (1983) when they studied the effects of glucose on phosphorylase and 
glycogen synthase in hepatocytes isolated from acutely (40h) and chronically (90h) 
alloxan diabetic rats. The latter study did not substantiate the hypothesis of Miller 
(1979), discussed above, but proposed that glucose did induce some inactivation of 
phosphorylase, and speculated that the degree of diabetes could be a possible 
explanation. The reason for this lack of agreement may be that in earlier work changes 
in phosphorylase activity were obscured by an assay that was not specific for the a form 
of phosphorylase.
There is, thus, evidence to suggest differences in response of glycogen 
phosphorylase to insulin and / or glucose between normal and diabetic rats. It is, 
therefore, necessary to investigate the effect of any potential insulin-mimetic drugs in 
both normal and diabetic animals.
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1.4. ASSAY OF GLYCOGEN PHOSPHORYLASE.
The cell disruption buffer was used at pH 6 .1 (rat liver phosphorylase b is less 
active at low pH) and contained NaF which is a necessary addition in the assay to 
prevent the conversion of phosphorylase a to b and as an inhibitor of phosphorylase 
phosphatase. To the assay mixture caffeine is added in order to render the assay 
specific for phosphorylase a and inhibit phosphorylase b. Under these conditions, the 
activity of phosphorylase b is about 1% of that of phosphorylase a (Stalmans & Hers, 
1975).
1.5. STEROID M ETABO LISM .
Endogenous and exogenous steroids are metabolised by complex enzyme 
systems which are both cytochrome P450- dependent and - independent. The 
cytochrome P450-dependent monooxygenases are probably the most important 
oxidase system being responsible for the oxidation of endogenous substrates such as 
fatty acids, steroids, vitamins and also for the biotransformation of xenobiotics that 
gain entry into the living organism. It achieves this broad specificity by existing as a 
number of structurally distinct families of proteins, each with a characteristic with a 
substrate specificity (Lu & West, 1980; Gonzalez, 1990). Numerous stereospecific 
steroid hydroxylations serve as sensitive fingerprints for characterising individual 
forms of cytochrome P450 (Arlotto et al, 1991); e.g testosterone 6/3-, 2a-, 7a- and 15 
a- hydroxylase and androstendione 16/3- hydroxylase are, respectively, specific 
indicators of rat cytochrome P450 3A, 2C11, 2A1, 2A2, and 2B1 expression 
(Waxman, 1991 a,b; Arlotto et al., 1991; Pampori & Shapiro, 1994). Identifying 
individual monohydroxylated products of commonly used P450 substrates, such as 
testosterone and androstenedione, is however complicated by the fact that each steroid
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can be metabolised to more than 20 hydroxylated derivatives (Waxman, 1991 a; 
Arlotto et a l, 1991).
In this study, we employed the well-characterised steroid substrate, androst- 4- 
ene- 3,17- dione, and the metabolic routes of this steroid are illustrated in Figure 5. 4- 
androstene- 3,17-dione is a convenient and easy substrate to use, being readily 
available in both an unlabelled and O ^Q - labelled form. Metabolism of this steroid 
substrate has been well characterised by Gustafsson and Stenberg (1974) and the 
metabolites can be readily separated in the laboratory by one- dimensional thin layer 
chromatography. Some instruments like high- performance liquid chromatography 
(HPLC) and gas chromatography mass spectrometry (GC-MS) are often used for the 
identification of steroid metabolites by comparison to authentic standards ( Waxman & 
Walsh , 1983; Waxman, 1991 a,b; Arlotto et al., 1991; Pampori & Shapiro, 1994). 
These methods are, however, expensive, time-consuming, and inappropriate for 
dealing with a large number of samples simultaneously. In contrast, silica gel thin-layer 
chromatography (TLC) is inexpensive and has advantages of rapidity of analysis 
combined with simplicity of the set-up needed for processing a large number of 
samples. Several laboratories have identified P450-dependent hydroxylases using TLC.
Cytochrome P450- dependent monooxygenases hydroxylate 4-androstene-3,17- 
dione predominantly at the 7a-, 6/3- and 16a- positions. The male specific cytochrome 
P4502C11 has been shown to catalyse 90% of the metabolism of 4-androstene- 3,17- 
dione at the 16a- position (Waxman, 1984) and the same isoenzyme also hydroxlates 
testosterone at the 16a- position (Morgan et al, 1985). 4-androstene-3,17- dione 
hydroxylation at the 6/3- position is thought to be catalysed by cytochrome P450 3A2 
(Waxman et al., 1985), although direct assessment of the activity of the purified 
enzyme has not yet been determined. Steroid hormone 6/3- hydroxylation is also 
catalysed by several other family 3A P450s, including rat CYPs 3A1 and 3A2 
(Waxman et al., 1985; Nagata et al., 1990). Cytochrome P4502A1 is responsible for 7 
a- hydroxylation of 4-androstent- 3,17-dione (Waxman et al., 1988) and it therefore
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appears in the uninduced liver, 4-androstene-3,17- dione metabolism is thus catalysed 
predominantly by three separate and selective cytochrome P450 isoenzymes.
5a- reductase is another 4- androstene- 3,17- dione metabolising enzyme but, 
although it is a membrane -bound microsomal enzyme, it does not contain cytochrome 
P450 as an integral component. It has been shown, however, that 5a- reductase exists 
as part of a multicomponent system which possesses many similarities to the 
cytochrome P450 monooxygenase system. The electron transport chain is composed of 
three enzymes; steroid 5a- reductase, coenzyme Q10 and NADPH- cytochrome 
oxidoreductase. In this system, coenzyme Q10 is a cytochrome and electrons are 
passed from NADPH to coenzyme Q10 by NADPH- cytochrome oxidoreductase and 
thence from coenzyme Q10 to the steroid substrate by 5a- reductase, where they 
participated in the reduction of the double bond (Figure 5) (Golf & Graf, 1978). The 
final enzymes involved in the metabolism of 4-androsten-3,17-dione are 17a//3 and 3a/ 
/3 hydroxysteroid dehydrogenase, both of which are microsomal, although details of 
their mode of action remain to be fully elucidated.
1.5.1. The Effect of Diabetes Mellitus and Insulin On Androst-4-Ene 
3,17-Dione Metabolism.
Diabetes mellitus is known to affect drug and steroid metabolism in the rat liver. 
In rats, it has been clearly demonstrated that chemically induced diabetes mellitus 
produce changes in hepatic microsomal drug metabolism (Reinke et al., 1978). Overall 
testosterone metabolism was significantly increased in streptozotocin diabetic liver 
microsomes, whereas it was markedly decreased in alloxan diabetes. Mixed function 
oxidase activity towards aminopyrine was similar affected. Glucuronidation reaction 
rates towards morphine, oetsrone and 4-nitrophenol were also markedly distinct in 
both models as well as after insulin treatment. This demonstrates that diabetogenic 
agents modify the isoenzymes of cytochrome P-450 differently and selectively reduce 
the synthesis of certain UDP-glucuronyltransferase forms (Vega e ta l , 1993).
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Reports from various studies have indicated that streptozotocin (STZ)- 
induced diabetes mellitus can influence hepatic steroid metabolism in the rat (Learning 
et al., 1982; Subbiah & Yunker, 1984). The effect of diabetes on hepatic steroid 
metabolism can be prevented or reversed by insulin administration to diabetic animals. 
An early report by Skett (1986), that STZ - induced diabetes mellitus exerts a substrate 
and sex -dependent effect on hepatic steroid metabolism in the rat which could be 
reversed by insulin treatment, indicated that insulin plays a role in the regulation of 
steroid metabolism.
The diabetic state resulted in an overall decrease in the rate of microsomal 
metabolism of androst- 4- ene- 3,17- dione, compared to control. A differential effect 
on metabolism was observed with individual metabolites. The hepatic microsomes 
from the diabetic rats exhibited an increase in the female- specific 7a- hydroxylase 
(Stenberg, 1976) and decreases in the male- specific 16a- hydroxylase, indicating a sex 
- differentiation in the effect of the diabetic state. All of these alteration were restored 
to normal when the diabetic rats were treated with insulin. This results is in good 
agreement with previous reported work relating to drug metabolism where the diabetic 
state produced a sex- dependent effect by interfering with androgen- dependent 
microsomal pathways in the rat (Kato & Gillette, 1965; Kato et al., 1971). Skett 
(1986) also reported the sex- dependent effect of diabetes mellitus on steroid 
metabolism in rat where alterations were only seen in the male and the effect was 
always to abolish the sex differences in steroid metabolism found in the intact animals. 
In the late 1980s work was concentrated on the alteration in cytochrome P-450 
isoenzyme complement in the diabetic state. Cytochrome P-450 RLM5 (P-4502C11) 
has been shown to be the major from of cytochrome P-450 responsible for 16a- 
hydroxylase activity (Waxman, 1984). Favreau and Schenkman (1987) showed that 
testosterone 16a- hydroxylase activity was decreased in diabetes and this was 
accompanied by a dramatic decrease in immunodetectable cytochrome P-450 RLM5. 
Insulin treatment resulted in partial restoration of the 16a- hydroxylase activity and the 
cytochrome P-450 RLM5 levels.
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Further evidence of alterations in specific constitutive cytochrome P-450 
isoenzymes in the diabetic state was provided by Schenkman (1990) when he found 
that in diabetes there is a change in the microsomal P450 composition, with form 2C11 
(cytochrome P-450 RLM5) declining and 2A1 increasing (cytochrome P-450 PCN2) 
which is responsible for 7a- hydroxylation of 4-androstene -3,17- dione. One might 
also expect to see a fall in levels of form 3A2, which normally is responsible for about 
95% of microsomal testosterone 6/3- hydroxylase activity and this form does actually 
decline (Thummel & Schenkman, 1990).
Shimojo et al (1993) studied changes in cytochrome P450 isozymes in both 
hepatic and renal microsomes of rats with diabetes caused by streptozotocin and they 
demonstrated that the amounts of cytochrome P450 2A1 and 3A2 increased in hepatic 
microsomes of diabetic rats and P450 2CII decreased. Treatment with insulin restored 
these to the levels in the control. The catalytic activities of testosterone 7a- and 6/3- 
hydrxylase were high in the hepatic microsomes of diabetic rats and testosterone 16a- 
hydroxylation activities were low. These changes were reversed by insulin treatment. 
The induction and suppression of cytochrome P450 isozymes in diabetic rat were 
consistent with the changes in the catalytic activities.
Phenformin and tolbutamide: have been shown to have a direct effect on the 
liver in elevating androst-4-ene 3,17-dione metabolism. They are able to mimic the 
effect of insulin in normal and diabetic rat hepatocytes with respect to androst -4-ene
3,17-dione metabolism. In normal rat hepatocytes phenformin has been demonstrated 
to cause a dose-dependent increase in all the enzyme activities. In diabetic hepatocytes 
phenformin still exhibited a dose-dependent increase in all the enzyme activities. In the 
same study using normal rat hepatocytes, insulin in the presence of phenformin 
selectively produced greater effect on the 6/3- hydroxylase, 17-OHSD and 5a- 
reductase activities than with insulin or phenformin alone. It seems that phenformin 
may inhibit the ability of insulin to increase the activity of 7a- and 16a-hydroxylases. 
In the diabetic hepatocytes, phenformin shows no potentiation of the effect of insulin 
on any of the enzymes except the 7a and 6/3 hydroxylase activity at physiological
34
insulin concentrations. In normal rat hepatocytes, tolbutamide elicited a dose- 
dependent increase in androst-4-ene-3,17-dione metabolism similar to that exhibited by 
phenformin. The mechanism by which tolbutamide increased all the steroid enzyme 
activities is unclear. In the diabetic rat, tolbutamide was still able to increase all the 
enzyme activities. In the normal rat, tolbutamide selectively inhibits the insulin- 
stimulated 5a-reductase activity. With regard to the other enzymes, increasing insulin 
concentrations potentiated the effect of tolbutamide when compared to tolbutamide 
alone. Similar to phenformin, tolbutamide reduces the responsiveness of insulin- 
stimulated steroid enzyme activities but the mechanism responsible for this is yet to be 
determined (Hussin, 1988).
The insulin - mimetic effects of vanadate in preventing the increase in the level 
and activity of several P450 proteins in streptozotocin- diabetic rats has also been 
examined. The diabetic state caused by the pancreatic beta cell toxin streptozotocin 
results, like the diabetes of genetic origin, in major alterations in expression of the P- 
450 isozymes (Verrecchia & Guaitani, 1993).
1.5.2. The Effect of Insulin on Androst 4-ene 3,17 dione Metabolism 
in Normal Male Rat Hepatocytes.
The role of insulin in rat hepatic drug and steroid metabolism is known indirectly 
from the effect of diabetes mellitus on both the above liver parameters since insulin is 
the principal hormone altered in the diabetic state.
In vivo parenchymal liver cells however, are exposed to many different hormonal 
stimuli and this makes it difficult to assign effects seen to particular hormones. For 
instance when animals are made diabetic by chemical treatment, growth hormone and 
glucagon serum levels are also affected and the effects seen on microsomal metabolism 
could be due to an effect of these hormones. The use of isolated liver cells would be 
expected to be an ideal solution to this problem (Hussin & Skett, 1987; Liddle et al., 
1992).
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Hussin (1988) observed that insulin increased all of the enzyme activities at 
physiological concentrations of the hormone in isolated rat hepatocytes. This is in 
contrast to the selective effect of insulin reported by Skett (1986) in the intact rat. In 
relation to the effect of insulin on steroid metabolism, in hepatocytes, the overall 
inhibition of the cyclic AMP-dependent protein kinase and the adenylate cyclase 
activity (Gabbay & lardy, 1987; Saltiel, 1987; Villalba et a l , 1988) and stimulation of 
the cyclic AMP - dependent phosphodiesterase by this inositol phosphate-glycan 
(Kiechle & Jarett, 1980; Saltiel et a l, 1986) would theoretically decrease the 
phosphorylation of cytochrome P450 to its inactive cytochrome P420 (Pyerin et al, 
1987) therefore, would explain the increased amount of substrate (i.e. androst-4-ene-
3,17-dione) being metabolized.
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PHASE 1 METABOLISM OF ANDR0ST-4-ENE-3.17-D10NE
16a -hydroxylase 
(CYP2C11)
androst-4-ene-3,17-dione
17a $  ) -hydroxysteroid 
dehydrogenase 4-androstene-16a-ol- 
3,17-dione5a -ireductase
OH - hydroxylase 
(CYP3A2)
testosterone
(epitestosterone)
OH
4-androstene-6|3-ol-
3,17-dione
5a-androstane-3,17-dione 7a -hydroxylase 
(CYP2A1)
3oi(fi) -hydroxysteroid 
dehydrogenase
’""OH
4-androstene-7a-ol-
3,17-dioneOH1
5a-androstane-3a(p) -ol -17-dione
Figure 5. The phase 1 metabolism of androst -4-ene- 3,17-dione in the
liver. Specific isoenzymes thought to produce the various metabolites are
given in the capital italic
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1.6. LIVER CELL PREPARATION
The liver occupies a central position in body metabolism. Its size, softness, and 
relative homogeneity have made it a favourite organ for biochemical investigation. For 
the study of intact liver functions under controlled conditions the isolated, perfused rat 
liver has been extensively used. This experimental system is excellent for many 
purposes, but has several major shortcomings: (1) the liver as an organ is not 
completely homogeneous, containing up to 40% nonparenchymal cells (Daoust, 1958):
(2) it is difficult to obtain many identical samples from one liver, and impossible to test 
different experimental treatments simultaneously; and (3) the viability of an isolated 
liver can be maintained only for a limited period of time (8-10 hours ). Numerous 
attempts have been made to overcome these problems by the isolation and purification 
of intact parenchymal liver cells. The early mechanical and chemical methods for liver 
cell preparation were relatively successful in converting liver tissue to a suspension of 
isolated cells, but unfortunately nearly all such cells were damaged. Isolated 
hepatocytes are now the most widely employed experimental model to investigate 
hepatic function ( 1987; Gabbay & Lardy, 1987)
1.6.1 M ethods
The cell preparation methods used by most laboratories concerned with 
hepatocyte culture have been based on the two-step collagenase perfusion procedure 
of Seglen (1976), although variations of the one-step procedure have also been used 
successfully (Flaim et al\ 1985). Almost every laboratory has its own modification of 
these methods and undoubtedly most of these give satisfactory preparations. In 
general, the aims should be to obtain the maximum yield of hepatocytes whilst 
minimising biochemical changes in the cells during isolation, minimizing contamination 
with non-hepatocytes and maximising the proportion of cells capable of attaching and
38
surviving in culture. In the final preparation this must be carried out under sterile 
conditions. There are only a few publication which discuss different collagenase 
perfusion isolation procedures in relation to the subsequent behaviour of cells in 
culture (Williams et al., 1977; Kreamer et a l, 1986).
1.6.2. The Role of Collagenase.
The introduction of collagenase as a liver- dispersing enzyme by Howard et al., 
(1967) greatly facilitated the preparation of intact cells, and when Berry and Friend 
(1969) introduced the use of physiological liver perfusion to make the tissue uniformly 
accessible to the action of collagenase, it became possible to prepare intact liver cells in 
high yield and convert the whole liver to a suspension of intact cells, i.e. both the initial 
yield and the cellular viability approach 100% under ideal circumstances (Seglen,
1972). The collagenase perfusion method is vastly superior to all previous techniques, 
and is likely to remain the ultimate method for the preparation of rat liver cell.
1.6.3. The Role of Ca2+*
Ca2+ has been found to play a dual role in liver dispersion. The inclusion of 
Ca2+ during perfusion with collagenase enhances enzymatic activity and accelerates 
dispersion. For the enzymatic dispersion to be effective, Ca2+ must be removed from 
the tissue by a pre perfusion, and then added again upon perfusion with collagenase 
(Seglen, 1972). The removal of Ca2+ can be accomplished by perfusion with EGTA or 
EDTA (Seglen, 1972) or, provided the perfusion is effective, simply by pre perfusion 
with a Ca2+ free buffer, thus combining the washout of blood and Ca2+ (Seglen,
1973). Since the effect of Ca2+ removal is irreversible, it must be due to some 
conformational change in the intercellular matrix which favours dispersion. Modjanova 
and Malenkov (1973) have described a Ca2+-dependent hepatic adhesion factor which
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is washed out of the mouse liver upon perfusion with a Ca2+-free medium. It would 
therefore seem likely that the dispersion -promoting effect of preliminary Ca2+ removal 
is due to the detachment and washout of this adhesion factor, in particular since the 
divalent catin specificity is the same in both cases.
1.6.4. The Use of a Two- Step Procedure.
Since the introduction of the two-step procedure for collagenase perfusion, 
several workers have adopted the practice of including Ca2+ along with collagenase 
(Berg & Boman, 1973; Bamabei et al., 1974; Baur et al., 1975; Christoffersen & Berg, 
1974; Edwards & Elliott, 1974; Nilsson et al, 1974; von Bahr et al., 1974; Williams & 
Gunn, 1974). Cells isolated by the two-step technique have been reported to retain K+ 
better, and to have a higher K+ uptake capacity, than cells prepared without Ca2+ 
addition (Bamabei et a l, 1974); this has also been shown with cells prepared from 
liver slices incubated with collagenase in the presence of Ca2+ (Howard et al, 1973). 
Cells prepared with Ca2+ activated collagenase furthermore have, on the average, a 
higher membrane potential than cells prepared without Ca2+ (Baur et al., 1975).
The two-step approach was introduced by Seglen (1976) as a consequence of his 
studies of the effects of collagenase on isolated perfused liver (Seglen, 1972). It was 
observed that the liver swelled more rapidly on addition of collagenase and 5mM Ca2+, 
than when collagenase alone was added, provided that there had been a preliminary 
perfusion with a medium when was very low in Ca2+- Seglen argued that since 
collagenase activity is dependent on Ca2+, and since a virtual absence of Ca2+ is a 
prerequisite for cell separation, it was good practice to first perfuse the liver with a 
medium free of Ca2+ and subsequently perfuse with a Ca2+ -rich medium containing 
collagenase.
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1.6.5. The Level of Glycogen.
Levels of glycogen depend very much on the nutritional state of the donor 
animal. The level is highest in fed animals and is very low in the cells of rats fasted for 
18 h . The levels in isolated cells correspond to those in the intact organ. The highest 
cell content of glycogen is observed in cells obtained from meal-fed animals (Katz et. 
al; 1975). However, to retain cell glycogen during the preparative procedures, it is 
necessary to ensure a level of at least 15mM glucose in the perfusion and washing 
media. If, in the subsequent experimental study, the cells are to be incubated in the high 
concentration glucose, then- glucose must be added at the last washing solution. Under 
these circumstances, it is particularly important to ensure that a temperature close to 0- 
4°C is maintained during the washing procedures or else considerable glycogen 
breakdown will occur at this stage. The standard temperature for incubation of rat 
hepatocytes is 37°C. Temperature only a few degrees higher will rapidly cause cell 
damage (Bowers et al., 1981).
1.6.6. The Incubation Time with Test Drug.
The observation from our laboratory on the incubation time of the biguanides, 
guanamines and insulin on the activity of glycogen phosphorylase suggests that the 
time course of activation and inactivation is very rapid, occurring within minutes if not 
seconds. The administration of insulin to rabbits caused a rapid inactivation of 
phosphorylase which, within 3 minutes, lost about 60% of its activity. Phosphorylase 
kinase was concomitantly inactivated. In contrast, insulin did not change the hepatic 
concentration of cyclic AMP (vanderWerve et. al, 1977). Van derWerve and co­
workers also demonstrated that the addition of glucagon to a suspension of isolated
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hepatocytes activated phosphorylase kinase and phosphorylase. This effect was at its 
maximum within 2 minutes of the addition of the hormone and then decreased 
progressively during the following 30 minutes. During the same experiments, the dose- 
dependence of glucagon, was measured 2 minutes after the addition of the hormone 
and its antagonism by insulin.
A phospho-oligosaccharide which is the polar head group of a novel insulin- 
sensitive glycophospholipid has been implicated in insulin action. Alvarez and 
coworkers (1987) have investigated the insulin-like effects of this phospho- 
oligosaccharide on glycogen phosphorylase a and pyruvate kinase activities in 
hepatocytes incubated in the presence of glucagon. Both insulin and phosphos- 
oligosaccharide antagonise the action of glucagon after 5 minutes to 75% of original 
glycogen phosphorylase activity. Glucose caused an important inactivation of liver 
phosphorylase within 1-2 minutes (Stalmans et al., 1974). Further studies of isolated 
rat hepatocytes have show that this lag is the time required for the inactivation of 
glycogen phosphorylase by different concentrations of glucose with or without K+ ions 
in the external medium (Hue et al., 1975; Witter & Avruch, 1978). 2-Deoxyglucose 
and 5-thioglucose, in the same fashion as glucose, caused the inactivation of rat 
hepatocyte glycogen phosphorylase. The change was preceded by a short lag (2-5 
minutes). In hepatocytes isolated from fed rats, sulfonylureas (tolbutamide and 
glipizide) in the incubation medium caused significant activation of glycogen 
phosphorylase. The greatest effects were observed two minutes after sulfonylurea 
addition (Mojena et al., 1989; Alarcon et al., 1993). Phenacyl imidazolium compounds 
have been shown previously to lower blood glucose levels without causing lactic 
acidemia in fed dogs, fed rats, and obese- diabetic insulin resistant mice and rats but 
not in starved or insulin- dependent streptozoctocin diabetic rats (Dominianni & Yen, 
1986). In studies conducted with isolated hepatocytes, phenacylimidazolium activation 
of glycogen synthase and inactivation of glycogen phosphorylase, the time course was 
in the order of 5 min (Harris et al., 1989). The glucagon stimulated activation of 
glycogen phosphorylase in rat hepatocytes occured within 4 min (Deeg, et. al, 1993).
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The literature thus, agrees with our proposed timing of 5 minutes as the pre 
incubation time for effects on glycogen phosphorylase.
1.7. AIM S OF THE PROJECT.
1. To study the effect of synthesized biguanides and guanamines on the activity of 
glycogen phosphorylase in normal rat hepatocytes as a measure of their insulin - like 
action. The biguanides such as phenyl-, phenylethyl-, benzyl were cyclized into 
triazines to see the effect of cyclization on the activity of the compounds and to 
determine the effect of changing substituents in various positions.
2. To determine the structure - activity relationship of compounds synthesized for 
their insulin-like action.
3. To investigate the effect of guanamines (cyclised biguanides) on the activity of 
glycogen phosphorylase in cultured hepatocytes from STZ diabetic rats.
4 . To see the effect of guanamines ( cyclised biguanides) on the activity of glycogen 
phosphorylase in the cells isolated from insulin treated diabetic rats.
5. To determine the effect of guanamines (cyclised biguanides) on the activity of 
glycogen phosphorylase from normal rats in the presence of different concentrations of 
glucose.
6 . To determine the effect of guanamines (cyclised biguanides) on the activity of 
glycogen phosphorylase in hepatocytes from STZ diabetic rats in different glucose 
concentration.
7. To determine the effect of guanamines (cyclised biguanides) on androst -4 -  ene-
3,17- dione metabolism in normal rat hepatocytes.
The overall aim was to see if guanamines had any direct insulin-like actions on 
hepatocytes which would suggest that they may be useful.
MATERIALS AND METHODS
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MATERIALS AND METHODS
The methods can be separated into three main sections
(1) The synthesis of benzylbiguanide, N phenylguanamine (1), N
phenethylguanamine (2) and N benzylguanamine (3).
(2) The assay of the effect of test compounds on glycogen phosphorylase a in
isolated rat hepatocytes.
(3) The assay of the effect of test compounds on the metabolism of androst 4-ene-
3,17-dione in isolated rat hepatocytes.
The methods used in each of these three sections is summarised below.
2.1 CHEMISTRY
2.1.1 Synthesis of Benzylbiguanide and Guanamines
The work to be discussed in this report is concerned with the synthetic 
pathways to some triazines, to be tested as potential antidiabetics, namely N 
phenylguanamine (1), N phenethylguanamine (2) and N benzylguanamine (3).
1
N
CH2— CH2— NH—I  
J  N2
NH2
3
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Phenylguanam ine (1)
Phenylguanamine (1) was synthesized by the method of Overberger et al 
(1954). Phenylbiguanide (4) (Aldrich Chemical Company Inc.) was dissolved in 
methanol and ethyl formate added to give the product (1) in 69% yield. Microanalysis 
(C, H and N) of the product gave values in agreement with theory. The melting point 
agreed with the literature value (see Overberger et al 1954). The synthetic method is 
shown in Scheme I.
NH NH O
II II II Me OH
NH— C —  NH— C — NH2 + E t O  — C — H ----------- ►
Scheme I
N ^ 'N
N1, " n ^ " NH2 
1
Phenylguanamine(l)hydrochIoride.
Phenylguanamine hydrochloride was prepared from phenylguanamine (1) by 
addition of methanol:conc hydrochloric acid (5:1) to pH 2.5, according to published 
procedures (Shapiro et al 1957).The solvents were removed by distillation and the 
residue was dissolved in water .Addition of sodium chloride with stirring precipitated 
the hydrochloride of phenylguanamine.
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Phenethylguanam ine (2)
Phenethylguanamine (2) was prepared from phenethylbiguanide hydrochloride 
(5) (Sigma Chemical Co.) and ethyl formate in the presence of sodium methoxide as 
shown in Scheme II.
Phenethylguanamine (2) hydrochloride
Phenethylguanamine hydrochloride was prepared from phenethylguanamine (2) 
by addition of methanol: concentrated hydrochloric acid (1:1) to pH 2.5, according to 
the published procedure (Shapiro et al 1957). The solvents were removed by
stirring precipitated the hydrochloride of the phenethylguanamine (2). The melting 
point was in agreement with the literature value (Shapiro et al 1957), also the 
microanalytical data agreed with theoretical values.
Benzylbiguanide hydrochloride (8)
Benzylamine hydrochloride was prepared from benzylamine and methanolic 
hydrogen chloride as described in the experimental section.
+
NH NH2CI 0
+ Na OMe Me OH
nh2
Scheme II
distillation and the residue was dissolved in water. Addition of sodium chloride without
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Benzylbiguanide hydrochloride (8) was prepared (Erienmyer et al 1899) (Scheme III) 
by melting benzylamine hydrochloride(6) and dicyandiamide(7) together.
Benzyl guanamine(3)hydrochloride.
Benzyl guanamine (3) hydrochloride was prepared (Shapiro et al 1957) by 
treating the benzylbiguanide (8) with methanol containing sodium methoxide and 
methyl formate was added. The product was converted to the hydrochloride as 
described in the experimental section. The synthetic method is shown in Scheme IV
NH
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2.1.2 Experimental Section
1H NMR spectra were recorded on either a Perkin Elmer 90 MHz or a Bruker 
200 MHz spectrometer. Spectra were recorded with d6DMSO [(CD3)2SO] as the 
solvent and Me4Si as the internal standared. lH  and 13 C NMR spectra were recorded 
by Dr. D. Rocroft and Mr. J. Gall with a Bruker AM 200 Sy and WP 200 Sy 
spectrometer. Combustion analysis for C, H and N were performed by Mr. Kim Wilson 
using a Carlo Erba Analyser, Mod. 1106. Melting points were taken on a Kofler hot 
stage apparatus.
2-Amino-4-PhenyIamino-l,3,5-Triazine (Phenylguanamine) (1)
Phenylbiguanide (4) (Aldrich Chemical Company) (1.77 g, 0.01 mol) was 
dissolved in methanol (7.5 ml) and ethyl formate (0.74 g, 0.01 mol) was added at room 
temperature. The product began to precipitate in 5 min and a thick slurry was formed 
within 1 h. The solid was filtered off after being left standing overnight and was 
washed with water to give phenylguanamine (1) (1.31 g, 72%). The product 
crystalised from dioxane as small white needles, m.p. 235-236°C (lit.m.p. 235-236 °C). 
The product Rf 0.82 was shown to be pure by TLC on silica plates developed with 
ethanol, water, formic acid (5 :1 :1). Analytical TLC plates were viewed under an ultra 
violet lamp (254 nm) or were developed by iodine vapour. Phenylguanamine (1) 
(Found C, 57.7; H, 4.7; N, 37.45 Calc for C9H9N5: C,57.7; H,4.8; N,37.4%) 
_H(,200 MHz) 6.98 (t, J. 7.3 Hz, P-phenyl-H), 7.02 (brs,NH2,exch with D20), 7.28 
(2H,t,J 8.3Hz. m. phenyl-H), 7.77 (2H, d. J .7.6 Hz O-phenyl-H), 8.20 (S, 6-H) and 
9.51 (S, Ph NH, exch with D20),_c (50.3 MHz) 119.9 (O-Ph-C), 122.0 (P. Ph. C) 
128 (m-ph-c) and 139.6 (ipso-Ph-C), 163.7 (C-2 or -4) 165.9 (C-6) and 166.2 (C-4 or 
-2).
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2 - Amino - 4 - Phenylamino -1, 3, 5- Triazine (phenylguanamine) (1) 
hydrochloride
Phenylguanamine (2.98g) was converted into the hydrochloride by dissolving in 
methanol : hydrochloride (6:1) to pH 2.5. The solvents were removed by distillation 
and the residue (2.6397g) dissolved in 39.5ml of water. Addition of sodium chloride 
(7.9g) with stirring precipitated the hydrochloride of phenylguanamine.This was 
filtered off and washed with saturated sodium chloride. The solid was dried at 70°C in 
a dryer pistol under vacuum, recrystallized from isopropyl alcohol by dissoliving in a 
minimum of solvent (20), with heating under reflux. It was kept at room temperature 
overnight, filtered off, washed with isopropyl alcohol and, dried at 70°C under 
vacuum. Yield (1.36g,60.8%), m.p. 200-201°C, (Found:C, 48.20; H, 4.48; N,31.39; 
Cl, 15.83 Calc for C9H10N5C1; C, 48.32; H, 4.47; N, 31.32; Cl, 15.88). _H (200 
MHz) 6 (brs, NH2, exch with D20), 7.15 (t. J7.3Hz, p-phenyl-H), 7.35 (2h, t.J7.8Hz. 
m.phenyl-H), 7.7 (2H, d.J.7.7Hz. o-phenyl-H), 8.45 (s.phNH, exch with D20), 8.55 
(s.6-H) and 8.9 (brs,NH,exch.with.D20), _C (50.3MHz), 122 (p.ph.c), 125 (o-ph-c), 
129 (m,ipso-ph-c,c-6), 137.4 (c-2or-4), 157.5 (c-4or-2)
2- Amino- 4 - Phenethylamino - 1,3,5 - Triazine (Phenethylguanamine) (2)
Phenethylbiguanide hydrochloride (5) (2.42g, O.Olmol) (Sigma Chemical Co.) 
was dissolved in methanol (10.3 ml). Ethyl formate (0.74g, O.Olmol) and sodium 
methoxide (0.54g, O.Olmol) were added at room temperature. The product began to 
precipitate immediately and a thick slurry was formed. The solid was filtered off after 
being left standing overnight and was washed with water to give phenethylguanamine
(2) (1.32g, 61.6%). Phenethylguanamine (2) crystallised from dioxane as rectangular 
plates, m. p. 159-160°C (Lit. m.p. 159-161°C). (Found: C, 61.13; H, 6.07; N, 32.36 
Calc for C11H13N5: C, 61.39; H, 6.05; N, 32.56%). _H (200 MHz) 2.81 (2H, t, J 
7.9Hz, CH2), 3.48 (2H, t, J 7.9Hz, CFI2), 6.71 (br S, NH2, exch with D20), 6.85 (br
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S, Ph NH, exch with D20) 7.26 (5H, m. ph) and 7.92 (S, 6-H); _ c  (50.3 MHz) 34.7 
CH2, 41.5 CH2, 126, 128, 129 and 139.5 (ph), 164.5 (C-4), 165 (C-6) and 166 (C-2).
2-Amino-4-PhenethyIamino-l,3,Triazine(PhenethyIguanamine)(2)
Hydrochloride
A mixture of (6.32g, 0.04mole) phenethylamine hydrochloride and (3.36g, 
0.04mol) of dicyandiamide was ground until it became fine powder then it was heated 
and stirred in an oil-bath maintained at 148-150°C. The reaction mixture, upon 
reaching 130°C, was completely fluid and was maintained with continued stirring for 
lhr. The reaction mixture was then mixed with a solution of 30.6ml of methanol 
containing (2.2g, 0.94mol) of sodium methoxide, (1.7g, 0.03mol) of methyl formate 
was added and the reaction mixture was allowed to stand for 24hr. The mixture was 
treated with 1:1 methanol-hydrochloric acid (cone) 26ml at pH 2.5. The solvents were 
removed by distillation under vacuum (Rota vapour), the residue (7.8g) was dissolved 
in water (18.3ml). Addition of aqueous sodium chloride (20g/100ml) to the reaction 
mixture with stirring quickly precipitated the hydrochloride of phenylethylguanamine. 
The mixture was kept overnight at room temperture then it was filtered off and washed 
with saturated sodium chloride. The solid was dried at 70°C in a vacuum and 
recrystallised from isopropyl alcohol by dissolving in the solvent (11.4ml) with heating 
under reflux. It was kept at room temperture overnight, filtered off and then washed 
with isopropyl alcohol, dried at 70°C under vacuum. Yield (4.24g, 42%), phenethyl 
guanamine hydrochloride recrystallized from isopropyl alcohol as, plates, m.p 185- 
186°C (Lit 185-186°C, Shapiro e t  a l  1957). (Found: C, 52.24; H, 5.69; N, 27.92; 
Cl, 14.16 Calc for C11H14N5C1; C,52.48; H,5.56; N; 27.84; Cl, 14.11) _H (200 
MHz) 2.89 (2H, t, J7.4Hz, phCH2), 3.56 (2H, t, J 7.5Hz, NHCH2.exch with D20), 
7.3(5H, m, ph), 8.1 (brs, NH2 exch with D20) 8.4 (S, 6-H), 9.18 (1H, t, J10.35, NH 
exch with D20), _C (50.3MHz), 34 (C-4), 42 (C-4), 126.5, 129.5, 130, 130 and 139 
(ph), 156 (C-6), 157 (C-4) 160 (C2).
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Benzylam ine H ydrochloride
Methanol (4.5ml) and cone hydrochloric acid (4.5ml) were added gradually to 
benzylamine (5.35g, 0.05mol) until the pH was 2.5. The mixture was kept overnight 
and the methanol was then removed by vacuum distillation. The residue of the 
benzylamine hydrochloride (6.39g) was dried in a drying pistol at 40°C under vacuum 
for 2h. This salt had a m.p of 257-259°C (Lit. 255-257°C) it was seen under the 
microscope to be crystalline.
Benzylbiguanide Hydrochloride(6)
A mixture of (5.7g, 0.04mol) of benzylamine hydrochloride and (3.4g, 0.04mol) 
of dicyandiamide was ground until it became powder then it was heated and stirred in 
an oil-bath at 148°-150°C. The reaction mixture upon, reaching 130°C, was 
completely fluid, then it quickly solidified to light yellow crystals, it was removed and 
cooled. 3ml of hot water was added and left to stand overnight. The product was 
filtered off and washed with 3 ml of water then it was recrystalize in 3ml of water under 
reflux for 10 min . The product was removed by filtration after standing overnight and 
and dried at 70°C under vacuum. Yield (3.97g, 43.5%), m.p 197°-198° (lit m.p 
197°C). (Found: C, 47.36; H, 6.42; N, 30.61; Cl, 15.66 Calc for C9H14N5C1; C, 
47.26; H, 6.56; N, 30.63; Cl, 15.53). _H (200 MHz) 4.4 (2H, d, J 5.97Hz; CH2NH 
exch with D20) 7.05 (s, NH, NH, 2NH2 exch with D20), 7.35 (5H, m.ph), 7.98 (1H, 
t, J 5.97Hz, NH exch with D20), _C (50.3 MHz), 44 (c-4), 127, 127.5, 127.5, 129, 
129, 139 (ph), 158.5 (C2), 160.5 (c4)
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Benzyl Guanam ine (3)HydrochIoride
A mixture of (5.7g, 0.04mole) of benzylamine hydrochloride and (3.4g, 
0.04mole) of dicyandiamide was ground until it became powder then it was heated and 
stirred in an oil-bath at 148°-150°C. The reaction mixture upon reaching 130°C, was 
completely fluid and immediately solidified as a light yellow gummy solid when it was 
removed and cooled. The cooled reaction mixture was then treated with a solution of 
30ml of methanol containing (2.2g, 0.04mole) of sodium methoxide and (1.7g, 
0.03mole) of methyl formate was added .The mixture was treated with 1:1 methanol- 
hydrochloric acid to pH2.5 (19.5ml). The solvents were removed by distillation and the 
residue (7.2g) dissolved in 120ml water. Addition of sodium chloride (20g/100ml of 
reaction mixture) precipitated the hydrochloride. The product was filtered off, washed 
with saturated sodium chloride, dried and recrystalized from isopropyl alcohol. Dried 
at 70°C under vacuum. Yield (4.24g, 44.6%), m.p 200°-201°C (lit m.p 200°-202°C) 
(Found: C, 50.15; H,5.25; N, 29.20; Cl, 14.81 Calc for C11H14N5C1: C, 50.31; H, 
5.45; N, 29.35; Cl, 14.88), _H (200 MHz) 4.55 (2H, d, J 6.18Hz CH2NH exch with 
D20), 7.25 (5H.m.ph), 8.1 (brs, NH2 exch with D20), 8.4 (S, 6-H), 9.5 (1H, t, J. 
16.7Hz, NH exch with D20), _C (50.3 MHz), 43.5 (C-4), 3 (127.5), 2 (128.5), 137 
(ph), 165 (C-6), 158 (C-4), 161 (C-2).
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2.2. PHARMACOLOGICAL METHODS 
2.2.1 EXPERIMENTAL ANIMALS
Mature male rats of the Wistar strain, bred in the Department, were used 
throughout the study. The animals were allowed free access to water and food (CRM 
Nuts, Special Diets Services, Essex) and housed in light and temperature controlled 
condition (19+1°C, lights on 7:00-19.00 ) and were used when they were 10-12 
weeks old at the begining of the experiment. When comparing groups, age-matched 
animals were used and each group consisted of at least seven animals. The weights of 
individual rats ranged from 250-300g and the variation within each group was ±25g.
In experiments where diabetes mellitus was induced by streptozotocin (STZ), the rats 
were weighed before treatment and then 7-10 days post-treatment prior to sacrifice.
2.2.1.1 Induction of Diabetes by Streptozotocin
Diabetes mellitus could be induced in experimental animals by administering to 
the animals streptozotocin (STZ) . STZ is transported into pancreatic /5-cells through 
glucose transporters in the cell membranes and attacks mitochondria. Mitochondrial 
ATP generation is inhibited and the resulting high concentration of intacellular ADP 
causes its degradation providing hypoxanthine, a substrate of xanthine oxidase (XOD) 
whose activity is intrinsically very high in the /3-cell. The, XOD-catalyzed reaction 
produces uric acid and oxygen radicals, but /5-cells are inefficient in scavenging these 
radicals because of their extremely low activity of superoxide dismutase. On the other 
hand, STZ directly activates XOD and enhances oxygen radical generation. 
Consequently, the pancreatic /5-cells are subjected to a high concentration of oxygen 
radicals when exposed to STZ (Kawad, 1992).
The intravenous injection of a single high dose of STZ exerts direct toxicity on 
the /5-cell, which results in necrosis within 48-72h and overt permanent hyperglycaemia 
(Wang et al, 1993). Since STZ is unstable in solution , it was dissolved in distilled
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water immediately before use and then injected intravenously (60mg/kg) into the tail 
vein of the rat under halothane/nitrous oxide anaesthesia. The tail was rubbed to 
expose the vein before injecting the drug. Control animals were treated identically 
except that they were injected with vehicle only. The animals were left for 7-10 days in 
conventional animal cages and the weight of the animal was taken regularly during this 
period. The diabetic state was assessed by loss of weight (15%) and measurement of 
blood glucose as described below.
2.2.I.2. Insulin Treatment of STZ-Diabetic Rats
Insulin (from porcine pancreas, 24 I.U per mg) replacement, 4-8 I.U./lOOg 
body weight, subcutaneously was begun 48-72h after STZ injection as described 
above, a time when the diabetic state was well established. Daily determination of 
blood glucose was performed by the glucose oxidase method as described below and 
the dose of insulin adjusted as necessary to maintain blood glucose levels at or near to 
normal.
2.2.2 ISOLATION OF HEPATOCYTES
Hepatocytes were isolated by a modification of the two-step collagenase perfusion 
technique of Seglen (1976). The solutions were saturated for about 10 minutes with a 
mixture of oxygen and carbon dioxide (95:5 v/v) before the perfusion to meet the 
oxygen demands of the metabolically active parenchymal cells. This is important, since 
the avoidance of hypoxia has been shown to be necessary in the preparation of 
hormone-sensitive cells (Zahlten & Stratman, 1974). Other precautions taken were 
good temperature control and the use of the shortest exposure of the liver to 
collagenase (Berry et al, 1991). All buffers used in the isolation procedure had been 
previously heated in a water-bath set at 37°C. The temperature of the perfusate 
reaching the liver was maintained at 37°C for the duration of the perfusion process by
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storing the buffer in an insulated reservoir set at 45°C before pumping it into the liver. 
It should also be noted that any air bubbles in the system were eliminated using a 
simple bubble trap. While the rat was under anaesthesia (4% halothane; 800ml/min 
oxgyen : 800ml/min nitrous oxide using a Mini Boyle Anaesthetic Machine), (Figure 6) 
the abdomen was cut open and the portal vein was freed of any fat. 1000U of heparin 
was injected via the tail vein as an anticoagulant prior to commencing the perfusion.
A cannula (size 20 GA x 32mm length) was inserted into the hepatic portal vein at a 
position just before it branches into the liver and held in place with a piece of surgical 
string (1001/40). The needle was removed from the cannula to allow blood to flow 
back up the cannula, the inferior vena cava was cut and the tube from the pump was 
attached to the cannula. The thoracic cavity, via the diaphragm, was opened and the 
superior vena cava cut. Perfusion (using a Watson Marlow 501U perfusion pump) was 
commenced with 500ml of Ca2+-free Krebs-Henseleit buffer (see Composition of 
Buffers below ) at the rate of 35-40ml/min. The Ca2+-free conditions are necessary for 
the disruption of the tight junctions, which intimately connect the parenchymal cells 
and also the absence of Ca2+ during the first perfusion is essential for the effectiveness 
of the subsequent enzymatic dispersion (Seglen, 1972). In later experiments, O.lmM 
EGTA was incorporated into the first perfusion buffer to enhance the Ca2+-extracting 
properties of the perfusion. The dispersion was even more effective when EGTA was 
used in the first perfusion due to its calcium chelating properties. If EGTA was used in 
the first buffer, this was flushed out with 80ml Ca2+-free Kreb's-Henseleit buffer 
without EGTA as EGTA inhibits the action of collagenase used in the subsequent 
perfusion. This perfusion was followed by a recirculating perfusion with 100ml Krebs- 
Henseleit solution containing 0.3 IU/mg of collagenase and 4.2mM CaCl2. The buffer 
was allowed to run through for lmin to wash the first buffer out of the system and then 
the collagenase buffer was recycled for 9-1 lmin (or until the liver looked as if it is 
falling apart and gentle pressure on the lobes appeared to release the cells ). By this 
method of collagenase perfusion it is possible to convert the whole liver to a 
suspension of intact cells. After the perfusion, the liver was removed and placed in
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warm washing buffer. The Glisson's capsule was gently removed and the liver 
disrupted by gentle scraping with a spatula. The suspension of cells was filtered 
through gauze (Snowflake absorbent gauze) to separate connective tissue and 
undigested liver. Parenchymal cells were then harvested after washing with washing 
buffer ( see Buffers below ) and resuspending 3 times. The cells were sedimented 
between each wash by centrifugation at 200g for 2 min at a temperature of +5°C in a 
Damon-IEC refrigerated centrifuge. The supernatant containing non-parenchymal cells 
and damaged parenchymal cells was discarded each time. The cells were kept on ice 
for one hour to equilibrate.
The number of cell was counted in a haemocytometer. In the case of 
parenchymal liver cells, the intact cells with their well-defined outline and refractile 
appearance are readily distinguished from the flattened, ground-glass-looking damaged 
cells even without the addition of a vital stain such as trypan blue (Howard et al 
1967). 10/d of cell sample was taken and a 1 in 100 dilution carried out using washing 
buffer. Each large square of the haemocytometer, with cover-slip in place, represents a 
total volume of 0.1 mm3 or 10-4 cm3. Since 1cm3 is equivalent to approximately lml, 
the subsequent cell concentration per ml (and the total number of cells) can be 
determined using the following calculations:
CELLS PER ML = the average count per square x 106 
TOTAL CELLS = cells per ml x the volume of cell suspension.
10 squares were used for counting of each sample and an average count taken.
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2.2.3. ADDITION OF TEST COMPOUNDS TO ISOLATED 
HEPATOCYTES
2.2.3.1 Pre-Incubation for Glycogen Phosphorylase Assay.
The cells were suspended in a volume of buffer (Krebs-Henseleit medium 
containing 10 or 30mM glucose to simulate the control or diabetic condition ) to give a 
final concentration of 3-5x10^ cells/ml. 2ml aliquots of this suspension were then 
placed in a 20ml plastic scintillation vial and incubated at 37°C under 95% air and 5% 
C02 with reciprocal shaking at 90 cycles per min for 30min prior to the addition of 
drugs.
After pre-incubation as above, 500pl aliquots of cells were transferred to 1-ml 
microcentrifuge tubes containing 50pi of drugs at various concentrations (insulin at 
lO’^-lO ^M  dissolved in 0.1M HC1; test compounds at 10_10-10“3M dissolved in 
distilled water except for diazoxide which was dissolved in 0.1M NaOH) or vehicle 
(control) and incubated at 37°C in a dry Heating Block (Genesys Instruments). The 
incubations were terminated after 5min by dropping the tubes in liquid nitrogen (Figure
7. The tubes were then stored frozen at -70 °C until they were assayed for glycogen 
phosphorylase activity as described below. Duplicate incubations were made for each 
concentration. The assay of glycogen phosphorylase activity was performed within 24h 
as there is some inactivation of the enzyme even at this low temperature.
2.2.3.2. Pre-Incubation for Androst-4-ene-3,17-dione Metabolism Assay
Isolated hepatocytes ( 107cell/ml ) were plated out on sterile petri dishes 
(NUNCLON, Denmark, 9cm diameter) at a density of 3x10^ cells/cm^ in Krebs- 
Henseleit medium ( final volume 7ml ). The plates were swirled carefully to ensure 
even distribution of cells over the surface of the plates. 70pl of compound or hormone 
were added directly to the cell culture at concentrations 10"10 to 10'5M for insulin and
/
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10-10 t0  10"5m for the test compounds. Insulin was dissolved in 0.1M hydrochloric 
acid and the test compounds in distilled water ( except for diazoxide, which was 
dissolved in 0.1M NaOH ). The additions did not alter the pH of the medium. 
Controls were treated with a similar amount of vehicle. The plated cells were 
subsequently incubated at 37°C under 95% air and 5% C02 in a humidified incubator 
(Flow Laboratories) and shaken at 90 oscillation /min for 30min. At least six separate 
samples were taken for each control and test batch of cells.
2.2.4. ASSAYS
2.2.4.1 Glycogen Phosphorylase Assay
The assay of glycogen phosphorylase in this work depends on the reaction 
between D-glucose-1-phosphate (Glc-l-P) and glycogen in the reverse, 
unphysiological direction ( i.e. in the direction of glycogen synthesis). The principle 
involves the incorporation of [^CJglucose from Glc-lP into glycogen. The filter paper 
assay method of Tomas et al (1968), modified by Stalmans & Hers (1975) was used to 
determine the enzyme activity.
An equal volume (500pl) of ice-cold disruption buffer was added to the frozen 
samples from the pre-incubation step described above, allowed to thaw on ice and then 
shaken for about 60s in an ultrasonic bath. The mixture was centrifuged at 2500g at 5° 
C for 10 min in a Damon-IEC refrigerated centrifuge. 50pl of the supernatant was 
added to 50pl of assay mixture ( for composition of assay mixture see below ) in a 
microcentrifiige tube, mixed by means of a rotary mixer and incubated in a water bath 
at 37°C for 20min (Figure 8). The reaction was stopped by removing 30pl aliquots of 
the mixture and spotting it to filter paper pieces marked with the sample number in 
pencil ( Whatman 3MM chromatography paper, 10mm2), and dropping in a beaker 
containing 400ml of 66%(v/v) ethanol in water to precipitate the radioactively-labelled 
glycogen. Excess [U-14C] glucose-1-phosphate will disperse into the ethanol/water.
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Blank samples were prepared by mixing 50pl of disruption buffer with 50pl of assay 
mixture. The ethanol, mixed on a magnetic stirrer and screened from the paper squares 
with an aluminium mesh to prevent disintegration of the filter papers, was changed 
every 40min ( 3 times ) to wash the filter papers. After the final wash the filter paper 
squares were mixed for 3 min in acetone and dried in air. The radioactivity on each 
filter paper was measured in a Tri-Carb 2000CA scintillation counter ( Packard, Berks; 
England ), by placing the filter papers in 20-ml plastic scintillation vials with 2ml of 
Ecoscint scintillation (National Diagnostics, Atlanta, GA, U.S.A.). The total amount of 
radioactivity present in the assay mixture was measured by spotting 50pl of the assay 
bufer onto a filter paper, allowing to dry and counting as above. The method is 
illustrated in the flow diagram show on the following page.
2.2.4.2. Androst-4-ene-3,17-dione Metabolism Assay
The method first described by Gustafsson & Stenberg (1974) was used as 
modified by Hussin & Skett (1986). 7/xl of [4-14C]-androst-4-ene-3,17-dione (1.5xl05 
d.p.m, dissolved in acetone), 10/xl of androst -4-ene -3,17-dione (100/xg, dissolved in 
acetone) were added to each cell suspension and incubated for 30 minutes at 37°C in 
95% air and 5% CO2 in a humidified incubator whilst being shaken at 90 cycles/min . 
After the assay incubation, 50/xl from each sample was transferred to a 1ml 
microcentrifuge tube to assay the amount of protein in each cell suspension. The rest 
of the sample ( including the cells ) was transferred to a test tube and the reaction was 
stopped by adding 5ml ofFolch solution (chloroform: methanol, 2:1) to each sample, 
followed by 0.5ml of 0.9% NaCl solution to aid extraction of the substrate and its 
metabolites into the organic layer. Another 50/xl ( 500/xg ) of androst-4-ene-3,17-dione 
was added , the tubes shaken gently and left to stand overnight in the dark for phase 
separation into organic and aqueous layers. In order to acheive complete separation
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of the 2 phases, the tubes were centrifuged at 1500 g at 5 °C for 5 min in a Damon- 
IEC refrigerated centrifuge. The lower organic layer was transferred to another tube 
and dried at 50 °C under oxygen-free nitrogen ( to prevent degradation of the 
metabolites by atmospheric oxygen ) using a Techne Dri Block. The extract was 
redissolved in 5 drops of chloroform ( in the ultrasonic water bath for at least 30 
seconds ). Individual samples were then spotted onto 250/xm silica gel thin layer 
chromatography plates (20cm x 10cm, F-254, Merck, Darmstadt, Germany ) and 
separation of metabolites was achieved by running the plates in a mobile phase 
consisting of chloroform : ethylacetate (4:1,  v/v) in tanks equilibrated with the solvent 
for at least one hour before commencing the separation. The samples were spotted (
4 samples on a plate ) at the lower edge of the T. L .C. plate ( «1.5 cm in ), using a 
10 jA disposable micropipette. After the solvent front had run to about 1 cm from the 
top edge of the plates the plates were dried in warm air. Autoradiograph of the plates 
for 7 days with X-Omat film (Kodak, France) located each of the radioactive bands 
shown in Fig 9. The radiolabelled bands were scraped into polythene scintillation vials 
and suspended in Ecoscint liquid scintillant (National Diagnostics, Atlanta, GA, U.S.A. 
) and the amount of 14C label present in each band was evaluated in a Packard Tri-carb 
2000CA scintillation counter. The amount of each metabolite expressed as pmol 
metabolite formed per min per mg of protein was determined using the formula shown 
in the section on calculations and statistics (section 2 .2 .7.2)
It is apparent from Figure 9 that there are six main metabolites of androst-4- 
ene-3,17-dione which can be separated by this method. However, it has been shown 
that 3a/j8-oxosteroid oxidoreductase does not metabolise the parent compound, but 
that metabolism by this enzyme occurs subsequent to metabolism by 5a-reductase. 
Hence, for the purpose of this study, only the activities of the enzymes metabolising 
the parent molecule were evaluated and hence the amount of metabolite produced by 
subsequent metabolism of 5a-androstane-3,17-dione ( as produced by 5a reduction of 
androstenedione ) was not determined separately but the amount of metabolite 
produced by this enzyme was added to the amount of unchanged 5a-androstane-3,17-
solvent from
Figure  9. Schematic representation of  androst -4-ene-3 ,17-dione  
metabolites separation by one-dimensional thin layer chromatography
specific bands identified by autoradiography are indicated :
A. Spotting band
B. androst-4-ene-7a-ol-3,17-dione
C. androst-4-ene-6(3-ol-3,17-dione
D. androst-4-ene-16a-ol-3,17-dione
E. Testosterone / Epitestosterone
F. 5a-A ndrostane-3a(p)-ol-17-one
G. Unchanged substrate Androst-4-ene-3,17-dione
H. 5a-Androstane-3,17-dione
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dione to determine the total amount of metabolite produced by the activity of 5a 
reductase.
2.2.5. ASSAY OF SERUM GLUCOSE
In the experiments where blood was required for detection of serum glucose 
level, the blood was collected from the tip of the tail after it had been cut under 
halothane / nitrous oxide anaesthesia. Serum was prepared by centrifugation at 3000 g 
for 3 minutes in an MES Microcentaur centrifuge. The upper serum layer was removed 
using a micropiptte and assayed for glucose by a techinque based on the glucose 
oxidase method (Carroll et al, 1970) using a kit supplied by Boehringer Mannheim 
GmbH.
2.2.6 PROTEIN ASSAY
The amount of protein present in the supernatant of the freeze-thawed cells or 
the assay mixture of the steroid assay was measured using the Folin-phenol method 
(Lowry et al., 1951) with bovine serum albumin as a standard.
2.2.7. CALCULATIONS AND STATISTICS
2.2.7.1 Glycogen Phosphorylase
The activity of glycogen phosphorylase in a given sample was calculated as the 
amount of 14C-glucose incorporated in glycogen after subtraction of the blank values. 
Enzyme activity was calculated by the equation below and expressed as nmol of 14C- 
glucose 1-phosphate incorporated into glycogen min-1 mg of protein-1.
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ENZYME ACTIVITY=(DPMs -DPMB)/DPMTx[S]X(l/P)x(l/t)x(10,000/3) 
where,
DPMg, DPMB, DPMj , are the disintegrations/min for the sample, blank and total 
amount of radioactivity in the assay respectively.
[s]=substrate(GLU-1 -P) concentration (50mM in all the assays) 
p = protein conc.of the supernatant 
t=incubation time(min)
2 .2 .7.2. Steroid Metabolism
The amount of each metabolite of androst-4-ene-3,7-dione expressed as pmole 
metabolite formed per minute per 106 cell or mg of protein was determined using the 
formula shown below:
pmol metabolite/min/106 cell or mg of protein= S x Cm x l x l x l
Ct t n MW
S = amount of substrate added ( /xg)
Cm = d.p.m. metabolite
Ct = d.p.m.total
t = incubation time (minutes)
n = number of ceils (divided by 106) or mg of protien
MW = molecular weight of substrate (280)
Results were expressed a % of the relevant control. Mean and standard 
deviations were calculated using a custom-made computer program and statistical 
analysis was performed using ANOVA followed by Dunnet's test. A p value less than 
0.05 was considered statistically significant.
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2.2.8. SOURCES OF HORMONES, DRUGS AND REAGENTS
Hormones, chemicals and reagents are listed according to the manufacturer.
Sigma Chemical Co.Ltd.. St.Louis. USA 
MOPS
DL-dithiothreitol
caffeine
rabbit liver glycogen Type III 
HEPES 
Saccharin 
Phenformin 
Diazoxide 
Melamine 
Metformin.
Insulin (porcine)
EGTA
Streptozotocin 
Bovine serum albumin 
4-Androstene-3,17-dione 
a-D-Glucose-1 -phosphate
Hopkins &Williams..Essex. England:- 
sodium fluoride 
disodium EDTA
British Drug Houses. Poole.England 
Folin-Ciocalteu's phenol reagent
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Amersham International p.I.e.. Bucks. England:
D-[U- 14C]Glucose-1 -phosphate, potassium salt 
[4-14C]androst-4-ene-3,17-dione
Boehringer.Mannheim. Germany:
Collagenase A form Clostridium histolyticum 
Glucose assay kit
Fisons.Loughborough. England
salts, for physiological solutions and buffers.
NaCl, KC1, MgS04, KH2P04, NaHC03, Glucose.
Aldrich Chemical Co-Ltd
3.5-Diamino-1,2,4-triazole
1-phenyl biguanide hydrochloride
1.3.5-Triazine
Kodak. France 
X Ray film (X-Omat)
Developer (DX 24)
Fixer (FX-40)
2.2.9. BUFFERS AND PHYSIOLOGICAL SOLUTIONS
2 .10.1 Krebs-Henseleit buffers
a^ )Ca2+Free Krebs-Henseleit solution
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mM
NaCl 117.0
KC1 4.7
MgS04 1.2
k h 2p o 4 1.2
NaHC03 2.4
HEPES 10.0
Glucose 11.1
The above were dissolved in distilled water and the pH adjusted to 7.4 with 0.1M 
NaOH.
b) Collagenase buffer
As above (a) but with CaCl2(4.2mM) and the pH adjusted to 7.6.
c) Washing buffer
As in(a) but with CaCl2(1.3mM)
d) Cell disruption buffer
mM g/100ml
MOPS 100 2.090
NaF 200 0.840
EDTA 30 1.120
DTT 10 0.154
store at 4°C
e^Glvcoeen phosphorylase assay mixture
Caffeine ImM
mg/10ml
1.942
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Glycogen 2% 200
D-Glucose-1 phosphate lOOmM 336.3
D-[U^C]Glucose-l phosphate 50nmol 25 pi
(sp.activity: 284mCi/mmol) 
Stored at -20 °C
RESULTS
6 6
3.1 SYNTHESIS OF BIGUANIDES AND GUANAMINES.
The authenticity of the synthesised compounds was confirmed by melting point 
measurement using the Kofler hot stage apparatus. The melting points agreed with the 
literature values (Overberger et al; 1954; Shapiro et al; 1957). Microanalysis for C, H 
and N were performed using a Carlo Erba Analyser and the products gave values in 
agreement with theory. ^H, l^C-NMR spectra were recorded with Bruker AM 
200SY and WP 200SY spectrometers. Spectra were consistent with the proposed 
compounds.
3.1.1. NMR Spectra of Substituted Guanamines and Biguanides
Since the guanamines might be protonated when bound to receptors, the NMR 
spectra of the hydrochlorides were examined in the polar solvent (CD3)2SO to gain 
insight into the sites of protonation and the shapes of the cations.
The and 13C spectra of 2-amino-4-phenethylamino-1,3,5-triazine
hydrochloride showed that protonation had occurred on the triazine ring rather than on 
either of the amino substituents. The amino and alkylamino groups were planar rather 
than pyramidal and rotation about the C(2)-N and C(4)-N bonds was slow on the 
NMR time scale. The NH2 protons gave separate signals and the phenethyl side chain 
gave rise to a pair of geometrical isomers (rotamers) in a ratio ca. 3:1. Thus the 4-NH 
proton gave triplets {J 5.7 Hz) at 5 9.16 (major rotamer) and 9.06 (minor rotamer). 
Other pairs of strong and weak signals were observed, respectively, at 6 8.75 and 8.51 
(br s, NT/H), 8.40 and 8.48 (s, 6-H), 8.37 and 8.10 (br s, NH/7) and 3.54 and 3.58 (q, 
C//2NH). The phenyl group gave a multiplet at 5 7.27 and the phC/72 group a triplet (J 
7.4 Hz) at 5 2.87. No signal was discernible for the triazine ring NH, nor for water in 
the solvent. Apparently, intermolecular exchange of this proton between one or more 
of the triazine nitrogens and the water had caused extensive signal broadening. Pairs of
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strong and weak signals in the 13C spectrum confirmed the presence of major and 
minor rotamers.
The spectra of 2-amino-4-benzylamino-l,3,5-triazine hydrochloride also indicated 
the presence of rotamers (ratio ca. 3:1) arising from protonation of the triazine ring. 
Pairs of strong and weak signals were again observed, respectively, at 8 9.57 and 9.48 
(t, J 6  Hz, CH2N//)> 8.78 and 8.60 (br s, NtfH), 8.44 and 8.51 (s, 6-H), 8.40 and 8.11 
(br s, NHH), and 4.55 and 4.60 (d, J  6.2 Hz, CH2). The phenyl group gave a muliplet 
at 5 7.34. Again, no signals were observed for the triazine ring NH or for water in 
solvent. The 13C spectrum confirmed the presence of major and minor rotamers.
The spectra of the hydrochloride of the more weakly basic l-amino-4- 
phenylamino-l,3,5-triazine differed from those of the foregoing 4-alkylamino 
compounds. Signals for only one species were apparent, although the presence of two, 
distinct NH2 signals again showed that the triazine ring was protonated and that 
rotation of the planar NH2 group was slow on the *H NMR time scale. Also, a signal 
for the triazine ring NH was observed as a very broad singlet at 8 ca.6. This signal 
integrated for almost 2H, indicating exchange with solvent water. Apparently, rotation 
about the C(4)-N bond occurs as a result of only weak electron release from the 
anilino nitrogen. The *H spectrum showed 5 11.0 (br s, PhNiT), 8.90 (br s, N//H), 
8.56 (s, 6-H), 8.44 (br s, NHH), 7.73 (d, J l . l  Hz, o-Ph-H), 7.39 (t, /7.7Hz, m-Ph-H), 
7.22 (t, J13  Hz, p-Ph-H) and ca. (br s, NH).
The spectra of the hydrochlorides of phenethyl- and benzyl- biguanide were 
simpler. Only one species was observed for each salt and signals for only two kinds of 
NH proton were apparent. Thus, the phenethylbiguanide (phenformin) hydrochloride 
gave 8 7.62 (t, J5.4Hz, CH2Ntf), 7.27 (m,Ph), 7.05 (Br s, NH), 3.34 (q, J 6.8 Hz, 
C772NH) and 2.77 (t, J1A, PhC//2) while the benzyl derivative gave 8 7.96 (t, J6.0, 
CH2N//), 7.32 (m, Ph), 7.07 (br s, NH) and 4.36 (d, J6.0, CH2). The broad, NH 
singlets at 5 7.05 and 7.07 each integrated approximately for 6 protons, presumably, 
protonation occurs on one or other of the C=NH groups, but the signals for the 6 
distinct protons on the unsubstituted nitrogens give only on broad singlet.
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3.2. The effect of biguanides, guanamines, miscellaneous compounds 
and insulin on the activity of glycogen phosphorylase a in normal rat 
hepatocytes
Figures 10 and 11 show the effects of all of the compounds tested on the activity 
of glycogen phosphorylase a in isolated normal rat hepatocytes, in comparison to the 
control (100%). Insulin was used as standard in the experiments in order to investigate 
the insulin-like activity of the synthesised compounds as potential anti diabetic agents. 
Phenformin was used to test the efficacy of the synthesised compound against a known 
oral hypoglycaemic agent.
3 . 2 .  1. The effect o f  phenethvlbiguanide and phenethvlguanam ine.
In Figure 10A phenethylbiguanide (phenformin) in the concentration range of 10" 
10M to 10-3M caused a significant decrease in the activity compared to control (basal 
phosphorylase activity 17.8 ±1.3 nmol/ mg of protein/ min, p< 0.01) although the 
effect did not seem to be dose - related. The effect was more pronounced with 
phenethylguanamine (Figure 10A) at 10"6M, 10-7M,10-8M and 10'10M (which 
diminished the activity significantly to 35%-48% of control (p<0.01). Similarly, 
significant inactivation of glycogen phosphorylase a was observed at all insulin 
concentrations studied (10“10M to 10-5M) with approximately maximum activity at 
physiological concentration 10"9M (15% of control; p<0.01). In this experiment on the 
same cells, the insulin was more effective than phenethylbiguanide or 
phenethyguanamine (p< 0.001) except at low concentration 10-10M when there was 
no significant difference between insulin and phenethylguanamine.
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3 . 2 . 2 .  The effect o f phenvlbiguanide and phenylguanamine.
Both phenylbiguanide and phenylguanamine at concentrations between 10-10M 
and 10"4M caused a dose-dependent decrease in enzyme activity (Figure 10B). It was 
seen that insulin had more effect on the activity (inhibition to 6% of control) when 
compared to phenylbiguanide and phenylguanamine (p< 0.001). There was no 
difference seen between the effects of phenylbiguanide and phenylguanamine.
3. 2. 3. The effect o f  benzvlbiguanide and benzyl guanamine.
Benzylbiguanide, exhibited a significant inactivation of glycogen phosphorylase a 
(to 30% of control) a similar decrease to that seen with insulin (Figure 10C). The 
cyclization of benzylbiguanide to benzylguanamine did not improve the activity on 
glycogen phosphorylase, indeed there was less of an effect at lower concentrations.
3. 2. 4. The effect o f  phenethylbiguanide and 1,1- dim ethvlbiguanide
To show in which part of the chemical structure the activity resides, a comparison 
was made of phenethylbiguanide (phenformin) and 1,1-dimethylbiguanide (metformin) 
which belong to the same chemical class of anti diabetic drugs. As shown in Figure 
11 A, both compounds significantly inactivate phosphorylase a in comparison to control 
(100%) (p < 0.01; basal phosphorylase activity 47.7 +  2.3 nmol/ mg of protein/ min). 
The cells were more sensitive to metformin than phenformin with a greater effect 
occurring at most concentrations below lO^M and the greatest effect occurring at 10“ 
6M (p< 0.001, compared to phenformin ). Neither compond had an effect as marked as 
insulin (p<0 .001).
Figure 10: Effect of various concentrations of (A) phenethylbiguanide (O) and 
phenethylguanamine (•), (B) phenylbiguanide (O) and phenylguanamine (•), (C) 
benzylbiguanide (O), benzylguanamine ( • )  and insulin (V) on glycogen phosphorylase 
a activity in normal rat hepatocytes compared to control (100%). The cells were pre 
incubated for 30 min in Krebs-Henseleit medium and the effect of 5 min exposure to 
the compounds and hormone on the enzyme activity measured. Values are the mean ± 
s.d (n = 6), analysed by ANOVA followed by Dunnett's test. All value wre signficantly 
different from control, p< 0.01. Basal phosphorylase activity for control in graph A 
(17.8 ±1.3 nmol/ mg of protein/ min), B (29.1 ± 1.8 nmol/ mg of protein/ min) and C 
(28 ±1.5  nmol/ mg of protein/ min)
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3. 2. 5. The effect o f  phenethylbiguanide and saccharin.
Further examination was made of two chemical classes of potential 
hypoglycaemic agents containing N-groups and S-groups, phenethylbiguanide 
(phenformin) containing an amino group and o-sulfobenzimide (saccharin) containing a 
sulphur group. From the concentration response curve for glycogen phosphorylase a 
inactivation (Figure 1 IB), it is seen that both drugs significantly inactivated the enzyme 
at concentration of 10_10M-10‘3M (52% - 81%) compared to control (p<0.01; basal 
phosphrylase activity 38.2 ± 1 . 7  nmol/ mg of protein/ min). It was observed that 
phenformin (phenethylbiguanide) was equally as effective in inactivating the glycogen 
phosphorylase a as saccharin (o-sulfobenzimide) at most concentrations. Neither 
compound was as effective as insulin in inactivating glycogen phosphorylase a.
3 . 2 . 6 .  The effect o f  saccharin and diazoxide
The effect of saccharin, whose structure contains an amino group plus a sulphur 
group in a 5-membered ring, was compared with diazoxide (a hyperglycaemic drug), 
which contains the same groups in a 6-membered ring . Saccharin significantly 
decreased the activity of glycogen phosphorylase a at 10_9M - 10-3M (47% - 88%, of 
control; p< 0.01; basal phosphorylase activity 29.5 ±  1 nmol/ mg of protein/ min) 
whereas diazoxide caused the enzyme to respond in the opposite manner with a 
significant increase in the activity of glycogen phosphorylase at 10"1°M to 10’8M (p< 
0.01) (Figure 11C). Again insulin was more effective than either saccharin or 
diazoxide.
3. 2. 7. The effect o f  m elam ine and 3.5 -diam inotriazol
In addition melamine, an example of a triazine with a 6-membered ring with 3 
amino groups, and 3,5-diaminotriazole, which contains a 5-membered ring were used .
Figure 11. The effect of (A) phenethylbiguanide (phenformin) (O) and 1,1- 
dimethylbiguanide (metformin) (•), (B) phenethylbiguanide (O) and sulfobenzimid 
(saccharin) (•) , (C) sulfobenzimide (saccharin) (O), 7 chloro-3 methyl-2H-1,2,4- 
benzothiadiazine 1,1-dioxide (diazoxide) (•) , (D) 2,4,6-triamino-1,3,5-triazine 
(Melamine) (O), 3,5-diamino triazol ( • )  and insulin (V) on phosphorylase a activity in 
normal rat hepatocytes in comparison to control (100%). Hepatocytes were pre 
incubated for 30 min in Krebs-Henseleit medium and the effect of 5 min expsure to the 
compounds and hormone on the enzyme activity measured. Values are the mean ± s.d 
(n = 6), analysed by ANOVA followed by Dunnett's test p< 0.01 compared to basal 
phosphorylase activity (100%). All values are significant at p<0.01, exapet, * p< 0.05 
and t  (not significant). Basal activity of glycogen phosphorylase for control in graph A 
(47 ±2.3 nmol/ mg of protein/ min), B (38 ±  1.7 nmol/ mg of protein/ min), C (29 ±  
0.96 nmol/ mg of protein/ min), D (47 ±  2.2 nmol/ mg of protein/ min).
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Melamine completely inhibited enzyme activity but this was shown to be due to a 
decreased viability of the cells (Figure 1 ID). However 3,5-diaminotriazole significantly 
inactivated the enzyme in a dose- dependent manner with the maximum effect at 10" 
3M (51% of control; p< 0.01; basal phosphorylase activity 47.7 ±  2.2 nmol/ mg of 
protein/ min). Insulin was more effective than 3,5-diaminotriazole.
3. 3. The effect of streptozotocin - induced diabetes and insulin 
supplementation on glycogen phosphorylase a in rat liver.
Experiments were carried out with hepatocytes from control, diabetic and insulin 
treated diabetic animals. In in vivo studies, streptozotocin-induced diabetes resulted in 
a 52% decrease in glycogen phosphorylase a activity. When insulin was replaced in 
these diabetic rats glycogen phosphorylase a activity returned to its control values. The 
basal activity of phosphorylase a in the liver of the three groups of animals (n = 8) is 
shown Figure 12. It was significantly lower in diabetic animals (basal phosphorylase 
activity 19 ± 2.6 nmol/mg of protein/min, p< 0.01) than in the control (basal 
phosphorylase activity 36 ± 8.3 nmol/ mg of protein/ min) or insulin treated diabetic 
animals (basal phosphorylase activity 31 ± 1.1 nmol/ mg of protein/ min). No significant 
difference between the control and the insulin-treated diabetic rats was found.
3. 4. Effect of biguanides, guanamines, miscellaneous compounds and 
insulin on the activity of glycogen phosphorylase a in cultured 
hepatocytes from STZ diabetic rats.
The possibility that phenethylbiguanide and phenethylguanamine act like insulin 
on glycogen phosphorylase a activity in isolated hepatocytes from diabetic rats was 
explored. The basal activity of glycogen phosphorylase a in these hepatocytes was 8.8
CONTROL DIABETIC l -T R E A T -D
Figure 12. Glycogen phosphorylase a activity in control, streptozotocin-induced- 
diabetic and insulin-treated diabetic rat livers. Values are the mean ±  s.d. for eight 
animals. P values relative to the control values were obtained by ANOVA followed by 
Dunnet's test,**p< 0.01. Basal phosphorylase activity for control: 36 +  8.3 nmol/ mg 
of protien/ min, for diabetic 19 ± 2.6 nmol/ mg of protein/ min and for insulin treated 
diabetic 31 ±  1.1 nmol/ mg of protein/ min.
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± 0.4 nmol/ mg of protein/ min. This is very much lower than the basal activity found 
in control cells and is consistent with the data presented above in the in vivo 
experiments.
3. 4 . 1. The effect o f  phenethylbiguanide and phenethylguanamine.
Exposure of diabetic rat hepatocytes to phenethylbiguanide for 5min resulted in a 
significant increase in glycogen phosphorylase a (Figure 13A). This increase occurred 
at all concentration of phenethylbiguanide with the maximum effect at 10'9M ( 282% 
compared with the control). The cyclization of phenethylbiguanide to 
phenethylguanamine did not change the overall activation of phosphorylase a except 
that there was a tendency for diabetic hepatocytes to be more responsive to 
phenethylguanamine than phenethybiguanide at low concentrations (10"8 to 10“10M). 
This effect was statistically significant (p<0.001, p<0.01, p<0.05 at the three 
concentrations respectively). The effect of insulin was not as pronounced as that seen 
with phenethylbiguanide or phenethyguanamine. Insulin stimulated glycogen 
phosphorylase in a dose dependent manner with maximal effect at lO^M (275%) as 
shown in Figure 13 A.
3. 4 . 2. The effect o f  phenylbiguanide and phenylguanam ine
To further investigate whether the change in R- group had any effect on the 
activity of the glycogen phosphorylase, the effect of phenylbiguanide and 
phenylguanamine on the cells from diabetic rats was examined and compared to the 
effect of insulin. Figure 13B shows there is only a small change in glycogen 
phosphorylase a activity with phenylbiguanide at all concentrations (up to 175% of 
control) and the cyclization of phenylbiguanide to phenylguanamine gave only a small
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change in activity. The hepatocytes were more responsive to insulin than either of the 
phenyl derivatives at higher concentrations.
3. 4. 3. The effect o f  benzylbiguanide and benzyl guanamine.
Examination of the effect of another R- group on the activity of glycogen 
phosphorylase in diabetic hepatocytes, showed that the replacement of the phenethyl 
group by the benzyl group (Figure 13C) again resulted in a less effective compound. 
Benzylbiguanide had minor effects although the effect was significant on glycogen 
phosphorylase a activity (to 160% of control, p< 0.01). When the benzylbiguanide was 
cyclized to benzylguanamine there was little change in activity of the compound. The 
phenethyl derivatives are therefore the most effective of all the compounds tested on 
diabetic hepatocytes.
3. 4. 4. The effect o f  phenethylbiguanide and 1.1- dim ethvlbiguanide
Both phenethylbiguanide (phenformin) and 1,1-dimethylbiguanide (metformin) 
were added to the diabetic hepatocytes in order to determine which had more effect on 
the diabetic state, Phenethylbiguanide (phenformin) increased the activity significantly 
compared to the control (100%) (p<0 .01; basal phosphorylase activity 13 ±  1.6 nmol 
of 14C-glucose 1-phosphate/ mg of protein/ min) at all concentrations except at 10’8M 
where the activity was significantly increased at a significance level of (p<0.05) (Figure 
14A). The maximum effect of phenethylbiguanide was observed at a concentration of 
lO^M-lO^M. Attenuation of phenethylbiguanide's effect could be seen at 
concentrations of 10"5M and KHM. Exposure of diabetic hepatocytes to 1,1- 
dimethylbiguanide (metformin) at different concentrations significantly increased 
enzyme activity except at 10'7M. In diabetic rat hepatocytes, insulin gave a dose- 
dependent increase in enzyme activity. In contrast to the cells from normal rat 
hepatocytes, the cells from the diabetic animal were more responsive to
Figure 13. Increase in glycogen phosphorylase a activity in hepatocytes from a 
diabetic rat 5 min after stimulation by (A) phenethylbiguanide (O) and 
phenethylguanamine (•), (B) phenylbiguanide (O) and phenylguanamine (•) , (C) 
benzylbiguanide (O), benzylguanamine ( • )  and insulin (V) in comparison to control 
(100%). The cells were pre incubated for 30 min in Kerbs-Henseleit medium before 
exposure to the compounds and hormone. Values are the mean ±  s.d of six 
experiments, analysed by ANOVA followed by Dunnett's test p< 0.01 compared to 
basal phosphorylase activity (100%). All values were significant at p< 0.01 except f = 
not significant. Basal phosphorylase activity in graph A, B, C: 8.8 ± 0.4 nmol/ mg of 
protein/ min.
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phenethylbiguanide at various concentrations than to 1,1-dimethylbiguanide 
(metformin) (p< 0 .001).
3. 4. 5. The effect phenethylbiguanide and saccharin.
In contrast to hepatocytes from normal rats which exhibit a dose-dependent 
decrease in glycogen phosphorylase activity with all concentrations of 
phenethylbiguanide (phenformin) and o-sulfobenzimide (saccharin), with diabetic 
hepatocytes there is a significant difference in the activity of phenethylbiguanide and 
saccharin. Saccharin at low concentrations (10-10 M and 10"9M) and at high 
concentration (10"3M, 10"5M) decreased activity to 85% of control (p< 0.01, basal 
phosphorylase activity 8.8 ±  0.4 nmol/ mg of protein/ min), whereas
phenethybiguanides gave the expected increase (Figure 14B).
3. 4. 6. The effect o f  saccharin and diazoxide.
In a comparison between saccharin (which contains an amino group plus a sulphur 
group in a 5 member ring) and diazoxide (which contains the same groups but in a 6 
member ring) , it is seen that both compounds, when added to the same diabetic 
hepatocytes, gave few significant changes in enzyme activity (Figure 14C). When 
diazoxide was added at high concentration (lO^M and 10_3M), there was no 
significant change in the activity. A significant decrease in enzyme activity was, 
however, seen at 10’5M diazoxide (p<0.05). At 10~10M to lO^M diazoxide, the 
activity of the enzyme was reduced to significantly below the control (p<0.01). The 
maximum effect in the reduction of the activity was observed at a concentration 10’7M 
diazoxide (80% of control). Saccharin only gave significant reduction in enzyme 
activity at 10-10, 10-9, 10"5 and 10-3M.
Figure 14. Effect of different concentrations of (A) phenethylbiguanide (phenformin) 
(O) and 1,1-dimethylbiguanide (metformin) (•) , (B) phenethybiguanide (phenformin) 
(O) and sulfobenzimide (saccharin) (•), (FC) sulfobenzimide (saccharin) (O) and 7- 
chloro-3 methyl-2H-l,2,4-benzothiadiazine 1,1-dioxide (diazoxide) ( • )  (D) s-triazine ( 
O) and 3,5-diamino triazol ( • )  and insulin (V) on glycogen phosphorylase a activity in 
isolated rat hepatocytes from diabetic rats in comparison to control (100%). 
Hepatocytes were pre incubated for 30 min in Krebs-Henseleit medium and the effect 
of 5 min exposure to the compounds and hormone on the enzyme activity measured. 
Values are the mean ±  s.d of six experiments, analysed by ANOVA followed by 
Dunnett's test, compared to basal phosphorylase activity (100%), all values were 
significant at p<0.01 except *p< 0.05, |  and # = not significant.' Basal phosphorylase 
activity of glycogen phosphorylase for control in graph A (13 ± 1 . 6  nmol/ mg of 
protein/ min), B (8.8 ±  0.4 nmol/ mg of protein/ min), C (8.8 ±  0.4 nmol/ mg of 
protein/ min), D (10 ±  2.3 nmol/ mg of protein/ min).
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3. 4. 7. The effect o f s-triazine and 3.5-diaminotriazol.
In a further investigation to ascertain which part of the molecule is needed for 
activity, s-triazine, (containing a 6-membered ring) was compared with 3,5- 
diaminotriazol (a 5-membered ring). The results indicated that the activity of glycogen 
phosphorylase a was significantly stimulated by both 3,5-diaminotriazol and s-triazine 
in the concentration range 10-10M to 10"3M (120-137% of control, p<0.01; basal 
phosphorylase activity 10 +  2.3 nmol/ mg of protein/ min) (Figure 14D). The 
responsiveness to the different concentrations of compounds was not as marked as 
with insulin.
3. 5. Effect of biguanides, guanamines, miscellaneous compounds and 
insulin on the activity of glycogen phosphorylase a in isolated 
hepatocytes from insulin-treated diabetic rats
The Figures 15 and 16 show the effects of the compounds tested on the activity 
of glycogen phosphorylase a in hepatocytes isolated from insulin-treated diabetic rats 
in comparison to control (100%).
3. 5. 1. The effect o f  phenethylbiguanide and phenethylguanam ine.
In Figure 15 A, phenethylbiguanide (phenformin) in the concentration range of 
10"3M to 10’8M, showed a significant decrease in the activity to 59-88% of control 
(p<0.01 basal phosphorylase activity 32 + 1.4nmol/ mg of protein/ min). When 
phenethylbiguanide was cyclized to phenethylguanamine the activity of phosphorylase 
a only diminished at lO^-lO^M, (p<0.01) and at a low concentration of 10_9M 
(p<0.05). The insulin was more effective than phenethylbiguanide or 
phenethylguanamine (p< 0 .01).
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3 . 5 . 2 .  The effect o f  phenylbiguanide and phenylguanamine.
Similarly, significant phosphorylase inactivation was observed at all 
phenylbiguanide and phenylguanamine concentrations studied between 10-10M to 10" 
3M compared to control (p< 0.01; basal phosphorylase activity 37 ±  6.5 nmol/ mg of 
protein/ min) although little evidence of dose- dependence was seen (Figure 15B). A 
comparison with insulin showed that the hormone had more effect on the activity 
(inhibition to 20% of control) when compared to phenylbiguanide and 
phenylguanamine (p< 0 .001).
3. 5. 3. The effect o f  benzylbiguanide and benzyl guanamine.
In Figure 15C, benzylbiguanide at concentrations between 10"10M and 10"3M 
decreased enzyme activity (p< 0.01; basal phosphorylase activity 34 ±  3.5 nmol/ mg 
of protein/ min). Maximum activity was observed at the high concentration of lO^M . 
Insulin had more effect on the activity except at low concentrations where there is no 
significant difference between insulin and benzylbiguanide. There was no overall 
improvement in the activity when benzylbiguanide was cyclised to guanamine.
3. 5. 4. The effect o f  phenethvbiguanide and 1.1-dim ethvlbiguanide.
In simultaneous studies on the same cells comparing phenethybiguanide with
1,1-dimethylbiguanide (metformin) (Figure 16 A), it was shown that 1,1- 
dimethylbiguanide significantly decreased the activity to 38% of control at high 
concentration (KHM) compared to control (100%) (p<0.01; basal phosphorylase 
activity 32 ±  1.4 nmol/mg of protein/min). The cells were more sensitive to 
metformin, with greater effects occurring at all concentrations with metformin
Figure 15. Effect of various concentrations of (A) phenethylbiguanide (O) and 
phenethylguanamine (•), (B) phenylbiguanide (O) and phenylguanamine (• ) , (C) 
benzylbiguanide (O) and benzylguanamine ( • )  and insulin (V) on glycogen 
phosphorylase a activity in hepatocytes isolated from insulin treated diabetic rat 
compared to control (100%). The cells were preincubated for 30 min in Krebs- 
Henseleit medium and the effect of 5min exposure to the compounds and hormone on 
the enzyme activity measured. Values are the mean ± s.d (n = 6), analysed by ANOVA 
followed by Dunnett's test. All values are significant at p<0.01, except *p<0.05, f  and 
it = not significant. Basal phosphorylase activity for control in graph A (32 ± 1 . 4  
nmol/ mg of protein/ min), B (37 ±  6.5 nmol/ mg of protein/ min) and C (34 ±  3.5 
nmol/ mg of protein/ min).
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compared to phenethyl biguanide (p < 0.001). The effect of metformin was similar to 
insulin at low (10-10M) and high (10'5M) concentrations.
3. 5. 5. The effect o f  phenethylbiguanide and saccharin
On the basis of previous observations on the normal rat hepatocytes, we tried to 
compare the effect of saccharin (o-sulfobenzimide) and phenethylbiguanide. When the 
cells were treated with saccharin, it was seen that the activity decreased significantly at 
all concentrations compared to the control (p<0.01, basal phosphorylase activity 32 ±  
1.4 nom/ mg of protein/ min) (Figure 16B). The result was slightly different in the case 
of phenethylbiguanide (phenformin) where it was observed that there was no 
difference in the activity at concentrations of 10"5M, 10’7M ,10-9M and 10-10M. The 
activity of phenformin was detectable only at the higher concentrations (10“3M and 10" 
4M) and at 10'6M and 10'8M. Saccharin at concentrations of 10_5M and below 
decreased the activity significantly more than phenethylbiguanide (p< 0 .001).
3. 5. 6. The effect o f  saccharin and diazoxide.
The addition of diazoxide (a hyperglycaemic drug which contains the same 
groups (amino and sulphur) as saccharin but in a 6-membered ring to hepatocytes 
isolated from insulin-treated diabetic rats (Figure 16C) showed that saccharin and 
diazoxide decrease the activity significantly compared to control (p< 0 .01; basal 
phosphorylase activity 32 + 1.4 nmol/ mg of protein/ min). The effect of diazoxide in 
hepatocytes isolated from insulin-treated diabetic rats is in contrast to the effect of the 
drug on the normal rat hepatocytes.
Figure 16. The effect of (A) phenethylbiguanide (phenformin) (O) and 1,1- 
dimethylbiguanide (metformin) (•) , (B) phenethylbiguanide (O) and sulfobenzimid 
(saccharin) (•) , (C) sulfobenzimide (saccharin) (O), 7 chloro-3 methyl-2H-1,2,4- 
benzothiadiazine 1,1-dioxid (diazoxide) (•), (D) 2,4,6-triamino-1,3,5-triazine
(Melamine) (O), 3,5-diamino triazol ( • )  on phosphorylase a activity in hepatocytes 
isolated from insulin treated diabetic rats in comparison to control (100%). 
Hepatocytes were preincubated for 30 min in Krebs-Henseleit medium and the effect 
of 5 min exposure to the compounds and hormone on the enzyme activity measured. 
Values are the mean ± s.d (n = 6), analysed by ANOVA followed by Dunnett's test. All 
values are significant at p<0.01, except t  not significant. Basal activity of glycogen 
phosphorylase for control in graph A, B, C (32 ±  1.4 nmol/ mg of protein/ min), D 
(34 + 5.5 nmol/ mg of protein/ min).
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3. 5. 7. The effect o f melamine and 3. 5-diaminotriazol.
The same effect was observed when melamine was used in normal hepatocytes 
(Figure 11D) and hepatocytes isolated from insulin-treated diabetic rats (Figure 16D). 
It completely inhibited the activity but this was found to be due to a decreased viability 
of the cells. 3,5-Diaminotriazole behaved, in its effects on the enzyme activity, as in 
normal rat hepatocytes by a decrease in the activity to 44% of control at high 
concentration (lCHM) (p< 0.01; basal phosphorylase activity 34 ±  5.5 nmol/ mg of 
protein/ min). The maximum activity was observed at low concentrations (10_9M) 
(20% to control).
3. 6. A change in the effect of biguanides, guanamines, miscellaneous 
compounds and insulin on glycogen phosphorylase a activity in 
hepatocytes from normal rats in different glucose concentrations.
In a previous study (refer to section 3.4) exposure of hepatocytes isolated from 
diabetic rats to biguanides, guanamines and insulin resulted in an increase in glycogen 
phosphorylase a activity. This series of experiments deals with the effect of biguanides, 
guanamines and insulin in normal rat hepatocytes after the cells were preincubated in 
Krebs-Henseleit medium containing lOmM and 30 mM glucose (Figure 18-23). Figure 
17 shows that basal phosphorylase a activity was reduced by preincubation of 
hepatocytes in 30mM glucose to 37 + 6 nmol/ mg of protein/ min) compared to basal 
phosphorylase a activity in hepatocytes from normal rats when pre incubated in lOmM 
glucose (59 +  7 nmol/ mg of protein/ min).
For convenience, most presentations of results are divided into two graphs; the 
effect of biguanides, guanamines and insulin in the presence of lOmM glucose in
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Figure 17. Glycogen phosphorylase a activity in control (lOmM and 30mM glucose), 
streptozotocin-induced-diabetic rat (lOmM and 30mM glucose). Values are the mean 
±  s.d. for eight animals, p values relative to the control values were obtained by 
ANOVA followed by Dunnet's test,***p<0 .01 . Basal phosphorylase activity for 
control in lOmM glucose (59 + 7 nmol/ mg of protein/ min), in 30mM glucose (37 + 
6 nmol/ mg of protein/ min), basal phosphorylase activity for diabetic rat in lOmM (52 
+ 6 nmol/ mg of protein/ min), in 30mM glucose ( 3 3 + 4  nmol/ mg of protein/ min).
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normal rat hepatocytes are presented in one graph and the effect of biguanides, 
guanamines and insulin in the presence of 30mM glucose in a second graph.
3. 6. 1. The effect of phenethvlbiguanide and phenethvlguanamine.
In Figure 18A phenethylbiguanide (phenformin) in the concentration range 10" 
9M to 10'3M, gave a significant decrease in the activity of glycogen phosphorylase a 
to 77% - 90% of control (p< 0.05; basal phosphorylase activity 51 ±2 . 8  nmol/ mg of 
protein / min) in a dose-dependent manner in lOmM glucose as seen previously. There 
was no significant change in activity when phenethylbiguanide was used at a low 
concentration (10"10M). The cyclization of phenethylbiguanide to phenethylguanamine 
increased the effectiveness of the compound in lOmM glucose causing a decrease in 
the activity of the enzyme in all concentrations from 10"10M to 10_3M in a dose - 
dependent way. The maximum activity (64% of control) occurred at the concentration 
of 10”4M. Phenethylguanamine at concentrations 10“6M to 10‘4M decreased the 
activity of the enzyme significantly more than phenethylbiguanide (p< 0.01). Similarly 
phosphorylase inactivation was observed at all insulin concentrations studied between 
10-JOM and 10"5M.
Preincubation of rat hepatocytes for 30 min with 30mM glucose resulted in a 
marked decrease in the basal activity of glycogen phosphorylase a to 13 ±  2.1 nmol/ 
mg of protein/ min (compared to 51 ± 3  nmol/ mg of protein/ min of control). 
Exposure of these rat hepatocytes to phenethylbiguanide for 5 min resulted in a 
significant increase in glycogen phosphorylase a (Figure 18B). This increase occurred 
at all phenethylbiguanide concentrations from 10~10M to 10“3M and gave a maximum 
effect at 10_4M (196% of control). The cyclization of phenethylbiguanide to 
phenethyguanamine again increased the effectiveness of the compound exhibiting a 
dose-dependent effect on the activation of phosphorylase giving a maximum response 
of 270% of the control at 10‘4M. Phenethyguanamine increased enzyme activity more 
than phenethylbiguanide (p< 0.01). Insulin also increased the enzyme activity but in a
Figure 18. Dose response curves of glycogen phosphorylase to phenethylbiguanide ( 
O), phenethylguanamine ( • )  and insulin (V) in rat hepatocytes pre incubated for 30 
min in (A) lOmM glucose (B) 30mM glucose and the effect of 5 min exposure to the 
compounds and hormone on the enzyme activity measured. Value are the mean ±  s.d 
(n = 6), analysed by ANOVA followed by Dunnett's test. All value are signficant at p< 
0.01 except *p< 0.05, f  (not significant), basal phosphorylase activity for control in 
graph A (51 ± 3 nmol/ mg of protein/ min), B (13 ± 2nmol/ mg of protein/ min).
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biphasic manner. The maximum activity was observed at low concentration 10"10M 
with the effect disappearing at physiological concentration. Supraphysiological 
concentrations (greater than 10"7M) also caused an increase in enzyme activity 
resulting in a U-shaped dose-response curve.
3. 6. 2. The effect o f  phenvlbiguanide and phenylguanamine
As shown in figure 19A when hepatocytes were preincubated with lOmM 
glucose and then treated with phenylbiguanide, phenylguanamine or insulin, it was 
found that all concentrations of these drugs in the range 10-10M to 10_5M decreased 
the activity of glycogen phosphorylase a significantly compared to the control (p< 0.01 
basal phosphorylase activity 34 ±  2.6 nmol/ mg of protein/ min). The exception is 
phenylguanamine at 10“10M where p<0.05. Phenylguanamine exhibited a steeper dose 
response curve with maximum response achieved at 10"5M and caused a greater 
decrease in enzyme activity compared to phenylbiguanide at concentrations of 10"6M 
and 10~5M (p< 0.01). A comparison of both compounds with insulin showed that 
insulin had a greater effect on enzyme activity (giving an inhibition to 46% of control 
at 10_9M (p< 0.01)). This was significantly greater than the effect of phenylbiguanide 
or phenylguanamine (p< 0 .001).
When hepatocytes were preincubated in 30mM glucose and exposed to 
phenylbiguanide and phenylguanamine, the activity of glycogen phosphorylase a was 
increased as shown in Figure 19B. Phenylbiguanide significantly increased the activity 
of glycogen phosphorylase a to 155% - 265% of control (p< 0.01; basal phosphorylase 
a activity 8 ±  1 nmol/ mg of protein/ min). in a dose - dependent manner with the 
maximum response at 10"3M. A similar dose - response effect was seen for 
phenylguanamine, at concentrations of 10'10M to 10"6M reaching to about 194% to 
277% of the control with a maximum increase of enzyme activity occurring at 10‘6M 
and a subsequent fall in enzyme activity at the higher concentrations. Phenylguanamine
Figure 19. Effect of various concentrations of phenylbiguanide (O), phenylguanamine 
( • )  and insulin (V) on glycogen phosphorylase activity in normal rat hepatocytes to 
control (100%). The cells pre incubated for 30 min in (A) lOmM glucose (B) 30mM 
glucose and the effect of 5 min exposure to the compounds and hormone on the 
enzyme activity measured. Value are the mean ±  s.d (n = 6), analysed by ANOVA 
followed by Dunnett's test. All value were significant at p< 0.01 except *p< 0.05. 
basal phosphorylase activity for control in graph A (34 ± 3 nmol/ mg of protein/ min), 
B (8 ± 1 nmol/ mg of protein/ min).
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increased the enzyme activity significantly more at all concentrations (p< 0.05) than 
phenylbiguanide.
As shown in Figure 19B when cells were exposed to 30mM glucose followed 
by different concentrations of insulin, the enzyme exhibited a U-shaped-dose response 
curve with a significant increase in the enzyme activity at concentrations of 10~10M to 
10"5M. Insulin at 10"10M gave the maximum response reaching 600% of control (p< 
0.01; basal phosphorylase activity 8 ±  1 nmol/ mg of protein/ min). Enzyme activity 
declined sharply above this concentration but remained significantly above control. At 
the physiological concentration 10"9M activity was 256% of control and at 10"^M 
activity was 252% of control.
3. 6. 3. The effect o f  benzylbiguanide and benzylguanam ine.
In similar experiments, the actions of benzylbiguanide, benzylguanamine and 
insulin on glycogen phosphorylase a was studied (Figure 20). In hepatocytes from 
normal animals cultured in lOmM glucose, benzylbiguanide at concentrations in the 
range 10-10M to 10_3M decreased the enzyme activity in a dose dependent manner 
compared to control (p< 0.01; basal phosphorylase activity 34 + 2 nmol/ mg of 
protein/ min) with a maximum activity observed at 10'4M and 10"3M (Figure 20A). 
The cyclization of benzylbiguanide to benzylguanamine improved activity compared to 
the control (p< 0 .01) at all concentrations used up to lO^M. At concentrations up to 
10'7M the enzyme activity decreased significantly (p< 0.001) more than with 
benzylbiguanide. As shown in Figure 20A, insulin caused a dose - dependent decrease 
in enzyme activity and there was no significant difference in the effect compared to 
benzylguanamine.
In contrast to hepatocytes from normal rats preincubated in lOmM which 
exhibit a dose - dependent decrease in the enzyme activity with all compounds added 
preincubation with 30mM glucose led to a dose - dependent increase in enzyme 
activity with all compounds tested (Figure 20B). A similar dose - dependent effect for
Figure 20. Dose-response effect of glycogen phosphorylase a activity to 
benzylbiguanide (O), benzylguanamine ( • )  and insulin (V) after normal rat 
hepatocytes were pre incubated for 30 min in (A) 10 mM glucose (B) 30 mM glucose 
and the effect of 5 min exposure to the compounds and hormone on the enzyme 
activity measured. Value are the mean ± s.d (n = 6), analysed by ANOVA followed by 
Dunnett's test. Basal phosphorylase activity for control in graph A (34 ± 3 nmol/ mg of 
protein/ min), B (8 ± 1 nmol/' mg of protein/ min). All values were significant at
p<0.01.
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benzylbiguanide to that observed for phenyl and phenethylbiguanide was seen. At 
concentrations from 10"10M to 10“5M, benzylbiguanide elicited a dose - dependent 
increase in the activity of the enzyme reaching to 324% of the control at 10"5M. At 
higher concentrations the effect of benzylbiguanide was reduced, although it was still 
higher than control at 10”3M. Benzylguanamine significantly increased enzyme activity 
at all concentrations (p< 0.01; basal phosphorylase activity 8 ±  1 nmol of ^C-glucose 
1 phosphate/ mg of protein/ min) with the maximum effect observed at 10“^M. At 
higher concentrations 10"4M and 10"3M the effect of benzylguanamine was reduced 
despite being significantly greater than their respective control. Figure 20B, shows the 
cyclization of benzylbiguanide to benzylguanamine did not improve overall the activity 
on glycogen phosphorylase, indeed there was less of an effect at the lower 
concentrations of 10~9 and 10-8M). The same effect for insulin is shown in Figure 19B 
as was observed in Figure 20B with a U-shaped dose- response curve.
3. 6. 4. The effect o f  phenethylbiguanide and 1.1-dim ethvlbiguanide.
Both phenethylbiguanide (phenformin) and 1,1-dimethylbiguanide (metformin) 
were examined with normal rat hepatocytes cultured in lOmM and 30mM glucose to 
see which R- group has more effect and how change in the activity is affected by 
glucose concentration. In lOmM glucose, phenethylbiguanide (phenformin) decreased 
the activity significantly compared to control (p<0.01; basal phosphorylase activity 76 
±  5 nmol /mg of protein/ min) at all concentrations, as shown Figure 21 A. 
Furthermore 1,1-dimethylbiguanide significantly decreased the activity to 55% of 
control (p< 0.01). At some concentrations (10~6M, 10_4M and 10"3M)
dimethylbiguanide decreased the enzyme activity significantly more than 
phenethylbiguanide (p<0.001). Insulin decreased enzyme activity significantly at all
Figure 21. Effect of various concentrations of phenethylbiguanide (phenformin) (O),
1,1-dimethylbiguanide (metformin) ( • )  and insulin (V) on glycogen phosphorylase 
activity in normal rat hepatocytes compared to control (100%). The cells were pre 
incubated for 30 min in (A) 10 mM glucose (B) 30 mM glucose and the effect of 5 min 
exposure to the compounds and hormone on the enzyme activity measured. Value are 
the mean ± s.d (n = 6), analysed by ANOVA followed by Dunnett's test. Basal 
phosphorylase activity for control in graph A (76 ± 5 nmol/ mg of protein/ min) B (57 
± 4 nmol/ mg of protien/ min). All values are significant at p<0.01 except * p<0.05 
and f (not significant).
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concentrations compared to control (p< 0 .01) and compared to phenethylbiguanide 
and phenethylguanamine (p< 0 .001).
In simultaneous studies with the same cells, by changing the glucose
concentration from lOmM to 30mM, a comparison of the effects of 
phenethylbiguanide (phenformin) with 1,1-dimethylbiguanide (metformin) was made. It 
showed that, in 30mM glucose, phenethylbiguanide increased the enzyme activity 
significantly at all concentrations (Figure 2IB) (p<0.01; basal phosphorylase activity 
57 ±  4 nmol/ mg of protein/ min). It can be further seen from Figure 2IB that
l,ldimethylbiguanide increased the enzyme activity to a lesser extent than
phenethylbiguanide. Indeed, only at concentrations of 10~8M, 10“5M and 10“3M was 
the enzyme activity increased significantly (p< 0.01). At concentrations of 10"6M and 
10"7M the enzyme activity was reduced significantly below control. Insulin caused a 
dose - dependent increase in enzymes activity with a maximum response seen at 10“ 
5M. In comparison with phenethylbiguanide and 1,1-dimethylbiguanide, it was 
observed that insulin increased the activity significantly more (p< 0 .001) than
l,ldimethylbiguanide, but less than phenethylbiguanide (p< 0 .001).
3. 6. 5. The effect o f  phenethylbiguanide and saccharin.
It can be further seen from Figure 22A, when phenethylbiguanide was compared with 
saccharin (o-sulfobenzimide) in lOmM glucose, that saccharin decreases the enzyme 
activity significantly in all concentrations compared to the control (p<0 .01) (basal 
phosphorylase activity 76 ±  5 nmol/ mg of protein / min). There was no difference in 
the effect of the two compounds at low concentration (10"10M), but saccharin 
decreased the enzyme activity significantly more at concentrations of 10“9M and 
above.
Also in this experiment, the effects of the same compounds on normal rat 
hepatocytes cultured in 30mM glucose was examined. Figure 22B shows that there is
Figure 22. Dose response curves of glycogen phosphorylase phenethylbiguanide 
(phenformin) (O), saccharin (o-sulfobenzimide) ( • )  and insulin (V) in normal rat 
hepatocytes pre incubated for 30 min in (A) 10 mM glucose (B) 30 mM glucose and 
the effect of 5 min expousure to the compounds and hormone on the enzyme activity 
measured. Value are the mean ± s.d (n = 6), analysed by ANOVA followed by 
Dunnett's test, compared to basal phosphorylase activity (100%). Basal phosphorylase 
activity for control in graph A (79 ± 5 nmol/ mg of protein/ min), B (57 ± 4 nmol/ mg 
of protein / min). All values are significant at p< 0.01, except * p< 0.05, f  (not 
significant).
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no change in enzyme activity when saccharin was added at low concentrations (10" 
10M to 10-7M) but at higher concentrations (10"6M to 10’3M) saccharin increased 
enzyme activity significantly (p< 0.01; basal phosphorylase activity 57 ±  4 nmol/ mg 
of protein/ min). Phenethylbiguanide increased the activity significantly at all 
concentrations (p<0 .01) and was significantly better than saccharin (p<0 .001). 
Phenethylbiguanide also increased the enzyme activity significantly better at all 
concentrations compared to insulin (p<0 .001).
3. 6. 6. The effect o f  saccharin and diazoxide
In the comparison between saccharin and diazoxide, hepatocytes from normal 
rats preincubated in lOmM glucose were treated with diazoxide to compare with 
hepatocytes treated with saccharin. Diazoxide increased the enzyme activity 
significantly in all concentrations compared to the control (Figure 23A) (p<0 .01 ; basal 
enzyme activity 76 + 5 nmol/ mg of protein/ min). The maximum effect of diazoxide 
was seen at 10"8M. Attenuation of diazoxide's effect could be seen when the 
concentration was increased above 10"7M. Saccharin, as previously mentioned, caused 
a significant decrease in enzyme activity. When the cells were pre incubated in 30mM 
glucose and exposed to diazoxide, there was a significant increase in the enzyme 
activity compared to control (p<0.01 basal phosphorylase activity 57 +  4 nmol/ mg of 
protein/ min) (Figure 23B). Saccharin also caused a significant increase in enzyme 
activity at concentrations higher than lO'^M. Diazoxide was more effective than either 
insulin or saccharin in increasing enzyme activity significantly (p< 0 .01).
Figure 23. The effect of saccharin (o-sulfobenzimid) (O), diazoxide (7 chloro-3- 
methyl -2H-1,2,4- benzothiadiazine) ( • )  and insulin (V) on phosphorylase a activity in 
normal rat hepatocytes were pre incubated for 30 min in (A) lOmM glucose (B) 30mM 
glucose and the effect of 5 min exposure to the compounds and hormone on the 
enzyme activity measured. Values are the mean ± s.d (n = 6) analysed by ANOVA 
followed by Dunnett's test. All values are significant at p<0.01, except f  (not 
significant), basal activity of glycogen phosphorylase for control in graph A (76 ± 5 
nmol/ mg of protein/ min), B (57 ± 4 nmol/ mg of protien/ min).
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3. 7. Effect of biguanides, guanamines and insulin on the activity of 
glycogen phosphorylase a in hepatocytes isolated from STZ diabetic 
rats in different glucose concentrations.
The actions of biguanides, guanamines and insulin on glycogen phosphorylase a 
were further studied by analysing their effects in hepatocytes isolated from diabetic rats 
in 10 and 30mM glucose. Figure 17 shows that basal phosphorylase a activity was 
reduced to 31 ± 4  nmol/ mg of protein/ min when the hepatocytes isolated from 
diabetic rats were pre incubated with 30mM glucose compared with the activity when 
hepatocytes were pre incubated with lOmM glucose (52+6 nmol/ mg of protein/ min).
3. 7. 1. The effect o f  phenethylbiguanide and phenethylguanam ine.
Figure 24A depicts the dose dependent effect of phenethylbiguanide, 
phenethylguanamine and insulin on the glycogen phosphorylase a in diabetic 
hepatocytes incubated in lOmM glucose. Phenethylbiguanide in the concentrations 
range 10"8M to 10_3M increased the activity significantly to 140% of control at a 
concentration of 10"^M (p<0.01; basal phosphorylase activity 52 +  6 nmol/ mg of 
protein/ min) There was no significant change in the activity when phenethylbiguanide 
was used at low concentration (10"10M to 10_9M). The cyclization of 
phenethylbiguanide to phenethylguanamine increased the effectiveness of the 
compound causing dose - dependent increase in all concentrations from lO’^ M  to 10" 
3M. Maximum effect was seen at a concentration of 10“3M (158% of control). 
Phenethylguanamine at the concentrations of 10“8M, 10"5M and 10"7M increased the 
activity of the enzyme significantly more than phenethylbiguanide (p<0.01 and p< 0.05 
respectively). Insulin stimulated glycogen phosphorylase a in a dose-dependent manner 
with maximal effect at 10‘^M (275% of control) (p< 0.01). Insulin increased the 
activity significantly in the concentration range 10"8M to 10’5M (p<0.001) compared 
to phenethylbiguanide and phenethylguanamine.
Figure 24. Dose response curves of glycogen phosphorylase to phenethylbiguanide ( 
O), phenethylguanamine ( • )  and insulin (V) in diabetic rat hepatocytes pre incubated 
for 30 min in (A) lOmM glucose (B) 30mM glucose and the effect of 5 min exposure 
to the compounds and hormone on the enzyme activity measured. Value are the mean 
±  s.d (n = 6), analysed by ANOVA followed by Dunnett's test. All value are 
significant at p< 0.01, except f  (not significant). Basal phosphorylase activity for 
control in graph A (52 ± 6 nmol/ mg of protein/ min), B (33 ± 4 nmol/ mg of protein/ 
min).
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Preincubation of the hepatocytes for 30 min with 30mM glucose resulted in a 
marked decrease in basal activity of glycogen phosphorylase a (Figure 17). Exposure 
of these hepatocytes to phenethylbiguanide, phenethylguanamine and insulin for 5 min 
resulted in a further inactivation of the enzyme. Both phenethylbiguanide and 
phenethylguanamine in the concentration range 10"10M to 10”3M caused a dose 
dependent decrease in enzyme activity (Figure 24B) (p< 0.01; basal phosphorylase 
activity 31 ±  4 nmol/ mg of protein/ min). In this experiment, using the same cells, 
insulin was more effective than phenethylbiguanide or phenethylguanamine (p< 0 .001).
3 . 1 . 2 .  The effect o f  phenylbiguanide and phenylguanamine.
Changing the phenethyl group to a phenyl group was examined on the same 
set of cells isolated from diabetic rats in lOmM glucose. As shown in Figure 25A 
phenylbiguanide stimulated the activity of glycogen phosphorylase in a dose dependent 
way at all concentrations used (p<0.01; control value = 52 + 6 nmol/ mg of protein/ 
min). The cyclization of phenylbiguanide to phenylguanamine did not improve the 
activity, indeed less stimulation of glycogen phosphorylase a was seen, although 
statistically significant above control (p< 0.01). The same effect of insulin shown in 
Figure 24A was observed in Figure 25A with a dose-dependent increase. As shown in 
Figure 25B, when hepatocytes were preincubated with 30mM glucose and then treated 
with phenethybiguanide and phenethylguanamine, it is seen that with concentrations 
between 10~8M to 10"3M, the drugs decreased the activity of glycogen phosphorylase 
significantly compared to the control (p< 0.01; basal phosphorylase activity 3 1 + 4  
nmol/ mg of protein/ min). Phenethyguanamine did not alter activity as much as 
phenylbiguanide or insulin.
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3. 7. 3. The effect o f benzylbiguanide and benzylguanamine.
In the same set of cells isolated from diabetic rats, the action of 
benzylbiguanide, benzylguanamine and insulin on glycogen phosphorylase was studied 
(Figure 26A). In hepatocytes from diabetic animals preincubated in lOmM glucose, 
benzylbiguanide, at concentrations of 10"10M to 10“3M, increased the enzyme activity 
in a dose-dependent manner compared to control (p< 0 .01; basal phosphorylase 
activity 52 ±  6 nmol/ mg of protein/ min) with a maximum effect observed at 10"5M. 
The cyclization of benzylbiguanide to benzylguanamine gave a compound which 
increased activity significantly only at concentrations above 10~7M (p<0.01). Indeed, 
at 10_1° to 10'8M, a significant decrease in activity of the enzyme was seen. In 
contrast to hepatocytes from diabetic rats pre incubated in lOmM which exhibited a 
dose-dependent increase in the enzyme activity, preincubation of the same cells with 
30mM glucose caused a dose-dependent decrease in enzyme activity (Figure 26B). A 
similar dose-dependent effect for benzylbiguanide to that observed for phenyl and 
phenethybiguanide (Figure 24B and 25B) was seen. At concentrations of 10"10M to 
10“3M benzylbiguanide elicited a dose-dependent decrease in the activity of the 
enzyme reaching to 44% of control at high concentration (p< 0.01; basal 
phosphorylase activity 31 + 4  nmol/ mg of protein/ min). The cyclization of 
benzylbiguanide to benzylguanamine increased the effect on the enzyme activity.
3. 8. ANDROST-4-ENE-3,17-DIONE METABOLISM IN
HEPATOCYTES ISOLATED FROM NORMAL AND 
STREPTOZOTOCIN DIABETIC RATS IN DIFFERENT 
GLUCOSE CONCENTRATIONS.
A further aim of this study was to investigate the effect of biguanides and 
guanamines on androst-4-ene-3,17-dione metabolism, which has previously been 
shown to be insulin-dependent (Hussin & Skett, 1988). The assay for the metabolism
Figure 26. Effect of various concentrations of benzylbiguanide (O), benzylguanamine 
( • )  and insulin (V) on glycogen phosphorylase a activity in diabetic rat hepatocytes to 
control (100%). The cells pre incubated for 30 min in (A) lOmM glucose (B) 30mM 
glucose and the effect of 5 min exposure to the compounds and hormone on the 
enzyme activity measured. Value are the mean ±  s.d (n = 6), analysed by ANOVA 
followed by Dunnett's test. All values significant at p< 0.01. Basal phosphorylase 
activity for control in graph A (34 ± 3 nmol/ mg of protein/ min), B (8 ± 1 nmol/ mg of 
protein/ min).
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of androst-4-ene-3,17-dione enables the measurement of the activities of the enzymes 
7a-, 6/3- and 16a-hydroxylase, 17-oxosteroid oxidoreductase (17-OHSD) and 5a- 
reductase. Hepatocytes from normal and streptozotocin diabetic rats were isolated and 
preincubated in different glucose concentrations (lOmM and 30mM) to simulate 
normal and diabetic conditions. Such conditions have been shown earlier to influence 
the activity of another insulin-dependent enzyme, glycogen phosphorylase.
3.8.1. 7a- hydroxylase activity
As shown in Figure 27 there was no significant difference in the activity when 
normal rat hepatocytes were preincubated in 30mM glucose (basal 7a- hydroxylase 
activity 22 + 3 pmol/ mg of protein/ min) compared to cells which were preincubated 
in lOmM glucose (basal 7a- hydroxylase activity 22 ±  3 pmol/ mg of protein/ min). In 
diabetic hepatocytes the activity increased significantly to 94 ±  19 pmol/ mg of 
protein/ min in lOmM glucose compared to normal rat hepatocytes preincubated in 
lOmM and 30mM glucose (p< 0.001). The activity was increased significantly by 
preincubation of the cells in 30mM glucose (p< 0.05; basal 7a- hydroxylase activity 
118 +  24 pmol/ mg of protein/ min) compared to diabetic hepatocytes preincubated, in 
lOmM glucose.
3. 8 . 2. 6(3- hydroxylase activity.
Similar results were obtained for the 613-hydroxylase as were seen above for the 
7a-hydroxylase (Figure 28). Again there was no change in activity with changes in the 
concentration of glucose in normal rat hepatocytes whereas in diabetic hepatocytes 
activity was increased significantly to 85 + 17 pmol/ mg of protein/ min in lOmM 
glucose compared to normal rat hepatocytes in lOmM glucose and 30mM glucose (p< 
0.001). When the cells were preincubated in 30mM glucose the activity increased to
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Figure 27. 7a-hydroxylase activity in control and streptozotocin- induced diabetic rat 
hepatocytes (in lOmM glucose and 30mM glucose). Values are the mean +  s.d for 
eight animals, p values relative to control values were obtained by ANOVA followed 
by Dunnet's test, *** p< 0 .001 .
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105 +  20 pmol/ mg of protein/ min (p< 0.05) compared to diabetic hepatocytes which 
were preincubated in lOmM glucose.
3. 8 . 3. 16a- hydroxylase activity.
Figure 29 shows that a change in glucose concentration elicited no significant 
change in rat hepatocytes isolated from control or STZ-diabetic rats. In comparison 
with normal rat hepatocytes, enzyme activity in diabetic rat hepatocytes increased 
significantly (p< 0 .001).
3. 8 . 4. 17- oxosteroid oxidoreductase (17- OHSD) activity.
Unlike the effect of glucose on la -, 6/3- and 16a-hydroxylase (cytochrome 
P450-dependent activities), the basal activity for 17-OHSD was reduced significantly 
(p<0.001) in normal rat hepatocytes pre incubated in 30mM glucose when compared 
to the activity in normal rat hepatocytes preincubation in lOmM glucose (basal 17- 
OHSD; 808 +  30 pmol/ mg of protein/ min) (Figure 30). The activity was decreased 
significantly in diabetic hepatocytes (p< 0 .001) compared to normal rat hepatocytes 
but no significant change was seen in 17-OHSD when diabetic hepatocytes were 
preincubated in 30mM glucose.
3. 8 . 5. 5a - reductase activity.
An increase in this enzyme activity is seen with 30mM glucose preincubation 
(Figure 31) (p< 0.05) compared to the normal cells preincubated in lOmM glucose. 
There is no significant change in enzyme activity in diabetic rat hepatocytes compared 
to normal rat hepatocytes. The effect of glucose on diabetic hepatocytes as glucose 
concentration was increased to 30mM was not statistically significant.
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Figure 29. 16c*-hydroxylase activity in control and streptozotocin- induced diabetic 
rat hepatocytes (in lOmM glucose and 30mM glucose). Values are the mean ±  s.d for 
eight animals, p values relative to control values were obtained by ANOVA followed 
by Dunnet's test, *** p< 0.001.
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Figure 31. 5a- reductase activity in control and streptozotocin- induced diabetic rat 
hepatocytes (in lOmM glucose and 30mM glucose). Values are the mean ±  s.d for 
eight animals, p values relative to control values were obtained by ANOVA followed 
by Dunnet's test.
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3.9. THE EFFECT OF PHENETHYLBIGUANIDE, 
PHENETHYLGUANAMINE AND INSULIN ON ANDROST-4- 
ENE-3,17-DIONE METABOLISM IN NORMAL RAT 
HEPATOCYTES.
Experiments were carried out to test the effect of phenethylbiguanide and 
phenethylguanamine as insulin mimetics on the activity of all enzymes metabolising 
androst- 4-ene- 3,17-dione in isolated male rat hepatocytes.
3. 9. 1. The effect of phenethylbiguanide and phenethylguanamine on 7a- 
hvdroxvlase activity
Phenethylbiguanide caused an increase in 7a- hydroxylase activity which 
exhibited an inverse U- shaped dose response curve with the maximum response seen 
at low concentration (lO'^M) (Figure 32). At the concentration lO'^M to 10‘^M the 
activity of the enzymes diminished though still significantly higher than their respective 
control. There was no significant change in the activity when the biguanide was used at 
the lowest concentration (10‘^M ) and highest concentration (lO'^M).
The cyclization of phenethylbiguanide to phenethylguanamine increased the 
effect of the drug on the 7a-hydroxylase activity significantly in a dose-dependent way. 
Maximum effect again was observed at low concentration (lO'^M) where activity was 
712% of control. Above this concentration, the activity started to decline but 
phenethylguanamine still increased the activity of the enzyme significantly in all 
concentrations (p< 0 .01) and increased the activity significantly more at concentrations 
of 10"^M and 10"^M (p<0.001) than phenethylbiguanide and insulin.
An increase in the 7a-hydroxylase enzyme activity was seen at insulin 
concentration from 10" to 10"^M. Maximum response of 665% of control was 
observed at the physiological concentration of 10"^M. The percentage maximal
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Figure 32. Effect of various concentrations of phenethylbiguanide (O), 
phenethylguanamine ( • )  and insulin (V) on 7a- hydroxylase activity in normal rat 
hepatocytes compared to control (100%). The cells were preincubated with the 
compound and hormone for 30 min in Krebs- Henseleit medium. Values are the mean 
±  s.d (n = 6), analysed by ANOVA followed by Dunnett's test. Basal 7a- hydroxylase 
activity = 26 +  7 pmol/ mg of protein/ min. All values p<0.01 except * p<0.05, f  not 
significant.
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response against control seemed to fall as the concentration of insulin increased above 
the physiological level (Figure 32) although the activity was still above control by 
306% at the highest concentration (10"^M).
3. 9. 2. The effect of phenethylbiguanide and phenethylguanamine on 6(3 
hydroxylase activity.
Figure 33 shows the effect of phenethylbiguanide, phenethylguanamine and insulin on 
6/3- hydroxylase enzyme activity. The effect of phenethylbiguanide (1 0 '^ M  to 10"^M) 
on the enzyme activity was found to display a bell- shape dose-response curve with the 
maximum effect observed at a concentration of 10’^M and activity at the reported 
therapeutic concentration, 10"^M, is not statistically significant (p>0.05). 
Phenethylbiguanide increased the activity significantly at the concentrations from 10“ 
to 10“^ M (p< 0.01) and at the concentration 10“^ M (p< 0.05) compared to 
control.
The effect was more pronounced with phenethylguanamine at all 
concentrations. At low phenethylguanamine concentrations (from 10“ to 10“^ M), 
the enzyme activity increased in a dose - dependent manner to 750% of control but at 
higher concentrations (10“^ M-10“^ M), there was less effect. Phenethylguanamine 
increased the activity significantly more at concentrations from 10“^ M to 10‘^M (p< 
0.001) than phenethylbiguanide. When the same cells were preincubated with insulin, 
the activity of the 6/3-hydroxylase significantly increased. It is interesting to note that 
insulin at its physiological concentration (10“^ M) gave the maximum response increase 
in the l a - and 6/3-hydroxylase activity. At 10'9M insulin the activity increased 
significantly more compared to the effect of phenethylbiguanide and 
phenethylguanamine (p< 0 .001).
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Figure 33. The effect of phenethylbiguanide (O), phenethylguanamine ( • )  and 
insulin (V) on 6)8- hydroxylase activity in normal rat hepatocytes compared to control 
(100%). The cells were preincubated with the compounds or hormone for 30 min in 
Krebs- Henseleit medium. Values are the mean ±  s.d (n = 6), analysed by ANOVA 
followed by Dunnett's test. Basal 6)8- hydroxylase activity = 22 ±  8 pmol/ mg of 
protein/ min. All values p<0.01 except *p<0.05, f  not significant.
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3. 9. 3. The effect of phenethylbiguanide and phenethylguanamine on 16a- 
hvdroxvlase.
16a- hydroxylase is one of the five enzymes which metabolises androst-4-ene- 
3,17- dione. It was found to increase in activity when incubated with 
phenethylbiguanide, phenethylguanamine and insulin. Phenethylbiguanide at lower 
concentrations(10"^M to 10"^M) caused a dose -dependent increase in the enzyme 
activity with maximum response at 10“^ M (Figure 34). At higher concentrations the 
effect of phenethylbiguanide was markedly reduced with activity returning to control 
levels at 10"^M and lO’^M while at the lower concentration of 10-^ M  the activity 
was reduced significantly below control.
Phenethylguanamine still exhibited a dose- dependent effect on the enzyme activity at 
the lower concentrations of 10" to 10"^M. Maximum response was observed at 
10‘^M which was 730% of control (p< 0.01; basal hydroxylase 16a activity 32 ±  5 
pmol/ mg of protein/ min) with a subsequent fall in enzyme activity in the 
concentration range 10‘^M to 10"^M. However activity was still significantly higher 
than respective controls. Phenethylguanamine increased the activity significantly more 
at concentrations of 10"^M-10"^M (p<0.01) than phenethylbiguanide. A significant 
increase in activity could be seen at insulin concentrations as low as 10" but 
maximum response was shifted to the higher concentration of 10"^M. However, at the 
highest concentration used 10"^M enzyme activity decreased below the maximum but 
was still significantly above the control level.
3. 9. 4. The effect o f phenethylbiguanide and phenethylguanamine on 17- 
hvdroxvsteroid dehydrogenase.
The effect of phenethylbiguanide, phenethylguanamine and insulin upon the 
activity of 17-hydroxysteroid dehydrogenase is shown in Figure 35.
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Figure 34. Effect of different concentrations of phenethylbiguanide (O), 
phenethylguanamine ( • )  and insulin (V) on 16a- hydroxylase activity in normal rat 
hepatocytes compared to control (100%). The cells were preincubated with the 
compounds or hormone for 30 min in Krebs- Henseleit medium. Values are the mean 
±  s.d (n = 6), analysed by ANOVA followed by Dunnett's test. Basal 16a- 
hydroxylase activity = 32 + 5 pmol/ mg of protein/ min. All values p<0.01 except * p< 
0.05, f  = not significant.
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Phenethylbiguanide at the lower concentration of 10" decreased the activity 
significantly (p< 0.01) to 38% of control. By increasing the concentration of drug to 
10"9m  the activity of the enzyme increased significantly (p<0.01) to 251% of control. 
It appears that as the concentration of phenethylbiguanide increased (10"^M to 10" 
^M), there was a gradual decline in 17-hydroxysteroid dehydrogenase activity but the 
activity was still higher than the control.
In comparison, phenethylguanamine caused a dose-dependent decrease in 
activity at concentrations from 10"^M to 10"^M (p<0.01) (Figure 35). The enzyme 
exhibited a biphasic response towards insulin. A significant increase in enzyme activity 
was found at 10" ^ M , whilst maximum increase of enzyme activity occurred at 10"^M 
with a subsequent fall in enzyme activity at concentrations of 10"^M and 10"^M. 
However activity was still higher than with the control. At higher concentrations (10" 
and 10"^M), the activity decreased significantly below the control (p< 0.01).
It can be observed from Figure 35 that the effect of phenethylbiguanide, 
phenethylguanamine and insulin on the 17-hydroxsteroid dehydrogenase was not as 
pronounced as the effect on the 7-a, 6/3- and 16a-hydroxylases.
3. 9. 5. The effect of phenethylbiguanide and phenethylguanamine on 5a- 
reductase activity.
A similar observation was noted for the 5a-reductase as seen for the 17-OHSD 
in that phenethylbiguanide increased the activity significantly (p<0 .01) at
concentrations of 10'^M and 10"^M. There was no significant change in enzyme
activity observed at the lowest concentration of 10" and at the highest 
concentration of 10"^M, 10"^M (Figure 36).
Phenethylguanamine increased the enzyme activity significantly at
concentrations of 10"^M , 10"^M, 10"^M and 10"^M (p< 0.05). There was no 
significant change in enzyme activity at concentrations of 10"^M and 10"^M. Insulin at 
the lower concentrations of 10" and 10"^M elicited increases in enzyme activity
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Figure 35. Effect of different concentrations of phenethylbiguanide (O), 
phenethylguanamine ( • )  and insulin (V) on 17a(/?)- hydroxysteroid dehydrogenase 
activity in normal rat hepatocytes compared to control (100%). The cells were 
preincubated with the compounde and hormone for 30 min in Krebs- Henseleit 
medium. Values are the mean ±  s.d (n = 6), analysed by ANOVA followed by 
Dunnett's test. Basal 17a(/3)- hydroxysteroid dehydrogenase activity = 346 ±  32 
pmol/ mg of protein/ min. All values p<0.01 except * p< 0.05, f = not significant.
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with the maximum effect again seen at 10"^M (the activity rose to 703% of the control 
value). At the concentrations of 10"^M and 10"^M , the effect of insulin was markedly 
reduced despite still being significantly greater than the respective control (p<0 .01) 
with activities of 400% and 341% of control respectively. High concentrations of 
insulin (>10‘5M) gave no significant effect.
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Figure 36. Effect of various concentrations of phenethylbiguanide (O), 
phenethylguanamine ( • )  and insulin (V) on 5a- reductase activity in normal rat 
hepatocytes compared to control (100%). The cells were preincubated with the 
compounds or hormone for 30 min in Krebs- Henseleit medium. Values are the mean 
± s.d (n = 6), analysed by ANOVA followed by Dunnett's test. Basal 5a- reductase 
activity = 92 +  22 pmol/ mg of protein/ min. All values p<0.01 except * p< 0.05, |  = 
not significant.
DISCUSSION
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4. 1. The effect of biguanides guanamines, miscellaneous compounds 
and insulin on the activity of glycogen phosphorylase a in normal rat 
hepatocytes
Hepatic glycogen metabolism provides a significant contribution towards 
glucose homeostasis. Glycogen breakdown in the liver releases glucose into the blood, 
thus, raising serum glucose levels. Conversely, excess glucose can be taken into the 
liver and converted to glycogen. The synthesis and breakdown of glycogen are 
controlled essentially by the two enzymes, glycogen synthase and glycogen 
phosphorylase respectively. Glycogen phosphorylase, which catalyzes the first step in 
the intracellular degradation of glycogen (see Introduction 1.3.2), is the rate limiting 
enzyme for glycogenolysis (Cao et al., 1993). The enzyme can exist in two different 
forms in the liver the b form, which is phosphorylated and essentially inactive, and the 
a form, which is not phosphorylated and is active. Conversion from one form to the 
other is controlled by a cascade mechanism involving cAMP and a series of kinases 
(Figure 2). Glycogen phosphorylase has been shown to decrease in diabetic rat 
hepatocytes and the enzyme activity was restored to control values by insulin therapy 
(Khandelwal et al., 1977; Studer & Ganas, 1989). Many studies have shown that 
glycogen metabolism in liver is regulated by insulin, which gives a suppression of 
hepatic glycogen phosphorylase in in vivo and in vitro studies (Hers et al., 1973; 
VandeWerve et al., 1977; Hartmann et al., 1987; Ruiz et al, 1993).
It was observed that insulin inhibited phosphorylase activity in liver by two 
separate mechanisms. In liver cells containing normal levels of calcium, it inhibits a- 
adrenergic activation of phosphorylase by decreasing the net mobilisation of Ca2+ ions 
from intracellular stores thus diminishing the cytosolic Ca2+ and hence stimulation of 
phosphorylase kinase. In calcium- depleted hepatocyt *' , however, it antagonises a- 
adrenergic action by inhibiting the accumulation of cAMP (Blackmore et al., 1979). 
Insulin, at physiological concentrations, decreases the phosphorylation state of the 
phosphorylase and phosphorylase kinase in skeletal muscle (Zhang et al., 1989) and it
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is thought that may also happen in liver. Thus the activity of glycogen phosphorylase is 
important for the maintenance of serum glucose concentrations and can be controlled 
by insulin as part of its regulation of glucose homeostasis.
The biguanides, 1,1-dimethylbiguanide (metformin) and phenethylbiguanide
in patients with non-insulin-dependent (type II) diabetes mellitus (Hermann, 1979; 
Schafer, 1983; Bailey & Nattrass, 1988; Bailey, 1992). They are said to act mainly by
these effects have not been resolved (Bailey, 1993). The cyclization of biguanide to the 
corresponding 1,3,5-triazine (guanamine) has previously been shown to give 
compounds which still lower blood glucose levels in normal as well as diabetic rats 
(Brzozwski et al., 1980 a, b; Gajewski et al., 1983 a, b; Gajewski et al., 1984; 
Tamasdan et al., 1987). In this series of experiments, a novel aspect of the beneficial 
effect of biguanides and guanamines in diabetes was explored by investigation of the 
effect of the compounds on the activity of glycogen phosphorylase a in normal and 
diabetic rat hepatocytes as a measure of insulin-like activity.
(phenformin) have been used for several decades to lower the elevated glucose levels
decreasing hepatic glucose production but the cellular mechanisms responsible for
NH NH
R—NH—C— NH— C— NH2 
1
2
IX
Phenethylbiguanide (IX, 1, R= C6H5[CH2]2) significantly inhibited the activity of 
glycogen phosphorylase a with the maximum effect observed at 10“*M. 
Phenethylbiguanide at a concentration of 4.8 x 1(HM has previously been shown to
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reduce glucose output by half, despite increasing glycogenolysis in adult liver culture 
(Brown et al., 1975). After oral treatment, the concentrations of phenethylbiguanide in 
the plasma of human diabetics are in the range of 1-2 x lO^M ( Hermann & Melander, 
1992; Bailey, 1993). In the present studies the effect of phenethylbiguanide could be 
seen at 10"6M. These observations raise the possibility that phenethylbiguanide could 
exert part of its blood glucose lowering effect via a direct effect on glycogen 
phosphorylase a in liver.
Phenethylbiguanide decreases the intracellular cyclic AMP content of isolated 
hepatocytes (Luly et al., 1977) analogous to the action of insulin. It can be inferred 
therefore that the inactivation of glycogen phosphorylase could be related to the 
decrease of intracellular cyclic AMP concentration. Recently Ubl - Joachim and co - 
workers (1994) demonstrated an effect of biguanides on phenylephrine ;-induced 
[Ca2+]i oscillations in rat hepatocytes by a direct negative interference with the 
IP3(inositol-l,4 ,5-trisphosphate)-sensitive Ca2+-channel. H^-induced release of Ca2+ 
from intracellular stores could be diminished by prior addition of biguanides. It may be 
that biguanides influence the agonist - induced [Ca2+]i oscillations predominantly by 
altering the cyclic cAMP signalling pathway. It has been shown that activation of 
cAMP-dependent protein kinase via increasing concentrations of cAMP potentiates 
IP3-induced Ca2+ mobilisation in permeabilized rat hepatocytes (Burgess et ah, 1991; 
Hajnoczky et a l , 1993) and increases the frequency of phenylephrine induced 
[Ca2+]i oscillation (Somogyi et al., 1992; Sanchez-Bueno et al., 1993). From our 
finding on the effect of phenethybiguanide on glycogen phosphorylase a we can 
speculate that the effect of phenethylbiguanide on the phosphorylase enzyme may be 
through one of these mechanisms.
A clear structure-activity relationship was observed with the synthesised 
biguanides, the most active compound of the biguanide series was benzylbiguanide 
(structure IX, 1, R= C6H5CH2), this compound was equal to insulin in activity, in 
agreement with that observed in vivo (Paul et al., 1963). When R is benzyl the 
hypoglycaemic activity of the compound is found to be greatly increased from that of
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the phenethyl derivative. Furthermore benzylguanidines carrying an amino group have 
been shown to have hypoglycaemic activity in mice with intact metabolism (Pfeiffer & 
Sarrazin, 1985) (structure X) indicating the effectiveness of the guanidino group in 
lowering blood glucose levels..
Moderate activity was shown by the compound having a phenyl group substitution 
(structure IX, 1, R= C6H5). The least active compound of this series was the phenethyl 
group substitution in Ri(I) (i.e. the clinically used oral hypoglycaemic, phenformin, is 
the least active).
Cyclization of the compounds to the corresponding 1,3,5-triazines (structure 
IX,2) still gives compounds which inhibit the activity of glycogen phosphorylase. Our 
results confirm the idea that stabilisation of the biguanide group by cyclization to a 
triazine might result in enhanced antidiabetic potency. In the guanamine series of 
compounds, benzylguanamine (structure IX, 2, R= C6H5CH2) had the highest 
potency (similar to insulin) as compared with substitution with the phenyl (structure 
IX, 2, R= C6H5) or phenethyl group (structure IX, 2, R= C6H5[CH2]2) .
The idea that cyclisation of the biguanide is required for activity can be tested 
by comparing the effects of phenformin and metformin. 1,1-dimethylbiguanide 
(metformin) (structure XI, 1, Rl,R2 = CH3) was more potent than phenethylbiguanide 
(phenformin) on the enzyme activity in normal hepatocytes. This finding was in 
agreement with other work which has demonstrated that alkylbiguanides are more 
active than aromatic biguanides in the action on carbohydrate metabolism in rats 
(Piccinini etal., 1960).
r
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1,1-dimethylbiguanide, however, cannot became cyclic and thus, cyclization may not 
be necessary for action. The results of this investigation are in agreement with results 
from another laboratory on the possible mechanism of 1,1-dimethylbiguanide action on 
glycogen metabolism (Jacobs et al, 1987). Gullo et al (1988) have suggested that 1,1- 
dimethylbiguanide improves insulin mediated [14C]-glucose incorporation into 
glycogen in cells isolated from the liver (Melin et al, 1990). Taken together these 
results suggest that biguanides activate liver glycogen synthase and also inactivate 
phosphorylase in cells isolated from the liver which is an organ of considerable 
importance with respect to body glucose homeostasis as discussed above.
In this effect the biguanides (phenformin and metformin) seem to be unique 
relative to other hypoglycaemic agents as only insulin has been shown to have effects 
like biguanides on the activity state of glycogen phosphorylase a (Hartmann et al., 
1987). Sulfonylureas have, however, been found to have interesting effects in isolated 
cell systems (Cabello et al., 1987; Lopez-Alarcon et a l, 1988; Lopez-Alarcon et al, 
1990) but it does not appear that the mechanism of action of biguanides is similar to 
that of sulfonylureas. Mojena et. al. (1989) have demonstrated that sulfonylureas exert 
a paradoxical activation of glycogen phosphorylase a, possibly by a calcium mediated 
mechanism. As a consequence of this stimulation of glycogenolysis, the cellular 
concentrations of hexose 6-phosphate and fructose-1,6- diphosphate are increased. 
They also suggested that sulfonylureas direct the glycogenolytic flux mainly to lactate, 
and to a lesser extent to glucose. Alarcon et al. (1993) confirmed the hypothesis that 
the activation of glycogen phosphorylase by sulfonylureas occurred as a result of an 
increase in hepatocyte [Ca2+]i and the subsequent allosteric effect of this ion on 
glycogen phosphorylase kinase activity (Khoo & Steinberg, 1975).
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In a further attempt to ascertain which part of the biguanide and/or guanamine 
structure may be involved in its potential hypoglycaemic (glycogen phosphorylase 
lowering) effect, a variety of other compounds were tested which had some structural 
similarity with biguanides and/or guanamines or had been shown previously to have 
effects on blood glucose levels.
The guanamine structure contains a six-membered ring containing three 
nitrogen atoms (a 1,3,5-triazine) and the biguanides are thought to be able to cyclize 
by hydrogen bonding in vivo to give what looks like a triazine but is, in effect, a five- 
membered ring resembling a 1,2,4-triazole. It was decided to try the effects of a 1,3,5- 
triazine and a 1,2,4-triazole on glycogen phosphorylase activity. Melamine (2,4,6- 
triamino-l,3,5-triazine) (structure XII) was compared with 3,5-diamino-l,2,4-triazole 
(structure XIII). Melamine completely inhibited enzyme activity but this was found to 
be due to its cytotoxic action. The triazole, however, exhibited glycogen 
phosphorylase lowering activity similar to the biguanides and guanamines From these 
results it may be concluded that the triazine ring with 2-amino groups may be all that is 
required for the hypoglycaemic activity. This points us towards an idea about the 
future work on cyclization of biguanides to triazole rings instead of triazines
XII XIII
In earlier in vivo work, it had been shown that saccharin could lower blood glucose 
levels (Debbri, 1995J and that the structures of the "cyclised" phenformin and 
saccharin could be overlapped with convergence of their charged groups (using a 
molecular graphics package, CHEMMOD, developed in the Department of Chemistry, 
University of Glasgow). We, thus, decided to compare the effects of phenformin and
101
saccharin on glycogen phosphorylase a activity. This was done in spite of the earlier 
evidence that sulphonylureas have a paradoxical effect on glycogen phosphorylase 
(they increase its activity (Mojena et.al., 1989)) and saccharin more resembles the 
sulphonylureas, having a cyclic sulphonamide ring structure (structure XIV). In a 
comparison between phenethylbiguanide (phenformin) and o-sulfobenzimide 
(saccharin), which is also used as a sweetening agent, the latter was shown to possess 
glycogen phosphorylase lowering properties and behaves in this respect like 
phenformin, whilst having no obvious structural resemblance (see sructure IX and 
XIV). This suggests that the guanadino group is not strictly necessary for the activity 
seen in this study, since the cyclic sulfonamide group in saccharin also had the same 
effect on glycogen phosphorylase activity. However, the guanadino group did have 
more effect on the activity than the cyclic sulfonamide group. It may be that the charge 
distribution over the molecule is of greater importance than the actual functional 
group.
XIV XV
Diazoxide, which contains a 6-membered cyclic sulphonamide ring (structure XV) was 
used to clarify the structure-activity relationship by comparing its effects to saccharin 
which contains a 5-membered ring with the same group. Diazoxide is an 
antihypertensive, with potent hyperglycaemic actions when given orally. 
Hyperglycaemia is reported to result primarily from inhibition of insulin and proinsulin
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secretion (Levin et al., 1975; Leahy, 1993). Diazoxide interacts with an ATP-sensitive 
K+ channel and either prevents its closing or prolongs the open time. This effect is 
opposite to that of the sulfonylureas (Misler et a l, 1989; Panteu et al., 1989; Moreau 
et al., 1992). The drug does not inhibit insulin synthesis, and thus there is an 
accumulation of insulin within the 6-cell. Diazoxide also has a modest capacity to 
inhibit peripheral glucose utilisation by muscle and to stimulate hepatic 
gluconeogenesis. This effect is opposite to that of the biguanides (Bailey & Puan,
1985). These result demonstrate that the oral hyperglycaemic agent diazoxide 
activated glycogen phosphorylase a in contrast to saccharin which inhibited its activity. 
These results suggested that it is not the presence of a cyclic sulphonamide group that 
decreases the activity of glycogen phosphorylase a but, perhaps, the resemblance to 
sulphonylureas that is lost in diazoxide.
CONCLUSIONS
1. All of the synthesised biguanides and guanamines mimic insulin in decreasing 
glycogen phosphorylase a activity.
2. In the biguanide series, the benzyl and phenyl derivatives were more potent than 
the phenethylbiguanide (phenformin).
3. Cyclization of the biguanides to the corresponding 1,3,5- triazines (guanamines)
still give compounds which inhibit the activity of glycogen phosphorylase
4. In the cyclized guanamine series, the most potent was benzylguanamine, which had 
a potency similar to insulin.
5. Cyclization does not seem to be strictly necessary for action, however, as
metformin which does not cyclise can also decrease glycogen phosphorylase 
activity.
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6. The triazine ring with 2- amino groups is all that is required for the hypoglycaemic 
activity. This can be tested in future work on cyclization of biguanides to triazol 
rings instead of triazines.
7. It is not only biguanides and guanamines that can have this effect, saccharin (a 
cyclised sulphonamide 5 membered ring) also decreases glycogen phosphorylase 
whereas diazoxide (a cyclised sulphonamide 6 membered ring) increases the same 
activity.
4. 2. Effects of biguanides, guanamines, miscellaneous compounds and 
insulin on the activity of glycogen phosphorylase a in cultured 
hepatocytes from STZ diabetic rats.
Since biguanides and guanamines have been shown to have an influence on the 
glycogen phosphorylase a activity (previous section) as insulin mimetics in normal rat 
hepatocytes, it is pertinent for us to extend our investigation to the effect of biguanides 
and guanamines on hepatocytes isolated from the diabetic rat. In order to discuss the 
possible mechanism of action of biguanides, guanamines and insulin in altering the 
activity of phosphorylase a, it is necessary first to look at the nature of the enzyme 
itself and how the diabetic state may affect the enzyme activity.
Glycogen phosphorylase a, is a key enzyme in the regulation of glycogen 
metabolism as discussed previously and its activity has been shown to decrease in 
diabetic rats (Khandelwal et al., 1977). A decrease in activity in diabetic rats was also 
observed by Bahnak & Gold (1982) when assayed by the method of Stalmans and Hers 
(1975). Similarly, total phosphorylase shows a significant decrease in activity in rats 
after injection with alloxan to induce diabetes when assayed by the same method as 
above (Miller, 1978) and by the high substrate (Glc-l-p) assay using liver homogenates 
from streptozotocin diabetic rats (Tan & Nattal, 1975).
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The activities of glycogenolytic enzymes, i.e. phosphorylase (both a and b), 
phosphorylase kinase and protein kinase (in the presence or in the absence of cyclic 
AMP), were significantly decreased in diabetic animals. The enzyme activities were 
restored to control values by insulin therapy. Glycogen synthase (I- form) activity, 
similarly decreased in diabetic animals and was also restored to control values after the 
administration of insulin (Khandelwal et al, 1977). The same results were found in the 
STZ diabetic hepatocytes in the acute model in that there was a decrease in glycogen 
phosphorylase activity and a corresponding reduction in cytosolic free calcium, 
corrected by insulin replacement (Studer & Ganas, 1989).
In STZ diabetic liver, phosphorylase (a and total) activities were significantly 
lower than those seen in normal animals during fasting and re-feeding. cAMP- 
dependent protein kinase and phosphorylase kinase activities also showed substantial 
reduction during fasting and subsequent feeding (Pugazhenthi & Khandelwal, 1991). In 
primary cultured hepatocytes, diabetes results in a loss of total phosphorylase activity 
similar to, although more pronounced than, that found in isolated perfused liver (Miller 
et al., 1986). Rulfs et al. (1989) demonstrated that the rate of glycogen phosphorylase 
synthesis is significantly decreased in diabetic hepatocytes compared with normal rat 
hepatocytes. No significant difference was seen in the rate of phosphorylase 
degradation in these cells. The decrease in the synthetic rate corresponds well with 
observed decreases in phosphorylase activity measured in these cells (Bahnak & Gold, 
1982) as well as in other liver preparations (Miller, 1978; Roesler & Khandelwal, 
1987). Reports from Roesler and Khandelwal (1986 a) on the diurnal rhythm of liver 
phosphorylase a activity in normal and genetically diabetic mice have indicated that 
total phosphorylase (a and b forms) is mainly governed by a change in enzyme protein 
concentration. Results from the same laboratory also confirm this relationship in rat 
liver (Roesler & Khandelwal, 1987).
In this study, the activity of glycogen phosphorylase a was lower in diabetic 
animals than in control or insulin-treated diabetic animals but there was no difference 
between the latter two groups. This result is in agreement with the observations of
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Khandelwal et a l, 1977. In the liver of diabetic rats, a decrease in total phosphorylase, 
phosphorylase a (Langdon & Cumow, 1983) and hormonal activation of the enzyme 
(Rodriguez et a l , 1989) should spare liver glycogen stores. However, such a sparing 
effect does not occur since liver glycogen and phosphorylase a decrease together as 
shown by Lavoie and VendeWerve (1991). The explanation for this paradox is 
probably that the lowered synthase phosphatase activity found in diabetes leads to an 
impairment in the activation of glycogen synthase and consequently to a reduction in 
glycogen synthesis despite low phosphorylase activity (Stalmans et al., 1987). The 
lower basal phosphorylase a could be the result of increased phosphorylase 
phosphatase activity due to low concentration of its inhibitor, glycogen (Stalmans et 
al., 1971) and this explains why basal phosphorylase a is lower in diabetic hepatocytes.
The results of this study on diabetic hepatocytes indicate that biguanides and 
guanamines have insulin - like effects on hepatic phosphorylase a i.e. an increase in 
enzyme activity. The effect is opposite to that seen in hepatocytes from control animals 
discussed above and may be compensation for the inhibition of glycogen phosphorylase 
activity seen in liver from diabetic animals (Khandelwal et al.y 1977; Pugazhenthi & 
Khandelwal, 1991) which is perhaps due to the low amount of glycogen seen in liver of 
these animals as discussed above (Lavoil & VendeWerve, 1991).
The activation of glycogen phosphorylase a elicited by phenethylbiguanide was 
in a non dose-dependent manner, approximately maximal effect was obtained when 
drug was used at lO^M. Phenethylbiguanide at this concentration acts directly to fully 
mimic the proteolytic inhibitory effect of insulin in the absence of extracellular 
hormone. The proteolytic process inhibited by insulin was identified as the lysosomal 
pathway in Langendorff-perfused rat hearts (Thome & Lockwood, 1990). The 
concentrations of phenethylbiguanide employed to lower blood glucose in man are 
approximately 3xl0"6M (Schafer, 1983) - similar to the concentrations of drug giving 
maximal effects in this study.
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The presence of the phenyl and benzyl group as a substitution does not increase 
the enzyme activity in diabetic hepatocytes as much as a phenethyl group. In contrast 
to normal rat hepatocytes, diabetic hepatocytes showed the greatest response to 
phenethylbiguanide and only moderate effects with benzylbiguanide. This confirms the 
previous observations in non - diabetic animals and man (Herman, 1979; Billingham et 
al., 1981; Bailey & Broabent, 1981; Lord et al., 1983).
Cyclization of the biguanides to the corresponding 1,3,5- triazine gave only 
small changes in activity. In the guanamine series of compounds, phenethylguanamine 
had the highest potency (more effect than insulin) as compared with substitution with 
the phenyl or benzyl group. This observation contrasts with the observation in the 
normal rat hepatocytes where benzylguanamine was more effective on the glycogen 
phosphorylase than phenethylguanamine. In the cyclization of phenethylbiguanide to 
phenethylguanamine, there was a tendency for diabetic hepatocytes to become more 
responsive to phenethylguanamine than phenethylbiguanide at low concentrations. We 
can concluded that the biguanides and guanamines still mimic insulin in their effect on 
glycogen phosphorylase. However, in contrast to normal cells, the structure-activity 
relationship was reversed.
Benzylbiguanide ^  phenylbiguanide ^  phenethylbiguanide (normal) 
Phenethylbiguanide ^  phenylbiguanide ^  benzylbiguanide (diabetic)
Benzylguanamine ^  phenylguanamine ^  phenethylguanamine (normal) 
Phenethylguanamine ^  phenylguanamine ^  benzylguanamine (diabetic)
Both phenethylbiguanide (phenformin) and 1,1-dimethybiguanide (metformin) 
stimulate the activity of glycogen phosphorylase a under similar conditions but the cells 
from diabetic rats were much more responsive to phenethylbiguanide. This effect is 
opposite to that which was observed in normal rat hepatocytes where 1,1- 
dimethylbiguanide was more effective. This relationship indicates that the cyclization 
of biguanides may be necessary for action in diabetic hepatocytes and also that
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phenethylbiguanide may exert its anti-diabetic actions through cyclization in body 
fluids. This result on the effect of biguanides on glycogen phosphorylase in diabetic 
hepatocytes was in agreement with what Reddi and Jyothirmayi (1992) who observed 
that hepatic and skeletal muscle glycogen phosphorylase activity is significantly lower 
in diabetic than in control. This decrease has also been reported in alloxan and 
streptozotocin diabetic rats ( Khandelwal, et al, 1977; Pugazhenthi & Khandelwal,
1990) where diabetic mice were treated orally with biguanides for 28 weeks, which 
stimulated the activity of glycogen phosphorylase a in the liver, whereas it did not have 
any effect on the muscle enzyme. Since phosphorylase a is involved in the breakdown 
of glycogen, biguanides enhance glycogen breakdown in the liver of diabetic rats. 
Stimulation of both glycogen synthase and phosphorylase a by biguanides may thus 
cause increased turnover of hepatic glycogen.
Further structure-activity relationship studies on diabetic hepatocytes by the 
use of s-triazine demonstrated that the presence of a triazine ring in the guanamine 
structure may be important for the activity since the presence of a triazine ring 
increased the activity of glycogen phosphorylase in diabetic rat hepatocytes to 137% of 
control. A similar effect was observed when 3,5-diamino-l,2,4-triazole was used. This 
result suggests that the triazine ring part of the guanamine may be all that is required 
for activity and suggests that future work on cyclization of biguanides to triazole rings 
instead of triazine rings is still required to complete the investigation.
The effect of o-sulfobenzimide ( saccharin) on diabetic hepatocytes was also 
different to that seen in hepatocytes from normal animals. In diabetic hepatocytes, 
saccharin had no significant effect on the cells. From this result we can deduce clear 
differences in the effect on the glycogen phosphorylase activity between the guanadino 
group in phenethylbiguanide and the cyclic sulphonamide group in saccharin unlike the 
similar effects seen in normal cells, since the 5-membered cyclic sulphonamide does not 
affect the activity and seems to have no significance.
It was also clearly demonstrated that, as with insulin, there is no improvement 
in the activity of the enzyme with either saccharin, which contains a 5 membered cyclic
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sulphonamide, or diazoxide, which contains a 6 membered ring cyclic sulphonamide. 
This result confirms that both compounds (in diabetic hepatocytes) exert little effect 
and the presence of a 5 or 6 membered cylic sulphonamide does not improve the 
activity. In fact it appears that, in the diabetic hepatocytes the guanidino group may 
possess the most significant hypoglycaemic activity.
CONCLUSION
1. The effect of synthesised biguanides and guanamines mimics insulin in that they 
increase glycogen phosphorylase a activity in diabetic hepatocytes as opposed to the 
effect seen in hepatocytes from control animals.
2. In the biguanide series, the phenethylbiguanide was more potent than the phenyl 
and benzyl derivatives in contrast to the effect in normal rat hepatocytes.
3. Cyclization of the biguanide to the corresponding 1,3,5- triazine (guanamines) still 
gave compounds which increase the activity of glycogen phosphorylase.
4. In the cyclized guanamine series , the most potent was phenethylguanamine, which 
had a potency more than insulin in contrast to the effect seen in normal rat 
hepatocytes.
5. Cyclization may be necessary for action since phenformin showed more effect than 
metformin , again in contrast to the effect in normal rat hepatocytes.
6 . The triazine ring seems to be all that is required for the hypoglycaemic activity but 
cyclization of biguanides to a triazole ring may still be worth investigating.
7. The guanadino group is necessary for the activity on diabetic hepatocytes since the 
cyclic sulphonamides (saccharin and diazoxide) do not possess any significant effect on 
diabetic cells.
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4. 3. Effect of biguanides guanamines, miscellaneous compounds and 
insulin on the activity of glycogen phosphorylase a in isolated 
hepatocytes from insulin treated diabetic rat.
In the previous series of experiments it had been shown that the biguanides and 
guanamines had insulin-like effects on the activation of glycogen phosphorylase a in 
diabetic hepatocytes, which may be a compensation for the inhibition of glycogen 
phosphorylase seen in the liver from diabetic rats. Insulin treatment of STZ- diabetic 
rats is known to reverse other diabetes-related parameters, such as the increase in 
serum glucose levels, back to control levels. In this study we have tried to extent our 
experiments to see the effect of biguanides and guanamines on the activity of glycogen 
phosphorylase in cells isolated from insulin treated diabetic rats to see if the effects 
seen in control animals could be restored. It was previously observed that the defect in 
the activity of glycogen phosphorylase in the liver of alloxan- and streptozotocin- 
diabetic rats can be repaired by injection of insulin in vivo (Miller et al.y 1986). This 
supports the contention that the defect is due to insulin deficiency rather than a 
hepatotoxic effect of alloxan or streptozotocin (Miller, 1978; Haverstick et al, 1979; 
Bollen & Stalmans, 1984).
Our results, comparing the activity of glycogen phosphorylase a in 
streptozotocin-induced diabetes, insulin treated diabetic and control, showed that there 
is no significant difference between the control and the insulin-treated diabetic group. 
Khandelwal and co-workers (1977) also demonstrated that there is no significant 
difference in protein kinase and phosphorylase kinase activities between the control 
and insulin-treated diabetic rat.
This study has also clearly demonstrated that phenethylbiguanide actually 
inactivates glycogen phosphorylase in hepatocytes isolated from insulin-treated 
diabetic rats in a dose-dependent manner. This effect is in contrast to the effect of the 
compound on normal rat hepatocytes where there is little enhancement in the activity 
with increasing concentrations and in hepatocytes isolated from diabetic rats where a
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significant increase in enzyme activity was seen. The effect of phenformin is, thus, 
similar but not identical to that seen in the control animals.
Examination of the effect of the side-chain by changing the phenethyl to the 
phenyl or benzyl group indicates that phenyl and benzyl substitution leads to an 
increase in the activity of the compound. The same effect was observed when the 
activity relationships in the normal hepatocytes was studied. In comparing the effects 
of the biguanides on hepatocytes isolated from insulin-treated diabetic rats, it was 
found that the most potent compound in this series was benzylbiguanide as in normal 
rat hepatocytes. With the cyclization of biguanides to guanamines there is no clear 
improvement in the activity of the compounds on the same cells under similar 
experimental conditions. This is again similar, though not identical, to the changes in 
activity observed in the cells from the normal animals.
The result of a comparison between phenethylbiguanide (phenformin) and 1,1- 
dimethylbiguanide (metformin) demonstrated that the cells from insulin treated diabetic 
hepatocytes were more sensitive to the 1,1- dimethylbiguanide than to the 
phenethylbiguanide (phenformin). This effect was similar to that in normal rat 
hepatocytes but it appears clearer in the insulin-treated diabetic hepatocytes. From this 
result we can concluded again that cyclization may not be entirely necessary for action 
in this type of cells.
The triazole ring in 3,5-diamino-1,2,4-triazole possesses the same effect as 
guanamines, as seen in normal rat hepatocytes.
It was seen that saccharin was more potent than phenethylbiguanide 
(phenformin) in its effect on the insulin-treated diabetic hepatocytes. This observation 
is in contrast to the effect of saccharin in normal and diabetic rat hepatocytes when the 
compounds containing the guanadino group are more effective than the cyclic 
sulphonamide group in saccharin.
When cells isolated from insulin-treated diabetic rats are exposed to diazoxide, 
the activity of glycogen phosphorylase a is decreased and the compound behaves as if 
it was an insulin-mimetic although diazoxide is known to be a hyperglycaemic drug. In
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this respect, diazoxide gave a paradoxical effect but the mechanism of this effect is not 
understood. This effect of diazoxide is in contrast to the effect on the normal rat 
hepatocytes.
CONCLUSION
The effect of biguanides and guanamines on the glycogen phosphorylase a in insulin 
treated diabetic rat were much more like the effect of the compounds on the normal rat 
hepatocytes. Some differences did appear, however, such as the unexpected effects of 
the cyclic sulphonamides, saccharin and diazoxide, indicating that they may work by 
different mechanisms.
4. 4. Effect of biguanides, guanamines, miscellaneous compounds and 
insulin on the activity of glycogen phosphorylase a from normal rats 
in the presence of different concentrations of glucose.
As has been discussed above, the effect of synthesised biguanides, guanamines 
and insulin depends on what animals the cells have been isolated from i.e. there are 
different effect in hepatocytes from control , diabetic and insulin-treated diabetic rat. 
The next series of experiment were performed to try and elucidate the reason for this 
difference in effect of the compounds on glycogen phosphorylase activity by 
preincubation of normal rat hepatocytes in different concentrations of glucose. There 
are similarities between the enzymatic change induced in the present study by different 
glucose concentrations in the isolated liver preparation and the findings of Hue et al. (1975) 
and Witter and Avruch (1978). In the liver of rats in vivo Stalmans et al., (1974), 
indicated that the isolated preparation may be used with confidence in the investigation of 
the effect of biguanides, guanamines and insulin on the activity of glycogen 
phosphorylase in the presence of different concentrations of glucose. Since biguanides,
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guanamines and insulin have been shown to have an influence on glycogen 
phosphorylase in different types of cells in normal, diabetic and insulin treated diabetic 
rat and have been implicated in the overall picture of the diabetic condition, it was 
considered pertinent for us to extend this investigation to the effect of biguanides, 
guanamines and insulin on rat hepatocytes in normoglycaemic (lOmM glucose) and 
hyperglycaemic conditions (30mM glucose) to try and reproduce the metabolic 
conditions of the diabetic rat, inother words hyperglycaemia. It was noted that the 
effects of biguanides, guanamines and insulin on hepatic glycogen phosphorylase a in 
normal cells preincubated in 30mM glucose were very similar to those for cells isolated 
from diabetic animals. This result suggested that there is no difference between the 
cells themselves whether isolated from normal or diabetic rats but only that they have 
been exposed to different glucose concentrations in the animal. It was further 
demonstrated that an increase in the glucose concentration of the medium caused a 
rapid and extensive fall in the level of phosphorylase a in the liver. This effect is 
adequately accounted for by the stimulation of the phosphorylase phosphatase reaction 
by glucose (Stalmans et al.t 1970). This effect is said to be the result of binding of 
glucose to glycogen phosphorylase a (Stalmans etal., 1974). Carabaza and co-workers 
(1992) confirmed that glucose is the molecule responsible for the inactivation of 
glycogen phosphorylase (Watson et al., 1994) and at the same time they clearly 
demonstrated that, contrary to what Stalmans and co-worker (1974) observed, that the 
inactivation of glycogen phosphorylase is a signal for glycogen synthase activation. 
Carabaza and co-workers (1992) have used several glucose analogues such as 
deoxyglucose and 5-thioglucose, which caused the inactivation of glycogen 
phosphorylase and the activation of glycogen synthase. However, 6-deoxglucose and 
1,5-anhydroglucitol inactivate phosphorylase without increasing the activation state of 
glycogen synthase, indicating that the two effects are not causally related.
Acute hyperglycaemia causes a marked inhibition of hepatic glucose production 
in normal rats mainly through the suppression of glycogenolysis (Rossetti et al., 1993; 
Liu et al., 1993). Increasing the concentration of glucose in the medium reduced and
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even fully suppressed (20mM glucose) glycogen breakdown (Meury et al., 1994). In 
our studies, both biguanides and guanamines mimic insulin in the inactivation of 
glycogen phosphorylase in the presence of lOmM glucose. When the concentration of 
glucose is increased in the medium to 30mM, the effect of biguanides and guanamines 
on glycogen phosphorylase was reversed and an increase in the activity was seen. This 
result is similar to that of Bollen et al. (1983), who showed that phosphorylase was 
partially inactivated in the presence of 5mM glucose and almost completely inactivated 
at a very high glucose concentration (60mM). With intermediate glucose 
concentrations, the same inactivation of phosphorylase was observed as seen in this 
study.
When hepatocytes in a high glucose medium (30mM) are exposed to 
biguanides, guanamines and insulin there is an increase in the activity of glycogen 
phosphorylase to a level which does not exceed the basal phosphorylase activity when 
hepatocytes are in lOmM glucose. From this observation we can speculate that 
biguanides, guanamines and insulin correct the effects of the hyperglycaemic state by 
restoring glycogen phosphorylase activity back to near the control level. It is 
interesting to note that when the activity is decreased by biguanides, guanamines and 
insulin in lOmM glucose and when the activity is increased by biguanides, guanamines 
and insulin in 30 mM glucose, the activity reached approximately the same level. It 
must be assumed that the increase in enzyme activity is to correct the defect which 
results from exposure of the cell to a high concentration of glucose (30mM). Weak 
inhibitors of glycogen phosphorylase are weakly hypoglycaemic (Kasvinsky et al., 
1978). Amylin, the major component of amyloid fibres in the pancreas of NIDDM 
patients, causes a dose-dependent increase in phosphorylase activity (Young et al.,
1991). Our observations and those of Martin et al., 1991 suggest that inhibitors of 
glycogen phosphorylase may help shift the balance between glycogen synthesis and 
glycogen degradation in favour of glycogen synthesis in both muscle and liver. 
Therefore they may be useful therapeutic agents for the treatment of diabetes.
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A clear structure-activity relationship was observed when cells were pre­
incubated in 10 mM and 30 mM glucose. When hepatocytes, preincubated in lOmM 
glucose, were exposed to biguanides, the most active compound was benzylbiguanide. 
By changing the concentration of glucose to 30mM and using the same series of 
biguanides, it appeared that the most potent compound was still benzylbiguanide 
although the effect was different (the effect was always similar to insulin). This is in 
agreement with in vivo experiments which show that anti hyperglycaemic biguanide 
increase the blood glucose-lowering efficacy of insulin in hyperglycaemia (Pagono et 
al., 1983; Gin et al., 1985; Prager et al, 1986; Leblanc et al., 1987; Nosadini et al., 
1987; Hother-Nielsen et al., 1989; Reaven et al., 1992).
Cyclization of biguanides to the corresponding 1,3,5-triazine still gives 
compounds that mimic insulin. When control hepatocytes are incubated in lOmM 
glucose, benzylguanamine seemed to have more effect on activity than phenyl- or 
phenethylguanamine. When the concentration of glucose was increased to 30mM and 
the same series of guanamines was tested, there was little change in enzyme activity, 
but it was observed that the phenethylguanamine was more effective than phenyl- or 
benzylguanamine.
Benzylguanamine ^  phenylguanamine ^  phenethylguanamine (normal) 
Phenethylguanamine ^  phenylguanamine ^  benzylguanamine (diabetic)
From these observations we can suggest that the cells isolated from diabetic rats differ 
only from normal cells in that they have been pre-exposed to high glucose 
concentrations in vivo.
In a comparison between phenethylbiguanide (phenformin) and 1,1- 
dimethylbiguanide (metformin), to determine the requirements for cyclisation of the 
biguanide for the possession of hypoglycaemic activity (the effect on glycogen 
phosphorylase) it was seen that cells were more sensitive to 1,1 dimethylbiguanide 
(metformin) than phenethylbiguanide (phenformin) in lOmM glucose but that there
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was greater response to phenethylbiguanide than 1,1-dimethylbiguanide in 30mM 
glucose. Again the same was observed in diabetic hepatocytes as was observed in 
normal rat hepatocytes when preincubated in 30mM glucose which confirms the theory 
that the cells from the diabetic rat seem to be simply normal cells pre-exposed to high 
glucose concentrations. Experimental studies have demonstrated that the anti- 
hyperglycaemic effects of metformin in the clinical condition of NIDDM are primarily 
due to suppression of hepatic glucose production, which is mediated, at least in part, 
by suppression of free fatty acid and lipid oxidation (Venura et a l, 1994). Presumably, 
the biguanides also affect hepatic glucose production through decreasing the activity of 
glycogen phosphorylase in lOmM glucose and increasing the activity in 30mM 
glucose.
A number of structural features of biguanides were examined to further define 
the breadth of their activity. One examination involved comparison between 
phenethylbiguanide (phenformin) and o-sulfobenzimide (saccharin). The latter reduced 
the activity more than phenethylbiguanide when the cells were preincubated in lOmM 
glucose but when the concentration of glucose was increased to 30mM glucose, the 
phenethylbiguanide still increased the enzyme activity significantly at all concentrations 
whereas the effect of saccharin was only seen at high concentration. The same effects 
as found in 30mM glucose were also observed in diabetic hepatocytes.
CONCLUSION
1. The effect of biguanides and guanamines mimic insulin in decreasing glycogen 
phosphorylase a activity in the normal rat hepatocytes preincubated in lOmM glucose 
and increasing the activity in the same cells preincubated in 30mM glucose. The latter 
effect is similar to the effect in diabetic hepatocytes. From the above findings, it can be 
concluded that the hepatocytes isolated from the diabetic rat are similar to normal cells 
pre-exposed to high glucose concentrations.
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2. The most active compound of biguanides series was benzylbiguanide in 
concentrations of lOmM and 30mM glucose. They were hence considered to be 
worthy of further development as substituted biguanides.
3. Cyclization of biguanides to the corresponding 1,3,5- triazine still gave compounds 
which inhibited the activity of glycogen phosphorylase in lOmM glucose and increasing 
the activity in 30mM glucose.
4. In the cyclised guanamine series, the most potent compound was 
phenethylguanamine in cells preincubated in 30mM glucose.
5. Cyclization is thought to be necessary for action in 30mM glucose since phenformin 
was more effective than metformin. This again is similar to the effects in diabetic 
hepatocytes.
6. Further structure - activity relationship studies demonstrated that the guanadino 
group is probably necessary for activity since saccharin did not behave as a 
hypoglycaemic drug in high glucose.
4. 5. Effect of biguanides, guanamines and insulin on the activity of 
glycogen phosphorylase a in hepatocytes isolated from STZ diabetic 
rats in different glucose concentration.
In comparing between the effects of the synthesised compounds in normal rat 
hepatocytes preincubated in lOmM and 30mM glucose (previous section) and diabetic 
hepatocytes (section 4.2), it was suggested that there is no difference between the cells 
isolated from normal and diabetic rats since the effect of the compounds in normal cells 
preincubated in 30mM glucose was the same as the effect in diabetic hepatocytes. In 
this section we have tried to see the effect of the same series of compounds on the 
hepatocytes isolated from STZ diabetic rats preincubation in lOmM and 30mM 
glucose to confirm this hypothesis.
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The results show that inactivation of glycogen phosphorylase a by glucose is 
not impaired in diabetic hepatocytes, although basal phosphorylase a activity is lower 
than in normal rat hepatocytes. This result is in a agreement with Miller and co- 
workers (1973) who have reported that glycogen phosphorylase was inactivated by 
glucose in livers isolated from rats made diabetic for 2-6 days (Miller et al., 1973; 
Miller, 1978 b) and the observation from Bollen et al (1983) on the effect of glucose 
on glycogen phosphorylase in hepatocytes from acutely (40h) and chronically (90h) 
alloxan - diabetic rats. Bollen found that the glucose- induced inactivation of 
phosphorylase proceeded normally in all conditions. Similar observation were made in 
a study on the response to glucose and fructose in streptozotocin-diabetic rats. When 
hepatocytes isolated from diabetic rats were incubated with 20mM glucose plus 3mM 
fructose this resulted in a more intense inactivation of phosphorylase than when 20mM 
glucose was added alone (Ciudad et a l, 1988). Inactivation of phosphorylase by 
glucose results from direct interaction of glucose with the enzyme, rendering it a better 
substrate for phosphorylase phosphatase (Stalmans et al, 1971; Hers, 1981).
It was observed from our results that all of the synthesised compounds mimic 
insulin in stimulating the activity of glycogen phosphorylase when the diabetic cells are 
preincubated in lOmM glucose and in decreasing glycogen phosphorylase a activity 
following preincubation of the cells in 30mM glucose. This is the exact opposite of the 
effects seen in control cells. In the biguanide series , the most active compound was 
phenylbiguanide when the diabetic cells were preincubated in either concentration of 
glucose (10 or 30mM). In the cyclised guanamine series the most potent was 
phenethylguanamine in lOmM and 30mM glucose which confirmed that the 
stabilisation of phenethylbiguanide by cyclization to a triazine might results in 
enhanced anti-diabetic potency. It was observed that the effect of biguanides and 
guanamines on the diabetic cells incubated in 30mM glucose was opposite to that seen 
in hepatocytes from normal rats. From this result we can suggest that the cells 
isolated from the diabetic rat are not normal since the effect of the compounds on 
hepatocytes isolated from STZ diabetic rats was opposite to that seen in normal rat
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hepatocytes. This results also suggests that guanamines act as insulin-mimetics in 
potentiating the effect of glucose on the glycogen phosphorylase in diabetic cells. The 
reasons for this are, however, unclear.
CONCLUSION
1. All of the synthesised compounds mimic insulin by stimulating the activity of 
glycogen phosphorylase a when the diabetic cells were preincubated in lOmM glucose 
and decreasing glycogen phosphorylase a activity in cells preincubated in a glucose 
concentration of 30mM.
2. It was observed that the effect of biguanides and guanamines on diabetic cells 
incubated in 30mM glucose is opposite to that seen in hepatocytes from normal rats 
hepatocytes. This result suggests that the cells isolated from STZ diabetic are not the 
same as normal cells.
3. In the biguanide series, the most active compound was phenylbiguanide when the 
diabetic cells were preincubated in either lOmM or 30mM glucose.
4. In the cyclised guanamine series the most potent was phenethylguanamine in both 
lOmM and 30mM.
4. 6. ANDROST-4-ENE-3,17-DIONE METABOLISM IN
ISOLATED NORMAL AND STREPTOZOTOCIN DIABETIC RAT 
HEPATOCYTES.
Previous studies using liver microsomes, have indicated that diabetes mellitus 
can affect steroid metabolism in rats and this effect can be reversed by insulin 
administration to diabetic rats (Skett, 1986). Reports from various studies have 
indicated that streptozotocin (STZ)- induced diabetes mellitus can also influence
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hepatic steroid metabolism in rats (Learning et al., 1982; Subbiah & Yunker, 1984). 
The effect of diabetes on hepatic steroid metabolism can be prevented or reversed by 
insulin administration to diabetic animals. Diabetes, produced by streptozotocin, can 
induce CYP4A2 and P450K-2 (similar to CYP2C23) in rat kidney. Treatment of 
diabetic rats with insulin reversed the increase in the levels of CYP4A2 and P450K-2 
(Imaoka etal., 1993)
In this study it has been shown that STZ- induced diabetes mellitus causes a 
change in the metabolism of androst-4-ene-3,17-dione. The change in the enzyme 
activities were dependent on the enzyme being studied, with the basal activity of the 
cytochrome P450-dependent enzymes (7a-, 6/3- and 16a-hydroxylases) being 
increased while the cytochrome P45O-independent enzyme ,17-OHSD, was decreased 
and 5a- reductase was unaffected in diabetes. This data is in partial agreement with the 
results obtained from studies using hepatic microsomes (Reinke et al., 1978; Skett,
1986) in the elevation of 7a- and 16a-hydroxylase and no effect on 5a- reductase and 
also in agreement with that of Hussin and Skett (1988) who observed, using 3 day 
diabetic hepatocytes, an increase in 7a-hydroxylase and decrease in 17-OHSD and 
with the results of Schenkman (1991) using diabetic male rat hepatocytes in the 
elevation of 7a-hydroxylase. Hussin (1988) observed that the effect of diabetes 
mellitus on steroid metabolism in the rat is time-dependent and is not the same in the 
acute and chronic phase. As these experiments performed by Hussin were carried out 
in vitro, differences between these results and those reported here may be due to 
different experimental conditions, the number of days following induction of diabetes 
and the effect of extra hepatic factors. Insulin in normal rat hepatocytes acts as a 
general stimulator of the enzymes in the liver metabolising androst-4-ene-3,17-dione.
Phenethylbiguanide and phenethylguanamine were tested in this study in assays 
for insulin-like activity using the insulin-sensitive metabolism of steroids by isolated rat 
liver cells (Hussin, 1988).
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CONCLUSION
From the above finding it can be concluded that STZ- induced diabetes mellitus causes 
a change in the metabolism of androst- 4- ene- 3,17- dione. The changes in the enzyme 
activities were dependent on the enzyme being studied, with the basal activity of 
cytochrome P450-dependent enzymes (7a-, 6/3- and 16a-hydroxylases) being 
increased while the cytochrome P450-independent 17-OHSD was decreased and 5a- 
reductase was unaffected in diabetes.
4.7. THE EFFECT OF PHENETHYLBIGUANIDE, 
PHENETHYLGUANAMINE AND INSULIN ON ANDROST-4- 
ENE-3,17-DIONE METABOLISM IN NORMAL RAT 
HEPATOCYTES.
The insulin-mimetic effects of phenethylbiguanide and phenethylguanamine in 
increasing androst- 4- ene- 3,17- dione were examined, in order to extend our 
knowledge of the insulin-like actions of biguanides and guanamines from glycogen 
metabolism to steroid metabolism. As shown in this study, phenethylbiguanide 
increased the activity of the cytochrome P450-dependent enzymes (7a-, 6/3- and 16a- 
hydroxylases) at low concentration (10'9M to lO^M). The maximum effect was 
observed only at 10'9M and 10_7M. Investigations from our laboratory indicated that 
phenethylbiguanide has a direct effect on the liver in elevating androst-4-ene-3,17- 
dione metabolism. It is able to mimic the effect of insulin in normal and diabetic rat 
hepatocytes with respect to androst-4-ene-3,17-dione metabolism (Hussin, 1988). 
Vandate (another oral hypoglycaemic) has been shown to have an insulin- like effect
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on hepatic glycogen metabolism in non diabetic and streptozotocin - induced diabetic 
rats (Pugazhenthi & Khandelwal., 1990) and appears to exert insulin- mimetic actions 
on the P4503 and P4501 family of proteins (Verrecchia & Guaitani, 1993). Insulin also 
has this effect (Hussin & Skett, 1988).
Phenethylbiguanide exerted an inducing effect on the cytochrome P450 content 
in isolated hepatocytes from rats with experimental diabetes and this was markedly 
greater than observed in normal hepatocytes. When phenethylbiguanide was added to 
isolated hepatocytes from normal rats, induction of cytochrome P450 was observed 
only in the presence of added dibutyryl cAMP (Canepa et al., 1990). A study 
demonstrated that phenethylbiguanide stimulated a high affinity of isolated liver plasma 
membranes to cyclic AMP phosphodiesterase in a dose-dependent manner, decreasing 
the intercellular cyclic AMP content of isolated hepatocytes without being effective on 
plasma membrane- bound adenylate cyclase (Luly et al., 1977). The stimulation of liver 
membrane bound cyclic AMP phosphodiesterase by phenethylbiguanide led to a 
comparison of this effect with the similar effect known to be exerted by insulin on liver 
membranes (Tria etal., 1977).
Elevation of cyclic AMP levels, either directly or indirectly, has been shown to 
produce an inhibitory effect upon the metabolism of the steroid substrate, androst-4- 
ene-3,17-dione (Berry & Skett 1988). A role for cyclic AMP in the regulation of 
monooxygenase activity has been provided by Weiner and co- workers (1972), where 
it was reported that, in vivo, dibutyryl-cyclic AMP can inhibit metabolism of 
hexobarbitone. From these observation it appears that cAMP can inhibit cytochrome 
P450 whilst phenethylbiguanide activates cytochrome P450. It is possible to speculate 
that phenethylbiguanide has it effect on cytochrome P450 by inhibiting the generation 
or action of cAMP.
Similarly, phenethylbiguanide increased the activity of 17-OHSD significantly 
with maximum effect observed at low concentration (10"9M). The effect at the 
therapeutic concentration of 10'5M (157% of the control) was similar to that seen by 
Hussin and Skett (1988). At a concentration of 10_8M, phenethylbiguanide gave the
122
maximum response on the activity of 5a-reductase in this study. This is in contrast to 
the study of Hussin (1988) where there was no significant change at a concentration of 
10'5M in the control.
Several observations on the mechanism of action of the biguanide group 
suggest that these compounds have an effect at the post-receptor level. Metformin, in 
rat hepatomas cells, enhanced both basal and insulin-stimulated glucose incorporation 
into glycogen in a time- and dose-dependent manner and had no effect on insulin 
binding to the receptor. These studies suggest, therefore, that metformin may influence 
cellular metabolism by potentiating insulin action through a mechanism that goes 
beyond insulin receptor binding (Gullo, 1988). Biguanides have also been reported to 
have a role in the alteration of insulin stimulation of glycogen synthesis without 
affecting the insulin receptor binding (Alengrin et al., 1987). Metformin (1,1 
dimethylbiguanide) potentiates the acute action of insulin at the post-receptor level in 
normal liver cells by increasing the insulin- dependent stimulation of glycogen and lipid 
synthesis without alterating the insulin binding receptor (Melin et al., 1990). These 
observations suggest that biguanides exert their effects on androst-4-ene-3,17- dione 
metabolism by acting through mechanisms that go beyond insulin receptor binding in a 
way which has yet to be determined.
The cyclization of phenethylbiguanide to phenethylguanamine improved the 
effect of the compound on the activity of cytochrome P450-dependent enzymes (7a-, 6 
/?-, 16a-hydroxylases). Hepatocytes become more responsive to phenethylguanamine 
with the activity the 7a-, 6/3- and 16a-hydroxylases increasing to 712%, 750% and 
730% of the control respectively. This effect appeared to be two to three times greater 
than phenethylbiguanide. Phenethylguanamine showed a decrease in the activity of 17- 
OHSD in contrast to the effect of phenethylbiguanide. There was no improvement in 
the effect on the activity of 5a-reductase when phenethylbiguanide was cyclised to 
phenethylguanamine. It is interesting to note that only the cytochrome P450- 
dependent enzymes were involved. This possibly indicates that the three cytochrome
123
P450-dependent enzymes are more susceptible to alteration by a triazine ring than by a 
biguanide but that the flavin-dependent enzymes are not.
When the same cells were exposed to insulin, there was a significant increase in 
all of the enzyme activities and the maximum effect was observed at the physiological 
concentration of 10'9M. This is in agreement with the result of Hussin and Skett
(1988) in his study using the same incubation time. The role of insulin in the 
preservation and induction of cytochrome P450 isoenzyme activities and contents was 
investigated in rat hepatocytes for 4 days (Saad et al, 1994). The results of these 
investigations demonstrate that different tissue oxygen tension modulates the 
responsiveness of the cultured hepatocytes to insulin and glucagon. This modulation 
results in an altered activity of cytochrome P450 isoforms. Pyerin et al (1983) have 
reported the phosphorylation of monooxygenase components caused conversion of 
cytochrome P450 to its denatured form, cytochrome P420 (Taniguchi et a l, 1985) and 
is dependent on the presence of both ATP and cAMP-dependent protein kinase 
suggesting that cytochrome P450 is a physiological substrate of cAMP-dependent 
protein kinase. Pyerin et al (1984) also reported a significant decrease in 
monooxygenase activity when cytochrome P450 was phosphorylated. Thus one of the 
mechanisms which could elicit an increase in 7a-, 6fi- and 16a-hydroxylase is 
decreasing the intracellular concentration of cAMP.
CONCLUSION
Phenethylbiguanide and phenethylguanamine are both able to mimic the effect of 
insulin in normal rat hepatocytes with respect to androst-4-ene-3,17-dione metabolism. 
However the cyclization of phenethylbiguanide to phenethylguanamine gives a 
compound which is only effective on the cytochrome P450-dependent enzymes (7a-, 6 
/?- and 16a-hydroxylases). This possibly indicates that the three cytochrome P450 
dependent enzymes are more susceptible than the flavin-dependent enzymes to the 
triazine ring in phenethylguanamine.
124
4.8 GENERAL DISCUSSION
All of the results can be summarised as follows:
1. The effect of biguanides, guanamines, miscellaneous compounds and insulin 
on the activity of glycogen phosphorylase a in rat hepatocytes
i) In normal rat hepatocytes: the effect of biguanides and guanamines on the glycogen 
phosphorylase a is an insulin-like effect in inactivating the enzyme. A clear structure - 
activity relationship was observed and the most active compounds of the biguanides 
was benzylbiguanide. When the biguanides were cyclised to the corresponding 1,3,5- 
triazine (guanamine) the compounds still inhibited the activity of the enzyme, the most 
active compound in this series was benzylguanamine .
Cyclization is, however, not necessary for activity on the normal rat hepatocytes. 3,5- 
diamino-l,2,4-triazol exhibited glycogen phosphorylase lowering activity similar to the 
biguanides and guanamine which suggested future work on cyclization of biguanides to 
a triazole ring instead of a triazine. Cyclic sulphonamides e.g. in saccharin also had the 
same effect on glycogen phosphorylase activity as the biguanides, perhaps due to 
similarities in structure elucidated by molecular graphics techniques.
ii) In diabetic rat hepatocytes: The effect of biguanides and guanamines still mimic 
insulin in that they increase glycogen phosphorylase a activity. However the rank order 
of potency was opposite to that seen in hepatocytes from control animals. It was 
indicated that the cyclization of biguanides may be necessary for action in diabetic 
hepatocytes. Studies on 3,5-diamino-l,2,4-triazole demonstrated that the presence of a 
triazine ring may be important for the activity.
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iii) In insulin treated diabetic rat hepatocytes: These comparative experiments 
indicated in general that cells isolated from insulin-treated diabetic rats responded in a 
similar fashion to those isolated from control animals.
iv) In normal rat hepatocytes in the presence o f different concentrations o f glucose: 
The series of experiment were performed to try to elucidate the reason for the 
difference in effect of compounds on glycogen phosphorylase activity in different types 
of cells. A similar structure-activity relationship was observed in control cells 
preincubated in 30mM glucose as in cells isolated from STZ-diabetic rats, indicating 
that the latter cells are, perhaps, simply control cells that have been pre-exposed to 
high glucose concentrations.
v) In diabetic rat hepatocytes in the presence o f different concentrations o f glucose: It 
was observed from these results that all of the synthesised compounds mimic insulin in 
stimulating the activity of glycogen phosphorylase when the diabetic cells are 
preincubated in lOmM glucose and by decreasing glycogen phosphorylase a activity in 
cells preincubated in 30mM glucose. This result suggests that cells isolated from STZ- 
diabetic rats are not normal and respond differently to cells isolated from control liver.
2. The effect of phenethylbiguanide phenethylguanamine and insulin on androst 
-4-ene-3,17-dione metabolism in normal rat hepatocytes.
The insulin-mimetic effects of phenethylbiguanide and phenethylguanamine in 
increasing androst -4- ene- 3,17- dione metabolism were examined in order to extend 
our knowledge of the insulin-like action of biguanides and guanamines from glycogen 
metabolism to steroid metabolism. Phenethylbiguanide increased the activity of the 
cytochrome P450-dependent enzymes. Similarly phenethylbiguanide increased the 
activity of 17-OHSD significantly with maximum effect observed at the low 
concentration of 10_9M.
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The cyclization of phenethylbiguanide to phenethylguanamine improved the 
activity on the cytochrome P45O-dependent enzymes. This effect appeared to be 2-3 
times greater than with phenethylbiguanide. Phenethylguanamine gave a decrease in 
the activity of 17-OHSD in contrast to the effect of phenethylbiguanide. It is 
interesting to note that only the cytochrome P450-dependent enzymes were positively 
affected by the guanamine. This possibly indicates that the three cytochrome P450- 
dependent enzymes are more susceptible to alteration by the triazine ring.
Overall, biguanides and guanamines have been shown to have significant, 
direct, insulin-like effects on glycogen phosphorylase a activity and androst-4-ene- 
3,17-dione metabolism in hepatocytes isolated from control and STZ-diabetic rats. The 
effectiveness of the compounds depended on the enzyme under study and on the 
original state of the animal (diabetic or not).
Further investigation is warranted on the usefulness of congeners of the 
presently used biguanide, phenformin, and on the cyclised biguanides, such as the 
guanamines and, perhaps, the five-membered structures, the triazoles.
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ABBREVIATIONS
[Ca2+]i Intracellular free calcium ion concentration
DTT DL-Dithiothreitol
EDTA Ethylene diaminetetraacetic acid
Glclp Glucose-1-phosphate
HEPES N-[2-hydroxyethyl]piperazine- N'[2 ethanesulfonic acid]
MOPS 3-[N-Morpholino]propanesulphonic acid
STZ Streptozotocin
T.L.C Thin layer chromatography
AMP Adenosine-5'-monophosphate
ADP Adenosine-5'-diphosphate
ATP Adenosine-5-triphosphate
D.PM Disintegrations per minute
CyclicAMP Cyclic adenosine 3',5'- monophosphate
g  Centrifugal g-force
I.U International unit
EGTA Ethylene glycol-bis (13- aminoethyl ether). N,N,N,N-
tetra-acetic acid 
OHSD Oxosteroid oxidoreductase
Km substrate concentration producing half-maximal volecity.
G-6-P Glucose-6- phosphate.
NIDDM Non- insulin- dependent diabetes mellitus.
S.D Standard deviation
Ser Serine
NADPH Reduced nicotinamide adenine dinucleotide phosphate
kDa Kilodalton
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